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Abstract 
An association between diabetes mellitus and tuberculosis has been established: systematic 
reviews suggest that individuals with diabetes are three times more likely to develop active 
tuberculosis disease and have nearly a two-fold increased risk of death from tuberculosis than 
individuals without diabetes. The context of these associations in southern Africa may differ 
from the rest of the world due to the high prevalence of HIV and the high prevalence of poorly 
controlled diabetes mellitus in this region. Most prior studies have measured glycaemia at the 
time of tuberculosis diagnosis as a proxy for diabetes. Physiological stress from acute TB 
infection can also cause hyperglycaemia, so we use the term hyperglycaemia to encompass 
both diagnoses until the two can be differentiated. We conducted a case-control study in 
Lusaka, Zambia to determine if HIV modifies any association between hyperglycaemia and 
active tuberculosis. We recruited 3,843 tuberculosis cases and 6,977 controls and found no 
evidence of an overall association between hyperglycaemia and active tuberculosis, though 
there was a significant effect modification by HIV: among individuals with HIV there was a 
positive association. A subset of cases from the case-control study were recruited to a cohort 
study to determine whether a dose-response relationship exists between hyperglycaemia and 
tuberculosis treatment outcome. We found no evidence of a relationship. A study of diagnostic 
accuracy used a further subset of cases from the case-control study to determine the 
diagnostic accuracy for diabetes mellitus of measures of hyperglycaemia used at the time of 
tuberculosis diagnosis compared to a reference standard. We found a low proportion of 
hyperglycaemia measured at the time of tuberculosis diagnosis was due to diabetes mellitus, 
particularly among individuals co-infected with HIV. Glycated haemoglobin showed no greater 
test accuracy for diabetes diagnosis at the time of tuberculosis diagnosis than fasting or 
random blood glucose tests.  
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Preface 
This thesis is written as a research paper style thesis, in accordance with the guidelines and 
regulations specified by the London School of Hygiene and Tropical Medicine. Linking material 
is provided to maintain coherence of the thesis and ensure it is presented as one body of work. 
There are six papers, each as a separate chapter: three in the introduction section and three in 
the results section. The remainder of the introduction, aims and methods, and discussion 
sections comprise linking material. Repetition has been minimised wherever possible, though 
inevitably there is some repetition in papers and linking material, most notably in the methods 
sections. Nonetheless the thesis does not exceed the word limit of 100,000. The papers are in 
various stages of publication: three have been published, the others are being prepared for 
submission. Sarah Lou Bailey is the first author of all papers. Research paper cover sheets 
giving the publication details are provided at the end of the thesis, directly before the 
appendix. Regardless of publication status the papers are presented as unformatted 
manuscripts, to maintain a coherent style throughout the thesis. All papers and all linking 
material were written by Sarah Lou Bailey. 
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Introduction 
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Chapter 1: Background 
1 Historical context 
For centuries it has been recognised that diabetes mellitus (DM) is associated with tuberculosis 
(TB). Reports of the connection date back to 1000 AD, when Avicenna, a Persian physician and 
philosopher, observed that phthisis frequently occurred among patients with diabetes.1 In an 
ancient text, an Indian Siddhar, Yugimahamuni, discussed varieties of urinary disorders, their 
general symptoms and signs and the types of sufferings they can cause. He described 
progression from obesity to impotence, thirst, glycosuria and ultimately to unconsciousness or 
tuberculosis.2  In more recent history clinicians have again noted the connection, such as Root, 
an American physician in the 1930s, who stated: “During the latter half of the nineteenth 
century, the diabetic patient appeared doomed to die of pulmonary tuberculosis if he 
succeeded in escaping coma”.3 
In the latter part of the twentieth century, focus on the association diminished. Tuberculosis 
incidence declined in high income countries alongside improvements in sanitation, nutrition 
and overcrowding.4-6 Survival of people with diabetes improved following the discovery and 
introduction of insulin in 1922.7, 8 Consequently, the overlap of the two diseases was less 
discernible. Reports of joint TB-diabetes clinics occurring in the 1950s diminished in later years, 
possibly following the introduction of TB chemotherapy including streptomycin in 1944, p-
aminosalicylic acid in 1949, isoniazid in 1952, pyrazinamide in 1954 and cycloserine in 1955. It 
is possible that following the introduction of treatment for both TB and diabetes the overlap of 
the two conditions and consequent need for a joint approach to care diminished. 
Over the last two decades, however, interest in the association has intensified. In many low 
and middle income countries the incidence of tuberculosis is high, particularly where the 
prevalence of HIV is high.9 The prevalence of diabetes has been rising globally, particularly in 
low and middle income countries, due to ageing populations, increasing obesity and sedentary 
lifestyles.10-14 Therefore, once again, we have settings with both a high incidence of 
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tuberculosis and a high prevalence of diabetes. The co-existence of these two diseases in the 
same localities has stimulated interest in and exploration of the overlaps and associations 
between them.15 
2 Prior evidence of association between diabetes and tuberculosis 
Following growing interest in the subject, the first systematic review was published in 2007. 
This paper summarised the evidence from analytical studies reporting the association of 
diabetes as the exposure to TB incidence or disease as the outcome that had been published 
between 1995 and 2007.16 The authors identified nine studies – one prospective cohort study, 
four case-control studies and four studies based on routine data sources. The studies were 
located in North America, Asia, and one in Europe. All studies showed a statistically significant 
association between diabetes and TB, with the odds or risk of TB being between 1.5 and 7.8 
times greater for individuals with diabetes compared to those without diabetes, though few 
studies had controlled for potential major confounders.16 Heterogeneity of the studies 
prevented synthesis of findings. 
In 2008, a second systematic review was published, this time summarising studies published 
between 1965 and 2007 that were peer-reviewed and gave a quantitative effect estimate of 
the relationship between DM as the exposure and active TB as the outcome, and that 
controlled for possible confounding by age or age groups.17 The search identified 13 
observational studies – three cohort studies, eight case-control studies and two other studies 
using data from surveys. The studies were located in North America, Asia, and one in Europe. 
Random effects meta-analysis of the results from the cohort studies gave a risk of TB among 
individuals with DM of 3.11 (95% CI 2.27-4.26) times greater than the risk of TB among 
individuals without DM. Heterogeneity of case-control studies prevented synthesis but in all 
studies the odds of TB among individuals with diabetes was greater than for those without 
diabetes, ranging from 1.16 to 7.83 times greater.17 
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Subsequent reviews and summaries of the overlaps between TB and diabetes continued to 
discuss evidence of the association,18-20 and in 2011 the World Health Organization and the 
International Union Against Tuberculosis and Lung Disease produced a joint report on the 
association: Collaborative Framework for Care and Control of Tuberculosis and Diabetes.15 As 
part of this report they updated the recent systematic review on the association between 
diabetes and active tuberculosis that had been published in 200817 and found three additional 
papers, two located in Asia and one in North America.15 There were now four cohort studies 
showing the pooled random effects risk of TB to be 2.52 (95% CI 1.53-4.03) times higher in 
individuals with diabetes compared to those without, and ten case-control studies with odds 
of TB still ranging from 1.16-7.83 times higher among individuals with diabetes than among 
those without, but now with a random effects summary OR of 2.2 (95% CI not presented).15  
Additional systematic reviews and meta-analyses for the collaborative framework found the 
risk of death for individuals with TB and diabetes to be 1.89 (95% CI 1.52-2.36) times higher 
than for those with TB but no diabetes, and the risk of TB relapse for individuals with TB and 
diabetes to be 3.89 (95% CI 2.43-6.23) times higher than for those with TB but no diabetes.21 
The former systematic review identified 23 papers and the latter identified five papers, again 
located in North America, Asia and Europe, but additionally, two of the papers contributing to 
both reviews were located in Africa:21 one in Tunisia22 and the other in the Republic of the 
Congo.23 
Chapter 2 of this thesis presents an updated systematic review of the association between 
diabetes and active tuberculosis, but focuses specifically on studies located in Africa. 
3 Biological plausibility of association 
The underlying biological mechanisms that cause hyperglycaemia to increase the risk of TB 
incidence and worsen TB treatment outcome are currently poorly understood.17, 18, 21, 24-28 Most 
studies suggest that diabetes impairs innate immunity, including monocyte,29, 30 macrophage31, 
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32 and neutrophil function,33, 34 causing reduced chemotaxis and a decreased capacity to 
phagocytose Mycobacterium tuberculosis.27, 35 
Hyperglycaemia also has a negative effect on the adaptive immune response, which could be 
important for protection against Mycobacterium tuberculosis.27 Individuals with diabetes have 
been seen to have a hyper-reactive antigen-specific T-cell response to TB compared to the 
response seen in individuals without diabetes, which could contribute to increased lung 
pathology in individuals with diabetes.36-39  
However, few studies on this topic have been conducted in humans and so our understanding 
of these mechanisms remains poor.26, 27 
4 The effect of HIV 
Data on the association between HIV and hyperglycaemia/diabetes mellitus are conflicting. 
Rather than a direct association being a major concern, the main focus is on a possible causal 
association between antiretroviral therapy and diabetes in HIV-infected individuals, 
particularly protease inhibitors which interact with adipose tissue and decrease insulin 
secretion.40, 41 A recent 2017 systematic review and meta-analysis of published data from nine 
studies found no association between the use of protease inhibitors and the development of 
DM (hazard ratio 1.23, 95% confidence interval (CI) 0.66-2.30) but they did find an association 
between the use of protease inhibitors and metabolic syndrome (relative risk 2.11, 95% CI 
1.28-3.48).40 Metabolic syndrome is a precursor to DM and so it is possible that studies with a 
longer duration of follow-up may find an association between the use of protease inhibitors 
and DM. Another meta-analysis of data from ten observational studies exploring the 
association between antiretroviral therapy in general (not limited to protease inhibitors) and 
diabetes did find an association (pooled odds ratio 3.85, 95% CI 2.93-5.07).42 Further long term 
data is needed to better understand associations between HIV and hyperglycaemia/diabetes. 
However, this is not the case for the association between HIV and TB; HIV is well documented 
to be a major risk factor for TB.9 
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The dual effect of hyperglycaemia and HIV on the risk of developing TB disease or on its clinical 
evolution is unclear and is therefore a focus of this PhD research. It could be that the relative 
contribution of hyperglycaemia to TB risk is relatively small in HIV-positive individuals 
compared with its contribution to TB risk in HIV-negative individuals, as the greatly increased 
risk of TB among HIV-positive individuals could diminish any additional increased risk from 
hyperglycaemia. On the other hand, the effect of hyperglycaemia might be exacerbated in the 
presence of HIV infection if the contributions of each to increased TB risk are synergistic. A 
systematic review of the association between diabetes and tuberculosis incidence among 
participants with and without HIV is described in Chapter 2. 
5 The impact of diabetes control 
The differences in cell mediated immunity and cellular cytokine responses to M. tuberculosis in 
the presence of TB and DM compared to TB without DM are even more marked when there is 
poor glycaemic control.28, 30, 32, 36, 37 Effective cellular immunity is important for controlling 
growth of M. tuberculosis36, 43, 44 so we should expect to see a dose response relationship 
between hyperglycaemia and TB treatment outcome.  
A systematic review of the effect of diabetes control on tuberculosis treatment outcome 
revealed 4 relevant prior observational studies. No intervention studies to optimise glycaemic 
control in individuals with hyperglycaemia during TB treatment were identified.45  
5.1 Systematic Review Methods 
EMBASE, Global Health and PubMed databases were searched from 1910 until Jan 2013 using 
the following search strategy: 
1. Diabetes mellitus 
2. Hyperglycaemia 
3. 1 OR 2 
4. Tuberculosis 
5. Diabetes control 
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6. Glycaemic control 
7. 5 OR 6 
8. 3 AND 4 AND 7 
No restrictions on language or location were made. The titles and abstracts were reviewed for 
relevance to the study question and the full text of articles identified as potentially relevant 
were examined. The reference lists of final papers included in the review were searched to 
identify additional relevant papers. 
5.2 Systematic Review Results 
The database searches identified 75 papers after deduplication. 51 of these were excluded due 
to irrelevance after examination of the titles and abstracts. The full texts of 24 papers were 
reviewed, 4 of which were found to contain relevant data.  
The findings from the identified studies are conflicting, all but one are retrospective, none are 
located in Africa and all either exclude participants who are infected with HIV or have a very 
low prevalence of HIV in their study population. 
A retrospective cohort study in South Korea recruited 492 culture-confirmed pulmonary 
tuberculosis patients.46 Individuals infected with HIV were excluded. The study examined the 
effect of diabetes control on tuberculosis clinical and radiological features and found that 
those with uncontrolled diabetes (HbA1C ≥7.0) had more cavitary lesions (p=0.008) and higher 
rates of positive sputum smears (p<0.001) compared to those without diabetes. The authors 
also examined the rate of sputum culture conversion at 2-months. Two-month culture data 
were available for 214 participants. Of 28 participants with uncontrolled diabetes (HbA1c≥7%) 6 
had a positive culture at 2 months. Compared to non-diabetics, uncontrolled diabetes was 
found to be a significant risk factor for a positive sputum culture at 2 months  (OR 4.3, 95% CI 
1.3-14.3, p=0.017, adjusting for age, cavities and positive sputum smears before treatment 
initiation). However, this retrospective analysis was not the primary focus of the paper and had 
only a small number of participants with uncontrolled diabetes. 
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A retrospective record review in Kerala State, India, reviewed TB treatment outcome at the 
end of TB treatment for 3,116 patients.47 Diabetes status was recorded for 90%, of which, 137 
TB cases had uncontrolled diabetes (defined as a fasting blood glucose >100mg/dl or a random 
blood glucose >140mg/dl or a post-prandial blood sugar >140mg/dl). The prevalence of HIV 
among study participants was 1.5%. The association of poor glycaemic control and 
unfavourable TB treatment outcome was of borderline significance (RR 2.00, 95% CI 0.97-
4.13).  
A retrospective review of notification data and medical records for 1,473 TB cases in Taiwan 
found 276 individuals with uncontrolled diabetes (HbA1c >9%).48 The prevalence of HIV was 
0.3%. Uncontrolled diabetes was found to be associated with improved TB treatment outcome 
at the end of TB treatment compared to TB cases with well controlled and no diabetes 
(p<0.001). The effect size for this association was not reported in the study paper. 
A prospective cohort study in South Korea determined sputum culture positivity at two months 
of treatment for 661 individuals with pulmonary TB.49 Individuals with HIV infection were 
excluded. 108 participants had uncontrolled diabetes (HbA1C≥7.0%). Uncontrolled diabetes 
compared to no diabetes was found to be an independent risk factor for a positive sputum 
culture after two months of treatment (OR 2.11, 95% CI 1.03-4.31, p=0.042) and also for 
treatment failure or death (OR 4.11, 95% CI 1.23-13.78) p=0.027).  
There were 2 other papers identified that reported associations between diabetes control and 
tuberculosis incidence, with stronger associations found among those with poorer diabetes 
control. A population-based case-control study in Denmark recruited 2,950 tuberculosis cases 
and 14,274 controls without tuberculosis.50 The prevalence of HIV was 0.1% among both cases 
and controls. No association was found between TB and diabetes (defined by hospital contact 
involving diabetes or use of antidiabetic medication; adjusted OR 1.18, 95% CI 0.96–1.45). In a 
subset of participants with laboratory data for glycated haemoglobin, diabetic individuals with 
an HbA1c of <7, 7-7.9 and >8% had odds ratios for active tuberculosis of 0.91 (95% CI 0.51-
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1.63), 1.05 (95% CI 0.41-2.66), and 1.19 (95% CI 0.61-2.30), respectively, compared to 
individuals without diabetes. This is suggestive of a linear trend, though no statistical 
significance is seen. In a cohort study in Hong Kong of 42,116 participants, higher risks of 
active, culture-confirmed, and pulmonary tuberculosis were observed among those with 
diabetes with a baseline HbA1c ≥7% compared to those with diabetes with a baseline HbA1c 
<7%.51 Hazard ratios for these were 3.11 (95% CI 1.63-5.92) for active TB, 3.08 (95% CI 1.44-
6.57) for culture-confirmed TB and 3.63 (95% CI 1.79-7.33) for pulmonary TB. The prevalence 
of HIV was not reported. 
6 Causal association or reverse causality? 
When exploring these associations it is important to be certain that individuals diagnosed with 
diabetes truly have diabetes and do not instead have stress hyperglycaemia secondary to 
infection with tuberculosis. Diabetes can cause immune impairment that could increase 
tuberculosis risk (causal association). Physiological stress from tuberculosis infection could 
cause hyperglycaemia (reverse causality). Hyperglycaemia among newly-diagnosed 
tuberculosis cases could therefore be due to DM or stress-induced hyperglycaemia. This is an 
important distinction because individuals with tuberculosis are commonly tested for diabetes 
at the time of their tuberculosis diagnosis, which is the same time they are most likely to have 
stress-induced hyperglycaemia secondary to tuberculosis, before commencing treatment for 
tuberculosis. One would expect hyperglycaemia due to diabetes to be persistent, remaining 
after treatment and resolution of tuberculosis. Conversely, one would expect hyperglycaemia 
that is stress-induced to be transient, and return to normoglycaemia once the acute infection 
or disease has been treated and has resolved. Most prior studies have failed to distinguish 
between these two causes of hyperglycaemia52 and therefore risk falsely elevating any 
association between DM and TB. The focus of this thesis is therefore on hyperglycaemia rather 
than diabetes, so as to explicitly not presume a diagnosis of diabetes before confirming this. 
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It may be that hyperglycaemia regardless of cause contributes to worsening tuberculosis 
outcomes, but the management of hyperglycaemia both immediately and in the long term 
may differ depending on the underlying cause. Differentiation of the cause of hyperglycaemia 
among newly-diagnosed tuberculosis cases is therefore important not only for increasing 
biomedical understanding of these associations but also for the management of individuals 
and for population public health planning, particularly in the context of rising diabetes 
prevalence. A systematic review to identify prior studies that differentiate between persistent 
and transient hyperglycaemia has revealed 6 prior studies with relevant data. 
6.1 Systematic Review Methods 
EMBASE, Global Health and PubMed databases were searched from 1910 until Jan 2013 using 
the following search strategy: 
1. Hyperglycaemia 
2. Tuberculosis 
3. 1 AND 2 
No restrictions on language or location were made. The titles and abstracts were reviewed for 
relevance to the study question and the full text of articles identified as potentially relevant 
were examined. The reference lists of final papers included in the review were searched to 
identify additional relevant papers. 
6.2 Systematic Review Results 
The searches identified 96 papers after deduplication. Of these, 65 were excluded due to 
irrelevance after examination of the titles and abstracts. The full texts of 31 papers were 
reviewed, along with the reference lists of relevant papers, leading to a total of 6 papers 
identified to contain relevant data. 
A high proportion of transient hyperglycaemia in TB patients was found in all identified 
studies. 
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A study in Turkey performed glucose tolerance tests in 30 individuals with active pulmonary TB 
at the time of TB diagnosis.53 Impaired glucose tolerance was found in four individuals, but this 
returned to normal in three of these individuals when tested two months later, after receiving 
two months of antitubercular therapy. 
In 1990 Oluboyo performed sequential OGTTs on 54 Nigerian patients with active pulmonary 
TB. Only one of eight patients with initial impaired glucose tolerance remained with persisting 
glucose intolerance after 3 months of TB treatment.54  
An observational study among 106 patients with pulmonary TB attending a clinic in Pakistan 
found glucose intolerance (impaired glucose tolerance or diabetes mellitus) in 49% of patients 
at the time of TB diagnosis based on findings from standardised oral glucose tolerance tests.55 
After antitubercular therapy and sputum conversion the oral glucose tolerance test was 
repeated in 23 participants with initial glucose intolerance. Of these, 57% had reverted to 
normal glucose tolerance. 
A case-control study in Indonesia recruiting newly-diagnosed pulmonary tuberculosis patients 
and matched neighbourhood controls found that 13.2% (60 of 454) of tuberculosis patients 
were hyperglycaemic at the time of tuberculosis diagnosis.56 Following one month of anti-
tuberculosis treatment, the hyperglycaemia reverted in 3.7% of these hyperglycaemic cases. 
A prospective cohort study among 317 hospitalised new TB patients in Iran measured glycated 
haemoglobin in 158 participants at baseline and three months later.57 There were 54% of 
participants who had elevated glycated haemoglobin (defined as ≥6.5%) at baseline, but only 
24% has persistent hyperglycaemia 3 months later. 
In a more recent case-control study in Tanzania, 539 tuberculosis cases underwent sequential 
DM screening tests.58 At the time of active TB diagnosis, 4.5%, 6.8% and 9.3% had 
hyperglycaemia measured by FBG, oral glucose tolerance test (OGTT) and HbA1c respectively. 
After 5 months of receiving TB treatment and exclusion of patients with previously known DM, 
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75%, 64% and 71% of these initially hyperglycaemic participants were no longer 
hyperglycaemic on follow-up FBG, OGTT and HbA1c tests respectively.  
7 Choice of study location: Lusaka 
The number of adults with diabetes in SSA is predicted to rise from 14.2 million in 2015 to 34.2 
million in 2040.10-12, 59, 60 To appropriately respond to this now and prepare for a future higher 
prevalence of diabetes, a deeper understanding of associations between tuberculosis and 
hyperglycaemia in the context of SSA is needed. 
Lusaka, the capital of Zambia, which has an estimated TB incidence of 506 per 100,000 
pop/year,61 an adult hyperglycaemia prevalence of 3.2% (Chapter 3), and an HIV prevalence of 
15.2%,62 is well suited for studies of associations between TB, hyperglycaemia and HIV.  
A recently conducted population prevalence survey in Lusaka gives the opportunity to obtain 
background data on hyperglycaemia and tuberculosis prevalence in this location as well as to 
gain a deeper understanding of diabetes prevalence and risk factors. The Zambia South Africa 
TB and HIV Reduction (ZAMSTAR) study was a 2 x 2 factorial cluster randomised trial to 
evaluate the impact of two complex interventions on the prevalence of TB.63-65 The study took 
place in 24 communities: 16 communities from 5 provinces in Zambia and 8 communities from 
the Western Cape province of South Africa. The estimated total population in the study areas 
was 962,655, with an average population per community of 40,110. A cross-sectional 
prevalence survey was conducted between January and December 2010 in all study 
communities to measure the trial’s primary endpoint of prevalent TB. Along with TB and HIV 
data, the prevalence survey collected data on participants’ random blood glucose 
concentration, anthropometry, demographics, socioeconomic position and other risk factors 
for TB. The results of these analyses relating to hyperglycaemia and its association with TB are 
detailed in chapters 3 and 4 of this thesis. 
One other prior study has investigated the prevalence of diabetes mellitus in Zambia. A 
population-based cross-sectional study in 2008 used a modified World Health Organization 
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STEPwise approach to NCD surveillance in Lusaka District and found a prevalence of impaired 
glucose (fasting blood glucose concentration 5.51-8.49 mmol/L) of 1.3% and a prevalence of 
diabetes (fasting blood glucose concentration ≥8.5 mmol/L) of 2.7% among 1,800 randomly 
selected adults aged ≥25 years.66 The same study found a prevalence of obesity (body mass 
index ≥30 kg/m2) of 14.2%,67 and a prevalence of hypertension (average of three successive 
blood pressure readings >140/90 mmHg) of 34.8%68 among 1,928 participants aged ≥25 years. 
No other published population-based studies have explored the prevalence of diabetes or its 
major risk factors in Lusaka or Zambia. Prevalence estimates remain largely based on 
extrapolated data from surrounding similar countries.69 A greater focus on diabetes, 
hyperglycaemia and its associations in this setting is needed. 
8 Summary 
The concept that hyperglycaemia affects TB control is not new. Prior studies suggest that 
individuals with diabetes mellitus have a two-to-three times increased risk of developing active 
TB disease than individuals without diabetes. However, few studies contributing to this body of 
evidence have been based in Africa. The association probably results from pathophysiological 
changes that are common to all humans so there is no reason to suspect that the association 
would be different in African populations compared to the rest of the world, however, the 
context of the association in sub-Saharan Africa differs, primarily in two ways.  
Firstly, the prevalence of HIV in Africa is more than five times higher than in any other world 
region.62 It is inconclusive from current literature whether or not HIV modifies the association 
between diabetes and TB.  
Secondly, the prevalence of undiagnosed diabetes is high (≥40%)12 and those who are 
diagnosed have a high prevalence of poorly controlled diabetes (73% in a recent study in 
Cameroon).10, 12 Whilst it seems clear from existing literature that individuals with TB and 
diabetes have an increased risk of death and TB relapse from TB compared to individuals with 
TB but no diabetes,21 it is currently not clear whether or not individuals with higher levels of 
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hyperglycaemia and poor diabetes control have even worse TB treatment outcomes than 
individuals with less severe hyperglycaemia and good glycaemic control.  
This applies to individuals with persistent hyperglycaemia due to diabetes mellitus and also to 
those with transient stress hyperglycaemia due to active TB disease. It is often difficult to 
distinguish between these two causes of hyperglycaemia at the time of active TB disease and 
so we have chosen to focus on hyperglycaemia in general rather than on diabetes mellitus 
alone.  
This thesis therefore explores associations between hyperglycaemia, TB and HIV in Lusaka, 
Zambia and differentiates between diabetes mellitus and transient stress hyperglycaemia 
which resolves after treatment of acute TB disease. 
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Abstract 
Background: An association between diabetes mellitus and active tuberculosis has been 
established, though few studies contributing to prior systematic reviews on the topic originate 
from Africa. Two recent longitudinal studies have suggested that the association may be 
different among African populations. A possible explanation for this is that other risk factors 
for tuberculosis could act as effect-modifiers on the association. The most notable difference 
in the context of the diabetes-tuberculosis association in Africa compared to the rest of the 
world is the higher prevalence of HIV. Therefore, we aimed to determine current evidence for 
firstly, the association between diabetes and active tuberculosis in Africa and secondly, how 
HIV modifies, or not, any association between diabetes and active tuberculosis. 
Methods: We conducted a systematic review by searching the EMBASE, Global Health and 
Medline databases. Studies were eligible for inclusion if they explored the association between 
diabetes mellitus prevalence and active tuberculosis incidence or prevalence, used a 
comparison group, were conducted in an African population and adjusted the analysis for at 
least age. Study characteristics were compared and risk of bias was assessed. The range of 
effect estimates was determined for the primary association and for effect modification by 
HIV. 
Results: Three eligible studies were identified: two investigated the primary association and 
two investigated HIV as a potential effect modifier. All studies were case-control studies, 
including a combined total of 1,958 tuberculosis cases and 2,111 non-tuberculosis controls. 
Diabetes diagnostic methods and analysis strategies varied between studies. Individual study 
adjusted odds ratios of active tuberculosis for the effect of diabetes mellitus (unstratified) 
ranged from 0.88 (95% CI 0.17-4.58) to 10.7 (95% CI 4.5-26.0). Individual study p-values for HIV 
interaction ranged from 0.01 to 0.83. Quantitative synthesis of individual study data was not 
performed due to heterogeneity between studies. 
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Conclusions: Few data currently exist on the association between diabetes and active 
tuberculosis in Africa, or on the effect of HIV on this association. Existing data is disparate. 
More regional research is needed to guide policy and practice on the care and control of 
tuberculosis and diabetes in Africa. 
KEYWORDS: Diabetes mellitus, tuberculosis, HIV, Africa, systematic review 
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Background 
An association between diabetes mellitus (DM) and active tuberculosis (TB) has been 
established: systematic reviews and meta-analyses of studies exploring the relationship 
suggest that the incidence of active TB is two to three times higher in those with DM 
compared to those without DM.1-3 However, the data contributing to this body of evidence 
originate almost entirely from countries outside of Africa.1-3 There is longitudinal evidence that 
suggests this association may differ in African populations. A Danish study evaluated the effect 
of ethnicity and DM on the risk of incident TB over a follow-up period of 15 years through 
linking nationwide DM and TB registers at case level.4 They found a TB rate ratio of 1.9 in 
individuals with DM compared to individuals without DM, regardless of country of birth, with 
the exception of African-born individuals who had a rate ratio of 0.5. An ecological longitudinal 
study covering the years 2000 and 2012 studied the global relationship between the 
prevalence of DM and the incidence of TB to evaluate their coexistence worldwide.5 Only 
countries with a high DM prevalence (>7.6%) showed a significant positive association 
between DM prevalence and TB incidence based on linear regression time trend analysis 
(r=0.17, p=0.013). A non-significant inverse relationship was found for the African region (r=-
0.27).  
Whilst there is no reason to suspect the underlying pathophysiology of the association should 
differ between ethnographic populations, the context of the association in Africa could be 
different from the rest of the world and consequently lead to a different overall association. 
Other risk factors for tuberculosis could act as effect-modifiers on the association. The most 
notable difference relating to tuberculosis risk factors between Africa and elsewhere is the 
high prevalence of HIV in Africa, which is more than five times higher than in any other world 
region.6  
The dual effect of diabetes and HIV on the risk of developing TB disease or on its clinical 
evolution is unclear. It could be that the effect of hyperglycaemia on TB risk is relatively small 
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in HIV-positive individuals compared with its effect in HIV-negative individuals, as the greatly 
increased risk of TB among HIV-positive individuals could diminish any additional increased risk 
from hyperglycaemia. On the other hand, the effect of hyperglycaemia might be exacerbated 
in the presence of HIV infection if the contributions of each to increased TB risk are synergistic. 
The prevalence and incidence of tuberculosis remain high in many parts of Africa.7 The number 
of adults with diabetes in Africa is predicted to rise from 14.2 million in 2015 (uncertainty 
interval 9.5-29.4 million) to 34.2 million in 2040 (uncertainty interval 23.7-67.7 million).8-11 To 
appropriately respond to this now and prepare for a future higher prevalence of diabetes, a 
deeper understanding of associations between diabetes and tuberculosis in the context of 
Africa is needed. Therefore, we aimed to undertake systematic reviews to determine current 
evidence for firstly, the association between the prevalence of diabetes and the incidence or 
prevalence of active tuberculosis in Africa and secondly, how HIV modifies, or not, any 
association between the prevalence of diabetes and the incidence or prevalence of 
tuberculosis. 
Methods 
The EMBASE, Global Health and PubMed databases were searched. Studies that investigated 
the relationship between the prevalence of diabetes and the incidence or prevalence of active 
tuberculosis, included a comparison group, were conducted in an African population and 
adjusted for age were eligible for inclusion. As age has the potential to be a major confounder 
of the association, studies that did not adjust for at least age in the analysis, or present data 
that enabled this analysis, were not eligible. 
Reference lists of identified eligible papers were additionally hand-searched to identify further 
potentially relevant studies. 
The Embase Classic+Embase database was searched from 1947 until June 2016, the Global 
Health database was searched from 1910 until June 2016 and the Ovid MEDLINE® database 
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was searched from 1946 until June 2016, including Epub Ahead of Print, In-Process, Other Non-
Indexed Citations and Ovid MEDLINE® Daily. The search terms and strategies used were 
deliberately broad to increase the likelihood of all relevant studies being identified. Searches 
were restricted to human studies. No restriction on language was made. The following MESH 
and text search terms were used:  
1. Diabetes mellitus.mp. [mp=title, abstract, heading word, original title, keyword] 
2. Hyperglycaemia.mp. [mp=title, abstract, heading word, original title, keyword] 
3. 1 OR 2 
4. Tuberculosis.mp. [mp=title, abstract, heading word, original title, keyword] 
5. Africa.mp. [mp=title, abstract, heading word, original title, keyword] 
6. 3 AND 4 AND 5 
Deduplication of papers identified by the searches was performed using the Ovid database 
platform. The titles and abstracts were screened for eligibility and the full texts of articles 
identified as potentially relevant were examined. All studies meeting the eligibility criteria 
above were included for exploration of the first aim, to determine the association between the 
prevalence of diabetes and the incidence or prevalence of active tuberculosis in Africa. Studies 
which met the eligibility criteria and presented the primary age-adjusted association stratified 
by HIV were also included in assessment of the second aim, to determine how HIV modifies, or 
not, any association between the prevalence of diabetes and the incidence or prevalence of 
tuberculosis.  
It is possible that studies relevant to the second aim could take place in non-African 
populations, and so to ensure all relevant papers were identified a second search was 
performed using the same databases and the same search strategy, except no restriction on 
location was made and the following MESH and text search terms were used: Diabetes mellitus 
OR hyperglycaemia AND tuberculosis AND HIV. Studies were eligible only if they investigated 
the primary association between DM prevalence and TB incidence/prevalence and stratified 
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the analysis by HIV. Studies that investigated the prevalence of diabetes among TB patients 
stratified by HIV but did not include a non-TB population were not eligible for inclusion 
because it is not possible to assess for effect modification without data from a control 
population for the primary association. 
Individual study data were extracted from reports using data collection tables, to identify 
individual study characteristics, risk of bias and results. When necessary study authors were 
contacted for clarification of study data. Study characteristics sought were period of data 
collection, study design, study setting, study size and HIV prevalence among study participants. 
The risk of bias for individual studies was assessed by ascertaining study definitions for the 
exposure variable, outcome variable and comparison group and determining the variables 
adjusted for in the analysis. Qualitative description was used to synthesise the risk of bias 
results. The principal summary measures sought were the odds ratios or risk ratios for the 
association between DM and TB, overall and stratified by HIV. The range of effect estimates 
was determined for the primary association and stratified by HIV. The range of p-values for 
interaction was also determined. 
Results 
The database searches for studies investigating the primary association in Africa identified 314 
potential papers after deduplication (Figure 1). A further 3 potentially relevant papers were 
identified from reference lists. Therefore, 317 titles and abstracts were screened, of which 254 
were excluded due to failure to meet the eligibility criteria. We examined 63 full texts, of 
which 3 studies were found to meet the eligibility criteria for inclusion. All 3 papers 
investigated the association between DM prevalence and TB incidence in an African 
population,12-14 though only 2 reported the overall adjusted effect estimate.13, 14 Of the 3 
identified papers, 2 studies went on to also investigate HIV as an effect modifier of the 
association.12, 14 No papers investigating the association between DM prevalence and TB 
prevalence were identified. The additional database searches for any further papers 
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investigating the primary association plus HIV as an effect modifier identified 800 potentially 
relevant papers after deduplication, but no further eligible papers were found after screening 
and full text assessment for eligibility.  
The database searches identified 8 review papers that had relevance to associations between 
TB, diabetes and HIV,15-22 though none reported current evidence for the association between 
DM and TB in Africa and none explored how HIV modifies or not this association. Rather, they 
focused on related factors including current understanding of the underlying mechanisms of 
diabetes-related and HIV-related increased susceptibility to TB,15-17 the importance of and 
challenges faced with TB and diabetes co-management and control,16, 18-20 current research 
gaps and prioritised areas for research relating to TB and diabetes,21 and evidence of 
association between TB and diabetes from elsewhere in the world.16, 17, 22 None of the review 
papers identified additional primary research papers that had not already been identified 
through the database searches. 
Individual study characteristics are shown in Table 1. All 3 studies used a case control design, 
investigating a combined total of 1,958 tuberculosis cases and 2,111 non-tuberculosis controls. 
The prevalence of HIV ranged from 23% to 43% among cases and from 10% to 14% among 
controls. Definitions of DM and TB varied between each study. All studies tested for DM in TB 
cases around the time of TB treatment initiation or in newly-diagnosed TB patients. Boillat-
Blanco et al additionally undertook repeat testing for diabetes 5 months after TB treatment 
initiation.14 The analysis strategy varied between each study. All adjusted for age and sex. 
Faurholt-Jepsen et al presented the results for two separate analysis strategies, one including 
adjustment for the acute phase reactant alpha-1-acid glycoprotein and one without. 
Table 2 presents the individual study results based on the diabetes tests performed in newly-
diagnosed TB cases around the time of enrolment. Adjusted odds ratios of TB for the effect of 
DM range from 0.88 (95% CI 0.17-4.58) to 10.7 (95% CI 4.5-26.0). Figure 2 shows this 
graphically, along with odds ratios of TB for the effect of DM measured at follow-up. Boillat-
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Blanco et al found the prevalence of DM in cases reverted to the background prevalence of 
DM in controls after treatment for tuberculosis. Adjusted odds ratios of TB for the effect of DM 
correspondingly reverted to the null. 
The individual study effects of HIV on the association between DM and TB were different 
depending on the definition of diabetes and the factors adjusted for in the analysis (Table 2). 
Boillat-Blanco et al found no evidence for effect modification by HIV other than when diabetes 
was determined by HbA1c and measured at the time of enrolment, in which case individuals 
who were uninfected with HIV had a stronger association between DM and TB than individuals 
infected with HIV (p=0.048). Faurholt-Jepsen et al also found evidence for a stronger 
association among HIV uninfected individuals but only when adjusting for alpha-1-acid 
glycoprotein (p=0.01). 
Quantitative synthesis of individual study data was not performed due to heterogeneity 
between studies. 
Risk of bias 
The major risk of bias in all papers included in this systematic review was a lack of study 
power. Only one of the papers (Faurholt-Jepsen et al) had investigation of interaction by HIV as 
a primary study aim but none were powered for investigating effect modification. There is no 
mention in any of the papers that sample size calculations were performed for effect 
modification. Rather, the sample sizes and primary study aims suggest that the sample size 
calculations were performed for investigation of the primary association between TB and 
diabetes. Other potential sources of bias were present for each study. Faurholt-Jepsen’s study 
is difficult to interpret fully because they have omitted to report the p-value for effect 
modification by HIV for the main model adjusting for age, sex and socio-demographic factors, 
and instead have reported the p-value for a second model which additionally adjusts for an 
acute phase reactant. This is essentially a measure of acute physiologic stress. There is no clear 
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explanation for why they have adjusted for this or focused on this model in the results. It the 
acute phase reactant is a marker of stress hyperglycaemia it is possible that they have adjusted 
for a factor on the causal pathway of the association between TB and diabetes rather than a 
confounding factor.  Selection bias is a potential source of bias for Haraldsdottir’s study as 
although they recruited community controls they only included individuals who were at home 
at the time of the afternoon visit, and therefore they were more likely to recruit individuals 
with lower socioeconomic status and less likely to recruit individuals who were at work rather 
than at home. As socioeconomic status is known to be associated with both TB and diabetes 
this could have introduced bias. Boillat-Blanco’s study used local clinical guidelines and smear 
results to diagnose TB rather than culture or molecular methods. Whilst this reflects the 
situation in practice, it may have led to misclassification of the primary outcome of TB. 
Discussion 
This systematic review identified only three eligible studies conducted in African populations. 
Only two of these studies presented data on the adjusted association between DM and TB. 
One found no evidence of association and the other found evidence of a positive association 
only when diabetes was measured in cases around the time of TB treatment initiation. There 
was no evidence of association when DM was measured in TB cases after receiving TB 
treatment, suggesting that the initial association seen was due to an increase in stress-induced 
hyperglycaemia among newly-diagnosed TB cases rather than due to true diabetes. 
Only two studies stratified their analysis by HIV. The results depended on the analysis strategy 
and method of DM diagnosis used. There was little evidence of association among either HIV 
infected or uninfected individuals when DM was measured in cases after TB treatment. 
The results seen in this systematic review are in keeping with the idea that the association 
between DM and active TB may be different among African populations, but existing data is 
currently too sparse to be conclusive. It remains possible that HIV could modify the 
association, but again, there is currently insufficient data to be certain. 
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A limitation at the individual study level was the different criteria used for diabetes diagnosis 
in each study, both for the methods and the glycaemic cut-offs used to determine diabetes. 
This made comparison between studies problematic. Conformity with World Health 
Organization diagnostic criteria and presenting separate rather than combined analyses for 
each method of diagnosis used would mitigate this limitation. 
The results of this systematic review, and any future repeat review, have relevance to health 
care policy makers, academics and practitioners in Africa. The global collaborative framework 
for the care and control of tuberculosis and diabetes produced in 2011 by the World Health 
Organization and the International Union Against Tuberculosis and Lung Disease had few 
contributory studies from Africa.23 In 2016, this systematic review suggests there remain few 
studies based in African populations that can guide local and regional policy and practice on 
the care and control of TB and diabetes. It remains possible that the association between 
diabetes and active TB could be different in African populations compared to elsewhere in the 
world, and it remains possible that HIV could modify the association. Given the continued high 
incidence of tuberculosis in much of Africa and the predicted rising prevalence of diabetes 
throughout Africa,7, 8 further evidence on the nature and magnitude of their association in this 
setting would be valuable. 
Conclusions 
Few data currently exist on the association between diabetes and active tuberculosis in Africa, 
or on the effect of HIV on this association. Exploration of diabetes diagnosed both at the time 
of TB diagnosis and after TB treatment is valuable to distinguish between diabetes and stress-
induced hyperglycaemia secondary to infection with TB. More regional research is needed to 
guide policy and practice on the care and control of tuberculosis and diabetes in Africa. 
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Figure 1: Flow diagram of study selection for papers investigating the association between 
diabetes mellitus prevalence and tuberculosis incidence or prevalence in an African 
population 
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Figure 2: Forest plot for the adjusted odds ratios of active tuberculosis comparing those with 
diabetes mellitus to those without 
 
DM = diabetes mellitus; FCG = fasting capillary blood glucose; OGTT = oral glucose tolerance test; HbA1c = glycated 
haemoglobin; *DM in cases measured around the time of TB treatment initiation; **DM in cases measured a 
median of 5 months after TB treatment initiation 
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Chapter 3: Secondary data analysis paper 1: Diabetes mellitus in 
Zambia and the Western Cape province of South Africa: 
prevalence, risk factors, diagnosis and management 
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Abstract 
Background: Systematic reviews suggest that the incidence of diagnosed tuberculosis 
is two- to- three times higher in those with diabetes mellitus than in those without. Few 
studies have previously reported the association between diabetes or hyperglycaemia 
and the prevalence of active tuberculosis and none in a population-based study with 
microbiologically-defined tuberculosis. Most have instead concentrated on cases of 
diagnosed tuberculosis that present to health facilities. We had the opportunity to 
measure glycaemia alongside prevalent tuberculosis. A focus on prevalent tuberculosis 
enables estimation of the contribution of hyperglycaemia to the population prevalence 
of tuberculosis. 
Methods: A population-based cross-sectional study was conducted among adults in 24 
communities from Zambia and the Western Cape (WC) province of South Africa. 
Prevalent tuberculosis was defined by the presence of a respiratory sample that was 
culture positive for M. tuberculosis. Glycaemia was measured by random blood glucose 
(RBG) concentration. Association with prevalent tuberculosis was explored across the 
whole spectrum of glycaemia. 
Results: Among 27,800 Zambian and 11,367 Western Cape participants, 4,431 
(15.9%) and 1,835 (16.1%) respectively had a RBG concentration ≥7.0mmol/L, and 
405 (1.5%) and 322 (2.8%) respectively had a RBG concentration ≥11.1mmol/L. In 
Zambia, the prevalence of tuberculosis was 0·5% (142/27,395) among individuals with 
RBG concentration <11.1mmol/L and also ≥11.1mmol/L (2/405); corresponding figures 
for WC were 2·5% (272/11,045) and 4·0% (13/322). There was evidence for a positive 
linear association between hyperglycaemia and pulmonary prevalent tuberculosis. 
Taking a RBG cut-off 11.1mmol/L, a combined analysis of data from Zambian and WC 
communities found evidence of association between hyperglycaemia and TB (adjusted 
odds ratio=2·15, 95%CI [1·17-3·94]). The population attributable fraction of prevalent 
72 
 
tuberculosis to hyperglycaemia for Zambia and WC combined was 0.99% (95%CI 
0·12%-1.85%) for hyperglycaemia with a RBG cut-off of 11.1mmol/L. 
Conclusions: This study demonstrates an association between hyperglycaemia and 
prevalent tuberculosis in a large population-based survey in Zambia and Western 
Cape. However, assuming causation, this association contributes little to the 
prevalence of TB in these populations. 
KEYWORDS: Zambia; South Africa; logistic regression 
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BACKGROUND 
The number of adults with diabetes mellitus globally is predicted to rise from 382 million 
in 2013 to 592 million in 2035.1-6 Of those in the world who currently have diabetes, four 
out of five live in a low or middle income country.6 The burden of the anticipated rise in 
diabetes prevalence will fall largely to these low and middle income countries, the 
same countries that have some of the highest burdens of tuberculosis (TB) 
worldwide.4,7  
Associations between diabetes and tuberculosis are increasingly recognised: 
systematic reviews and meta-analyses suggest that the incidence of active diagnosed 
tuberculosis is two- to- three times higher in those with diabetes compared to those 
without diabetes;8-10 that diabetes increases the risk of death from diagnosed 
tuberculosis11, and that diabetes may increase the risk of tuberculosis relapse.9, 11 
Studies from Africa have shown even stronger associations between diabetes and 
active diagnosed TB; a four-fold increase in diabetes prevalence was seen in TB 
patients in Dar es Salaam compared to the general population;12 an odds ratio for TB of 
8·33 was seen in the Congo comparing those with diabetes to those without diabetes.13 
As the prevalence of diabetes rises in locations with a high burden of tuberculosis, a 
deeper understanding of these associations is increasingly important.  
We had the opportunity to measure glycaemia alongside tuberculosis in a population-
based cross-sectional survey, which took place as part of the ZAMSTAR (Zambia 
South Africa TB and HIV Reduction Study) trial.14-16 This trial was a 2 x 2 factorial 
community randomised trial to evaluate the impact of two complex interventions on the 
prevalence of TB in high HIV prevalence settings in Zambia and South Africa. The 
primary outcome for the study was the prevalence of tuberculosis after three years of 
intervention, measured through a cross-sectional survey of a random sample of adults 
from each community. We took this opportunity to also explore the association between 
hyperglycaemia and prevalent TB. 
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Both Zambia and South Africa have national TB control programmes, with a structured 
approach to TB diagnosis, management and control. Sputum smear microscopy is 
used for the diagnosis of pulmonary TB in Zambia. Few health care centres have 
access to culture or molecular tests. In South Africa Xpert MTB/RIF was introduced in 
2011 for the diagnosis of pulmonary TB, though interruption to the supply of cartridges 
has been a challenge. Supply of TB medication rarely suffers interruption and is 
provided free of charge to patients in both countries. The situation for diabetes 
management is less favourable. In Zambia, point-of-care glucometers are most 
commonly used for diagnosis, though frequently glucometer strips are unavailable. 
Metformin and glibenclamide are widely available but access to alternative oral 
hypoglycaemics can be challenging. Insulin is available but can be difficult to access in 
remote areas. Storage of insulin is frequently problematic for patients due to lack of 
access to refrigeration. Unlike for TB, diabetes medication is not provided to patients 
for free. 
Few studies have previously reported the association between diabetes or 
hyperglycaemia and prevalent tuberculosis in the general population, and to our 
knowledge none in a population-based study with microbiologically-defined 
tuberculosis. Most have concentrated on cases of tuberculosis that present to, and are 
diagnosed, at health facilities. Two historical studies did measure the prevalence of 
tuberculosis in the general population; one in Philadelphia, USA in 1946,17 the other in 
Kristianstad, Sweden in 1954.18 Both identified pulmonary TB by chest radiograph, and 
identified diabetes through referrals from clinics and through medical records 
respectively. Rather than being based in a general population, other studies that have 
focused on tuberculosis prevalence have investigated the prevalence among patients 
with diabetes in a clinic setting or identified through medical records, using either no 
comparison group or clinic patients without diabetes as a comparison group.10, 19, 20 
Exploration of the association of hyperglycaemia with prevalent tuberculosis in a 
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population-based study allows for estimation of the contribution of hyperglycaemia to 
the population prevalence of tuberculosis. 
The aims of this study are therefore to determine the association between 
hyperglycaemia and prevalent tuberculosis and to estimate the population attributable 
fractions of prevalent tuberculosis to hyperglycaemia, assuming causation, within our 
study communities in Zambia and the Western Cape region of South Africa. 
METHODS 
This population-based cross-sectional study was nested within a 2 x 2 factorial cluster-
randomised trial (the ZAMSTAR study14-16) and undertaken between January and 
December 2010 in 24 study communities: 16 from 5 provinces in Zambia and 8 from 
the Western Cape province of South Africa. Within each community, a two-stage 
cluster sampling design was used to recruit participants. Exclusion criteria were age 
<18 years, inability to give informed consent due to disability/incapacitation, refusal to 
submit a respiratory sample and any persons living in institutional settings. 
Each participant was required to give written informed consent. Individuals and 
household heads were interviewed in their homes using structured questionnaires. 
Each participant was requested to produce a spot respiratory sample for tuberculosis 
culture. Finger prick capillary blood was taken for HIV testing and random blood 
glucose (RBG) measurement, with pre- and post-test counselling for HIV tests. RBG 
concentration was measured using an Optium Xceed point-of-care glucometer. All 
individuals identified to have abnormal blood glucose or to be HIV positive were 
referred to existing local health facilities for appropriate management.  
Data were electronically entered directly onto personal digital assistants by field staff at 
the time of data collection, using pre-programmed questionnaires and result sheets. All 
information was downloaded daily into a SQL (structured query language) database 
and later exported into Stata.  
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All procedures for sputum sample collection and culture were identical in all study sites. 
Research staff in all sites were trained to instruct participants on adequate 
expectoration to achieve a lower rather than upper airways sample. Samples were 
collected daily from field sites and delivered to the laboratory in each study community. 
A standard liquid culture technique was used to isolate Mycobacterium tuberculosis 
(MGIT, Becton Dickinson). Growth detected by culture was identified using an 
immunochromatographic assay (Capilia TB), and all Capilia TB assay positive cultures 
were confirmed by 16S ribosomal RNA sequencing. Detailed methods are described by 
Ayles et al. in the final report of the ZAMSTAR trial.16 
The Optium Xceed glucometer uses a whole blood capillary sample but is calibrated to 
report the plasma equivalent result. The results presented here are therefore the 
plasma equivalent glucose concentrations. This device was chosen because of its 
documented accuracy in multiple independent studies combined with its availability in 
Zambia and South Africa. It was found to be one of the most superior glucometers in all 
published accuracy studies, with between 84% and 100% of the results from the finger 
prick capillary specimen being within the recommended limits compared to reference 
plasma estimation on laboratory analysers.21-27 When inaccuracy was seen, this was 
mostly for low rather than high glucose concentrations.24, 25, 27 All research staff were 
trained on the use of this particular glucometer and were required to undergo 
proficiency testing. Standardised control solution was used for performance checks on 
test strips and meters. 
Ethics approval was granted from the London School of Hygiene and Tropical Medicine 
Ethics Committee, the University of Stellenbosch Human Research Ethics Committee 
and the University of Zambia Biomedical Research Ethics Committee. 
Definitions 
 Hyperglycaemia, the exposure of interest for this study, is initially examined with 
RBG concentration as an ordered categorical variable. We then use sequential 
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RBG cut-offs – 7.0mmol/L, 7.8mmol/L, 9.0mmol/L and 11.1mmol/L – to explore 
increasing levels of hyperglycaemia. We based our cut-off levels on the current 
World Health Organisation guidelines for diabetes diagnosis and monitoring,28 
though this was only to allow for exploration of increasing levels of glycaemia 
and not intended to be indicative of diabetes diagnoses.  
 Prevalent pulmonary tuberculosis, the outcome of interest for this study, is 
defined by the presence of a respiratory sample that is culture positive for 
Mycobacterium tuberculosis. 
 HIV status is defined by a combination of blood sampling plus self-report for 
those with missing biological data. 
Analysis strategy 
Principal components analysis was used to create a measure of household socio-
economic position separately for each country. Unadjusted and adjusted odds ratios of 
the association between hyperglycaemia and prevalent tuberculosis were estimated 
using logistic regression analysis, accounting for within-cluster correlation resulting 
from the sampling design. Analyses were performed separately for Zambian and South 
African data due to heterogeneity between the two distinct locations. This enabled us to 
control for confounding differently for each location, which was necessary because of 
the big differences between the two settings. Fixed-effects meta-analysis of adjusted 
odds ratios from each country was then performed, with weights according to the 
inverse variance method to give overall odds ratios of the association between 
hyperglycaemia and prevalent tuberculosis. Population attributable fractions (PAFs) of 
prevalent tuberculosis to hyperglycaemia and HIV were calculated separately for each 
country and for combined estimates. These were calculated using the formula 𝑃𝐴𝐹 =
∑ 𝑝𝑘′(𝜃𝑘 − 1)/𝜃𝑘 where p’ is the proportion of cases exposed in the study population at 
exposure level k and θ is the adjusted odds ratio. Given that θ and p’ were estimated 
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from the same data, the 95% confidence intervals could be calculated using the 
following error factor for (1-PAF): 
𝐸𝑟𝑟𝑜𝑟 𝑓𝑎𝑐𝑡𝑜𝑟 = exp {1.96 × √
𝑛1𝑝′
2𝑉 + 2𝑝′(𝜃 − 1) + 𝑝′(1 − 𝑝′)(𝜃 − 1)2
𝑛1[𝜃(1 − 𝑝′) + 𝑝′]2
} 
where n1 is the total number of cases observed and V the variance of the adjusted log 
odds ratio (the standard error of the log odds ratio squared). Evidence for effect 
modification by gender and HIV was explored. All data analyses were performed using 
Stata 13. 
RESULTS 
The cross-sectional survey enrolled 57,809 (70·8% of eligible) participants from 31,300 
(88·6% of eligible) households in Zambia and 32,792 (77·7% of eligible) participants 
from 17,095 (85·3% of eligible) households in Western Cape (Figure 1). Evaluable 
sputum samples and complete RBG results were obtained for 27,800 (48·1% of 
enrolled) participants in Zambia and 11,367 (34·7% of enrolled) participants in Western 
Cape. Data from these participants were analysed. Comparison of individuals with 
evaluable sputum samples with those with non-evaluable samples in Zambia showed 
them to be much the same (data presented as supplementary material to the 
ZAMSTAR trial publication).16 
Among Zambian and Western Cape participants, 15.9% and 16.1% respectively had a 
RBG concentration ≥7.0mmol/L, and 1.5% and 2.8% respectively had a RBG 
concentration ≥11.1mmol/L. The prevalence of tuberculosis was approximately 500 per 
100,000 (0·5%) among Zambian participants and approximately 2,500 per 100,000 
(2·5%) among Western Cape participants. Tuberculosis prevalence stratified by 
glycaemia and baseline characteristics is shown in Tables 1 and 2. 
Among individuals included in the analysis, HIV status was determined by blood 
sampling for 23,067 (90·2%) participants and by self-reported status for 2,501 (9·8%) 
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participants in Zambia. Corresponding values for Western Cape participants are 10,106 
(94·8%) and 551 (5·2%). Among participants with RBG results, 2,232 participants in 
Zambia and 710 in Western Cape had missing data for both blood sampling and self-
reported HIV status. 
Among Zambian participants, as RBG concentration increased, the unadjusted and 
adjusted odds of prevalent TB initially increased compared to the baseline RBG 
concentration <5.6 mmol/L, peaking at RBG concentration 9.0-11.0 mmol/L (adjusted 
OR 4.31, 95% CI [2.07-8.97]). Although the odds of prevalent TB did not continue to 
increase with increasing RBG concentration beyond this, the number of individuals with 
a RBG concentration ≥11.1 mmol/L was low and the confidence interval was wide so 
there was still strong evidence of a linear association between RBG concentration and 
TB prevalence (p=0.006) after adjusting for age, sex, household socio-economic 
position, education, body mass index, HIV status and geographical location (Table 1). 
On multivariable analysis there was weak evidence of a linear association between 
glucose concentration and TB prevalence among Western Cape participants (p=0.06). 
In this location the adjusted odds of prevalent TB compared to the baseline was 
greatest for individuals with a RBG concentration ≥11.1 mmol/L (OR 2.49, 95% CI 
[1.29-4.79], Table 2). 
Unadjusted and adjusted odds ratios for prevalent TB using sequential RBG cut-offs to 
give increasing levels of hyperglycaemia are shown in Table 3. The findings from 
Zambia and Western Cape, combined with fixed-effects meta-analyses, showed 
increasing adjusted odds of prevalent tuberculosis for increasing cut-off levels of 
hyperglycaemia, though the increase was small; and, across successive cut-off levels, 
confidence intervals overlapped (Table 4). There was no evidence that the adjusted 
odds ratios differed between Zambia and Western Cape (Table 4). 
The evidence for association between hyperglycaemia and prevalent tuberculosis 
strengthened from univariable to multivariable analyses in both Zambia and the 
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Western Cape communities. In the Zambian communities the predominant negative 
confounding factors were body mass index and HIV status. The Western Cape 
communities had the same negative confounding factors, while the predominant 
positive confounding factor was age.  
On combined analysis, there was evidence of a contribution of hyperglycaemia to the 
population prevalence of tuberculosis throughout the spectrum of hyperglycaemia. 
(Table 4). However, the PAFs of prevalent TB to hyperglycaemia were small, 
particularly for the higher RBG cut-offs. For RBG concentration ≥11.1 mmol/L the PAF 
of prevalent TB was 0.99%, 95% CI [0.12-1.85]. When analysed as separate locations, 
the confidence intervals for the PAFs were wide and showed less evidence for a 
contribution of hyperglycaemia to the population prevalence of tuberculosis in both 
Zambia and Western Cape (Table 3). 
When stratified by age, for the highest RBG cut-off, the PAF of prevalent TB to 
hyperglycaemia increased with increasing age in Western Cape, reflecting the higher 
prevalence of hyperglycaemia in older age groups (Table 5). In Zambia, for this highest 
RBG cut-off ≥11.1mmol/L, there remained little evidence for a contribution of 
hyperglycaemia to the population prevalence of tuberculosis despite the rising 
prevalence of hyperglycaemia with increasing age, though confidence intervals were 
wide (Table 5).  
For purposes of comparison to HIV, the PAF of prevalent TB to HIV was 12.72%, 95% 
CI [7.70-17.47] in the Zambian communities, and 11.72%, 95% CI [8.25-15.06] in the 
Western Cape communities. 
For purposes of comparison to self-reported known diabetes, of individuals with a RBG 
<11.1mmol/L, 1.7% in Zambian and 6.8% in Western Cape communities reported 
having a previous diagnosis of diabetes, and 0.3% and 2.0% respectively reported 
being on treatment for diabetes. Of individuals with a RBG ≥11.1mmol/L, 27.9% in 
Zambian and 57.5% in Western Cape communities reported having a previous 
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diagnosis of diabetes, and 24.0% and 49.1% respectively reported being on treatment 
for diabetes. Incorporating participants with self-reported previously diagnosed 
diabetes into the highest category of hyperglycaemia made little difference to the odds 
ratio point estimates in Zambia and reduced the association seen with RBG 
concentration ≥11.1 mmol/L in Western Cape towards the null. Defining diabetes by 
self-report, the odds of prevalent TB for individuals with diabetes compared to those 
without was 0.83, 95% CI [0.20-3.46] in Zambia and 0.76, 95% CI [0.44-1.32] in 
Western Cape. For individuals in Western Cape with self-reported diabetes and RBG 
≥11.1mmol/L the odds of prevalent TB was 1.55, 95% CI [0.60-4.01] compared to 
individuals who did not report diabetes. For those with self-reported diabetes and RBG 
<11.1mmol/L this odds ratio was 0.61, 95% CI [0.32-1.18].  
Subgroup analyses were not possible for the Zambian data using the highest RBG cut-
off ≥11.1mmol/L due to limited data, and no difference was seen for gender and HIV 
categories using the RBG cut-off ≥9.0mmol/L. In the Western Cape using the RBG cut-
off ≥11.1 mmol/L, the point estimate of the adjusted odds of hyperglycaemia on 
prevalent tuberculosis was higher among women than men (for men OR=1·92, 95% CI 
[0·55-6·68]; for women OR=2·58, 95% CI [1·24-5·35]; but there was no evidence the 
odds ratio differed for men and women, test for interaction p=0·68). It was higher 
among those with HIV than those without HIV (among those with HIV OR=5·34, 95% 
CI [1·56-18·23]; among those without HIV OR=1·90, 95% CI [0·89-4·04]; but the 
evidence for interaction was weak (p=0·17)). 
DISCUSSION 
This is the first ever population based study of prevalent tuberculosis diagnosed 
microbiologically and glycaemia. We used participants who were randomly selected 
from the community rather than exploring the association among participants who had 
already been diagnosed with tuberculosis or hyperglycaemia. Among the Zambian 
participants of our study there was good evidence of a positive linear association 
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between hyperglycaemia and prevalent tuberculosis, and weak evidence for the same 
association in Western Cape. When data from the two locations were combined, there 
was evidence of association between hyperglycaemia and prevalent pulmonary 
tuberculosis across the spectrum of hyperglycaemia. On combined analysis the odds of 
prevalent tuberculosis was greatest for individuals with the highest level of glycaemia, 
though the magnitude of association was small. Those with a RBG concentration ≥11.1 
mmol/L, had 2.15 times the odds of prevalent tuberculosis than those with a RBG 
concentration <11.1 mmol/L.  
This association seen in the study communities between hyperglycaemia and prevalent 
tuberculosis is consistent with the association seen elsewhere in the world between 
diabetes and prevalent TB17, 18 and also between diabetes and active diagnosed TB.8-10  
Assuming causation, hyperglycaemia contributes little to the prevalence of tuberculosis 
throughout the spectrum of hyperglycaemia in the Zambian and Western Cape 
populations. This suggests that hyperglycaemia has only a small impact on the 
prevalence of TB in the study areas of Zambia and Western Cape despite the positive 
association seen between hyperglycaemia and prevalent TB in these locations. When 
stratified by age, however, we can see that the contribution of hyperglycaemia to the 
prevalence of tuberculosis in Western Cape is greater for older age groups, reflecting 
the higher prevalence of hyperglycaemia among older individuals. The same trend is 
seen in the Zambian study population, but the lower prevalence of hyperglycaemia in 
this setting means that confidence intervals are wide and point estimates remain low 
even for the oldest age groups. 
The combined odds ratios were weighted towards the Western Cape estimates due to 
the larger number of individuals with hyperglycaemia and tuberculosis in this setting, 
particularly for RBG concentration ≥11.1 mmol/L. Given the uncertainty of the Zambian 
odds ratio for this higher level of glycaemia the combined analyses yield the more 
reliable conclusions. However, regardless of which analysis is used, the conclusion 
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remains the same, that the contribution of hyperglycaemia to the population prevalence 
of tuberculosis is low. 
In this study we measured hyperglycaemia using a single RBG test. To optimise the 
accuracy of the test research staff were carefully trained and tested, and the point-of-
care measure was carefully calibrated using standardised control solution, although not 
validated against laboratory glucose analyses. Use of this point-of-care test enabled 
glucose measurement of many participants in a large-scale field study located within 
the community. Use of a test that is more complicated to administer, such as a fasting 
blood glucose, oral glucose tolerance test or glycated haemoglobin, would have been 
logistically challenging and potentially less acceptable to participants, resulting in a 
much lower uptake of eligible participants and possibly introducing selection bias. 
Therefore, although not a test to diagnose diabetes, it was felt that the use of a RBG 
test was most likely to minimise overall bias and loss of study power in this setting of a 
large-scale population survey, spanning communities and countries. Therefore, rather 
than diagnosing diabetes, we have measured glycaemia and explored the effect of 
hyperglycaemia on tuberculosis prevalence. RBG tests normally have good specificity 
but sub-optimal sensitivity for diabetes.29, 30 A study in China found measurement of 
RBG concentration with a cut off of 11·1mmol/L to have a sensitivity for diabetes of 
only 54·8% compared to an oral glucose tolerance test.31 This would suggest that 
association seen with hyperglycaemia based on RBG concentration would be an 
under-estimate of any association with diabetes.  However, in the context of active TB 
disease the specificity of this test for diabetes could also be reduced, as those with 
stress-induced hyperglycaemia secondary to their TB disease could also have a high 
RBG concentration. This would result in an over-estimate of the association with TB 
based on RBG concentration, compared to association with diabetes. A final 
consideration is a single RBG measurement fails to give data on chronic 
hyperglycaemia, so we are unable to explore the effect of chronic hyperglycaemia on 
tuberculosis prevalence from these data. We did explore the effect of participants 
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having previously diagnosed diabetes who may be on treatment and therefore may be 
normoglycaemic at the time of RBG testing but have longer term hyperglycaemia. The 
number of these participants were few in both Zambia and Western Cape and when 
incorporated into the categories of hyperglycaemia did not increase the odds ratio point 
estimates of the association with prevalent TB in either study location. Regardless of 
whether the hyperglycaemia measured was due to diabetes, was a consequence of TB 
disease or was transient from any other cause, the conclusion remains that in our study 
communities hyperglycaemia contributes little to the population prevalence of 
tuberculosis. 
Regression dilution bias is another factor that could have led to an underestimate of the 
prevalence of hyperglycaemia and consequently an underestimate of PAFs, because a 
single measurement of a continuous factor tends to underestimate the strength of 
association of repeated measurements with a given outcome. Further, blood glucose 
level is continually changing in response to multiple factors including time of day and 
food consumed and so this particular measure is likely to be particularly susceptible to 
regression dilution bias.  
The population attributable risks presented here should be interpreted with caution 
because the measure fails to account for onward transmission, which is important 
when focusing on pulmonary tuberculosis. 
The substantial losses of evaluable respiratory samples in this study resulted largely 
from a failure of the positive mycobacterial control to grow in two of the laboratories in 
Zambia, causing whole batches to be non-evaluable. This has resulted in reduced 
study power, but is unlikely to have introduced bias to the study results, as the process 
could not have been associated with the presence or absence of hyperglycaemia in the 
individuals affected by these missing data. The missing glycaemic data is similarly 
unlikely to produce bias and was probably the consequence of the lack of prioritisation 
during data collection, a consequence of nesting this study within a larger cluster-
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randomised trial. Therefore, this too is unlikely to have been associated with the 
presence or absence of disease and so is also unlikely to have introduced substantial 
bias. 
The participants in this study were randomly selected from their communities and so 
are representative of the general population within each community. The communities 
included were from urban and peri-urban settings and so rural populations are under-
represented in this study. The prevalence of both hyperglycaemia and tuberculosis 
would therefore likely be lower in a general population sample. 
In subgroup analysis, the association between hyperglycaemia and prevalent TB 
among those with HIV was stronger than among those without HIV, which could 
suggest that hyperglycaemia and HIV work synergistically to increase one's risk of TB, 
or could instead reflect an increase in stress-induced hyperglycaemia among those 
with HIV compared to those without HIV. These findings should be seen as hypothesis 
generating as the evidence for effect modification was weak and our data are 
underpowered for formal assessment of effect modification. 
CONCLUSION 
In our study communities in Zambia and Western Cape, there is evidence for a positive 
linear association between hyperglycaemia and prevalent pulmonary tuberculosis. On 
combined analysis, individuals with RBG concentration ≥11.1 mmol/L had 2.15 times 
the odds of prevalent tuberculosis than individuals with a RBG concentration <11.1 
mmol/L. Despite this, assuming causation, hyperglycaemia contributes little to the 
tuberculosis prevalence in our study communities. Investigation of the associations 
between hyperglycaemia, diabetes and active diagnosed tuberculosis in these study 
communities would be a valuable addition to the findings from this study, and would 
allow for sub-group analysis of association with smear-negative, smear-positive and 
drug-resistant tuberculosis. 
LIST OF ABBREVIATIONS USED 
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 CI: confidence interval 
 FBG: fasting blood glucose 
 HbA1c: glycated haemoglobin 
 HIV: human immunodeficiency virus 
 OR: odds ratio 
 PAF: population attributable fraction 
 RBG: random blood glucose 
 TB: tuberculosis 
 WC: Western Cape 
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Figure 1: Number and flow of participants and cases in this cross sectional study in 
Zambia and the Western Cape of South Africa 
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Table 1: Logistic regression estimates of the unadjusted and adjusted odds ratios of 
prevalent tuberculosis in the Zambian study sites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TB=tuberculosis; OR=odds ratio; CI=confidence interval; ARTI=annual risk of infection; All analyses accounted for the 
two-stage clustered sampling design through the use of a logistic regression model with random effects for 
enumeration area and inclusion of region as a fixed effect, with each region including 4 communities;  #Likelihood 
ratio tests;  ##23,414 participants included in analysis (299 missing data for age, 2,083 for BMI, 2,232 for HIV status), 
adjusted for variables shown plus household socioeconomic position and education. 
  
 
Characteristic 
 
Total number 
(%) 
Number (%) 
with 
prevalent TB  
Unadjusted OR  
(95% CI) 
P-value# Adjusted## OR 
(95% CI) 
P-value#  
Overall  27,800 (100) 144 (0·5) -  -  -  -  
Random blood 
glucose 
concentration 
(mmol/L) 
<5.6 14,741 (53.0) 67 (0.5) 1 0.029  
(test for 
linear 
trend 
p=0.017; 
test for 
departure 
from trend 
p=0.164) 
1 0.011 
(test for 
linear 
trend 
p=0.006; 
test for 
departure 
from 
trend 
p=0.141) 
5.6-6.9 8,628 (31.0) 42 (0.5) 1.06 (0.72-1.56) 1.13 (0.75-1.71) 
7.0-8.9 3,447 (12.4) 24 (0.7) 1.51 (0.94-2.41) 1.6 (0.96-2.66) 
9.0-11.0 579 (2.1) 9 (1.6) 3.44 (1.7-6.96) 4.31 (2.07-8.97) 
>11.0 405 (1.5) 2 (0.5) 1.06 (0.26-4.35) 0.97 (0.13-7.14) 
Age (years) 18-24 9,733 (35·4) 37 (0·4) 1 0·004 1 0·390 
25-29 4,665 (17·0) 32 (0·7) 1·79 (1·11-2·88) 1.27 (0.75-2.16) 
30-34 3,438 (12·5) 28 (0·8) 2·15 (1·31-3·52) 1.42 (0.83-2.46) 
35-39 2,381 (8·7) 16 (0·7) 1·79 (0·99-3·24) 1.09 (0.57-2.09) 
40-49 3,173 (11·5) 20 (0·6) 1·67 (0·97-2·89) 1.04 (0.56-1.92) 
50-59 2,113 (7·7) 7 (0·3) 0·87 (0·39-1·96) 0.74 (0.32-1.72) 
60+ 1,998 (7·3) 4 (0·2) 0·55 (0·20-1·55) 0.49 (0.16-1.45) 
Sex Male 9,265 (33·3) 64 (0·7) 1 0·003 1 0·008 
Female 18,535 (66·7) 80 (0·4) 0·60 (0·43-0·84) 0.59 (0.41-0.87) 
HIV status Negative 21,103 (82·5) 72 (0·3) 1 <0·001 1 <0·001 
Positive 4,465 (17·5) 66 (1·5) 4·22 (3·00-5·92) 3.57 (2.44-5.23) 
Body Mass Index  
(weight(kg)/ 
height2(m)) 
Healthy 
weight (18.5-
24.9) 
16,497 (64.2) 95 (0.6) 1 <0.001 1 <0.001 
Underweight 
(<18.5) 
2,604 (10.1) 27 (1.0) 1.87 (1.22-2.89) 1.70 (1.09-2.65) 
Overweight 
(25-29.9) 
4,402 (17.1) 13 (0.3) 0.49 (0.27-0.88) 0.56 (0.3-1.05) 
Obese (≥30) 2,214 (8.6) 1 (0.1) 0.07 (0.01-0.53) 0.10 (0.01-0.76) 
Region Rural, low 
ARTI 
7,712 (27·7) 24 (0·3) 1 0·012 1 0·002 
Urban  (non-
Lusaka), low 
ARTI 
6,033 (21·7) 34 (0·6) 1·83 (1·02-3·29) 
 
 
2.13 (1.12-4.04) 
Urban (non-
Lusaka), high 
ARTI 
5,158 (18·6) 22 (0·4) 1·39 (0·74-2·63) 
 
 
1.59 (0.81-3.14) 
Lusaka, high 
ARTI 
8,897 (32·0) 64 (0·7) 2·34 (1·37-3·98) 
 
2.88 (1.62-5.11) 
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Table 2: Logistic regression estimates of the unadjusted and adjusted odds ratios of 
prevalent tuberculosis in the Western Cape study sites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TB=tuberculosis; OR=odds ratio; CI=confidence interval; All analyses accounted for the two-stage clustered sampling 
design through use of a logistic regression model with random effects for enumeration area and inclusion of 
community as a fixed effect;  #Likelihood ratio tests; ##10,336 participants included in analysis (8 missing data for 
age; 341 for BMI; 710 for HIV status), adjusted for variables shown plus household socioeconomic position and 
education. 
 
  
 
Characteristic 
 
Total number 
(%) 
Number (%) 
with 
prevalent TB  
Unadjusted OR  
(95% CI) 
P-value# Adjusted## OR  
(95% CI) 
P-value# 
Overall  11,367 (100) 285 (2·5) -  -  -  -  
Random blood 
glucose 
concentration 
(mmol/L) 
<5.6 6,068 (53.4) 146 (2.4) 1 0.149 
(test for 
linear 
trend 
p=0.328; 
test for 
departure 
from trend 
p=0.121)  
1 0.059 
(test for 
linear 
trend 
p=0.098; 
test for 
departure 
from 
trend 
p=0.096) 
5.6-6.9 3,464 (30.5) 89 (2.6) 1.06 (0.81-1.39) 1.14 (0.85-1.53) 
7.0-8.9 1,269 (11.2) 35 (2.8) 1.14 (0.78-1.66) 1.15 (0.76-1.76) 
9.0-11.0 244 (2.2) 2 (0.8) 0.34 (0.08-1.40) 0.42 (0.10-1.76) 
>11.0 322 (2.8) 13 (4.0) 1.71 (0.95-3.06) 2.49 (1.29-4.79) 
Age (years) 18-24 2,953 (26·0) 59 (2·0) 1 0·059 1 0·014 
25-29 1,650 (14·5) 40 (2·4) 1·19 (0·79-1·79) 1.25 (0.80-1.95) 
30-34 1,325 (11·7) 24 (1·8) 0·89 (0·55-1·45) 0.81 (0.47-1.39) 
35-39 1,175 (10·3) 39 (3·3) 1·67 (1·11-2·52) 1.70 (1.07-2.69) 
40-49 1,902 (16·7) 52 (2·7) 1·36 (0·93-1·99) 1.34 (0.87-2.08) 
50-59 1,302 (11·5) 42 (3·2) 1·63 (1·09-2·44) 2.11 (1.31-3.39) 
60+ 1,052 (9·3) 29 (2·8) 1·39 (0·88-2·20) 1.72 (0.96-3.06) 
Sex Male 3,743 (32·9) 116 (3·1) 1 0·006 1 0·841 
Female 7,624 (67·1) 169 (2·2) 0·71 (0·56-0·90) 0.97 (0.73-1.29) 
HIV status Negative 8,768 (82·3) 164 (1·9) 1 <0·001 1 <0·001 
Positive 1,889 (17·7) 97 (5·1) 2·83 (2·18-3·66) 2.96 (2.23-3.93) 
Body Mass Index  
(weight(kg)/ 
height2(m)) 
Healthy 
weight (18.5-
24.9) 
4,302 (39.0) 132 (3.1) 1 <0.001 1 <0.001 
Underweight 
(<18.5) 
605 (5.5) 53 (8.8) 2.98 (2.13-4.17) 3.04 (2.14-4.34) 
Overweight 
(25-29.9) 
2,609 (23.7) 56 (2.2) 0.69 (0.50-0.95) 0.58 (0.41-0.83) 
Obese (≥30) 3,510 (31.8) 34 (1.0) 0.31 (0.21-0.45) 0.25 (0.16-0.39) 
Community SA1 1,131 (10·0) 29 (2·6) 1 0·308 1 0·351 
SA2 2,193 (19·3) 49 (2·2) 0·84 (0·49-1·42) 0.85 (0.47-1.55) 
SA3 (rural) 190 (1·7) 3 (1·6) 0·61 (0·18-2·15) 0.51 (0.11-2.39) 
SA4 1,618 (14·2) 57 (3·5) 1·33 (0·79-2·25) 1.49 (0.82-2.73) 
SA5 1,164 (10·2) 20 (1·7) 0·64 (0·34-1·22) 0.71 (0.33-1.51) 
SA6 (rural) 2,489 (21·9) 65 (2·6) 1·01 (0·61-1·67) 1.01 (0.57-1.78) 
SA7 1,557 (13·7) 40 (2·6) 1·02 (0·59-1·75) 1.05 (0.55-1.99) 
SA8 1,025 (9·0) 22 (2·2) 0·83 (0·45-1·52) 0.86 (0.43-1.72) 
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Table 3: Logistic regression estimates of prevalent tuberculosis and population attributable 
fractions of prevalent tuberculosis to hyperglycaemia for sequential random blood glucose 
concentration cut-offs 
Random 
blood glucose 
concentration 
(mmol/L) 
Total number 
(%) 
Number 
(%) with 
prevalent 
TB 
Unadjusted OR 
(95% CI) 
P-
value# 
Adjusted OR 
(95% CI)* 
P-
value# 
PAF (95% CI) of 
prevalent TB to 
hyperglycaemia 
(%) 
ZAMBIA 
<7.0 23,369 (84.1) 109 (0.5) 1 0.012 1 0.007 7.16 (2.51-11.59) 
≥7.0 4,431 (15.9) 35 (0.8) 1.68 (1.14-2.46)  1.82 (1.20-2.75)   
<7.8 25,444 (91.5) 123 (0.5) 1 0.017 1 0.018 4.12 (0.90-7.24) 
≥7.8 2,356 (8.5) 21 (0.9) 1.84 (1.15-2.93) 1.94 (1.16-3.25) 
<9.0 26,816 (96.5) 133 (0.5) 1 0.022 1 0.007 2.28 (0.12-4.38) 
≥9.0 984 (3.5) 11 (1.1) 2.25 (1.21-4.19) 2.86 (1.46-5.60) 
<11.1 27,395 (98.5) 142 (0.5) 1 0.921 1 0.818 0.00 (0.00-3.21) 
≥11.1 405 (1.5) 2 (0.5) 0.93 (0.23-3.79) 0.80 (0.11-5.85) 
WESTERN CAPE 
<7.0 9,532 (83.9) 235 (2.5) 1 0.525 1 0.386 2.34 (0.00-7.08) 
≥7.0 1,835 (16.1) 50 (2.7) 1.11 (0.81-1.51)  1.17 (0.82-1.66)   
<7.8 10,320 (90.8) 255 (2.5) 1 0.417 1 0.383 1.66 (0.00-4.96) 
≥7.8 1,047 (9.2) 30 (2.9) 1.18 (0.80-1.73) 1.22 (0.79-1.89) 
<9.0 10,801 (95.0) 270 (2.5) 1 0.787 1 0.308 1.35 (0.00-3.55) 
≥9.0 566 (5.0) 15 (2.7) 1.08 (0.63-1.83) 1.37 (0.77-2.44) 
<11.1 11,045 (97.2) 272 (2.5) 1 0.099 1 0.015 1.64 (0.28-2.99) 
≥11.1 322 (2.8) 13 (4.0) 1.67 (0.94-2.96) 2.38 (1.26-4.50) 
TB=tuberculosis; OR=odds ratio; CI=confidence interval; PAF=population attributable fraction; All analyses accounted 
for the two-stage clustered sampling design through the use of a logistic regression model with random effects for 
enumeration area and inclusion of region or community as a fixed effect; Negative PAFs were given a value of zero; 
#Likelihood ratio tests; *Adjusted for age, sex, HIV status, body mass index, household socioeconomic position and 
education. 
 
Table 4: Combined adjusted odds ratios of prevalent tuberculosis for Zambia and Western 
Cape and associated population attributable fractions of prevalent tuberculosis to 
hyperglycaemia for sequential random blood glucose concentration cut-offs 
Random blood 
glucose 
concentration cut-
off (mmol/L) 
Combined 
adjusted OR 
P-value# I2 p-value PAF (95% CI) of 
prevalent TB to 
hyperglycaemia (%) 
7.0 1.40 (1.07-1.84) 0.013 0.112 4.57 (1.27-7.77) 
7.8 1.48 (1.06-2.07) 0.020 0.176 2.82 (0.64-4.95) 
9.0 1.87 (1.21-2.90) 0.005 0.104 1.84 (0.56-3.11) 
11.1 2.15 (1.17-3.94) 0.013 0.306 0.99 (0.12-1.85) 
OR=odds ratio; CI=confidence interval; PAF=population attributable fraction; ORs combined through fixed-effects 
meta-analysis; #Likelihood ratio tests; All analyses accounted for the two-stage clustered sampling design through 
the use of a logistic regression model with random effects for enumeration area and inclusion of region or 
community as a fixed effect; Negative PAFs were given a value of zero; *Adjusted for age, sex, HIV status, body mass 
index, household socioeconomic position and education. 
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Table 5: Population attributable fraction of prevalent tuberculosis to 
hyperglycaemia for Zambian and Western Cape communities, stratified by age, 
using random blood glucose concentration cut-off 11.1mmol/L 
Age 
(years) 
Zambia Western Cape 
Hyperglycaemia 
prevalence (%) 
PAF (95% CI) Hyperglycaemia 
prevalence (%) 
PAF (95% CI) 
18-24 0.42 0.00 (0.00-0.96) 0.27 0.16 (0.00-0.52) 
25-29 0.51 0.00 (0.00-1.16) 0.42 0.24 (0.00-0.70) 
30-34 1.22 0.00 (0.00-2.72) 0.75 0.43 (0.00-1.05) 
35-39 1.18 0.00 (0.00-2.63) 2.04 1.18 (0.07-2.28) 
40-49 2.27 0.00 (0.00-4.95) 4.26 2.47 (0.67-4.24) 
50-59 4.69 0.00 (0.00-9.88) 7.76 4.50 (1.70-7.22) 
60+ 4.60 0.00 (0.00-9.70) 8.65 5.01 (1.97-7.97) 
Total 1.45 0.00 (0.00-3.21) 2.83 1.64 (0.28-2.99) 
PAF=population attributable fraction; CI=confidence interval; Hyperglycaemia defined as a random blood glucose 
concentration ≥11.1mmol/L; Negative PAFs were given a value of zero. 
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Aims and methods  
98 
 
Chapter 5: Statement of problem, research questions and 
rationale 
1 Statement of problem 
Systematic reviews and meta-analyses of studies exploring the relationship between 
tuberculosis (TB) and diabetes mellitus (DM) suggest that the incidence of active TB is two to 
three times higher in those with DM compared to those without DM;1-3 that DM increases the 
risk of death from active TB4 and that DM may increase the risk of TB relapse.2, 4 The context of 
these associations in sub-Saharan Africa (SSA) differs from the rest of the world in two ways. 
Firstly, the prevalence of HIV in Africa is more than five times higher than in any other world 
region.5 Secondly, the prevalence of undiagnosed diabetes is high (≥40%)6 and those who are 
diagnosed have a high prevalence of poorly controlled diabetes (73% in a recent study in 
Cameroon).6, 7  
When exploring these associations between DM and TB it is important to be certain that those 
diagnosed with diabetes truly have diabetes and do not instead have stress-induced 
hyperglycaemia secondary to infection with tuberculosis. Prior studies have frequently failed 
to distinguish between these two causes of hyperglycaemia.  
The number of adults with diabetes in SSA is predicted to rise from 14.2 million in 2015 to 34.2 
million in 2040.6-10 To appropriately respond to this now and prepare for a future higher 
prevalence of diabetes, a deeper understanding of associations between tuberculosis, diabetes 
mellitus, stress hyperglycaemia and HIV in the context of SSA is needed. 
2 Study Questions 
2.1 Overall Study Question 
In the sub-Saharan Africa context of high HIV prevalence and poor diabetes control, how does 
hyperglycaemia affect tuberculosis control? 
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2.2 Specific Study Questions 
1. Does HIV modify the association between hyperglycaemia and active tuberculosis? 
2. Is there a dose-response relationship between hyperglycaemia and tuberculosis 
treatment outcome? 
3. What proportion of hyperglycaemia among newly-diagnosed tuberculosis cases is due 
to diabetes mellitus rather than to stress-induced hyperglycaemia? 
4. How accurate for the diagnosis of diabetes mellitus are measures of random blood 
glucose, fasting blood glucose and glycated haemoglobin concentrations measured at 
the time of tuberculosis diagnosis, compared to the reference standard of fasting 
blood glucose concentration measured after stabilisation of tuberculosis disease. 
3 Research Aims 
1. To determine if HIV modifies the association between hyperglycaemia and active 
tuberculosis. 
2. To determine whether a dose-response relationship exists between hyperglycaemia 
and tuberculosis treatment outcome. 
3. To determine the proportion of hyperglycaemia among newly-diagnosed tuberculosis 
cases that is due to diabetes mellitus rather than to stress-induced hyperglycaemia. 
4. To evaluate the accuracy of random blood glucose, fasting blood glucose and glycated 
haemoglobin concentrations measured at the time of tuberculosis diagnosis for the 
diagnosis of diabetes mellitus as determined by the reference standard of fasting 
blood glucose concentration measured after stabilisation of tuberculosis disease. 
4 Rationale 
The rationale and justification for undertaking these studies lie in the need to improve current 
understanding of associations between diabetes, stress hyperglycaemia, TB and HIV in sub-
Saharan settings. Little is known about these associations in Africa and so these studies will 
provide new knowledge with specific relevance to this region. The studies will complement 
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previous and current studies into TB-diabetes associations elsewhere in the world, and are 
anticipated to justify and propel further research by quantifying the magnitude and strength of 
associations and the impact on TB treatment outcome. If we find that there are strong and 
deleterious associations between diabetes, TB and HIV, this study will highlight the need for an 
intensified focus on diabetes among TB populations (with or without HIV). Furthermore, if 
diabetes control is found to be negatively associated with tuberculosis treatment outcome, 
this would suggest that better management of diabetes could improve TB treatment 
outcomes. This would be beneficial not only to tuberculosis control but also for raising the 
importance of diabetes control. Should, however, the results show only a minimal association 
between diabetes and TB/HIV and/or TB treatment outcome in this sub-Saharan setting this 
would also be useful information to have obtained for public health planning and allocation of 
future health and research resources. 
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Chapter 6: Research Design and Methods 
1 Overview 
To address the four study aims, three separate but connected studies were undertaken. 
 Study 1 addresses aim 1. This was an unmatched case-control study. The study 
outcome was diagnosed active TB disease and the exposure of interest was 
hyperglycaemia.  Cases with TB were recruited from TB clinics in Lusaka; data for the 
controls were taken from a recently conducted population-based cross-sectional study 
(the ZAMSTAR prevalence survey; Appendix I). The analysis explores HIV as a potential 
effect modifier. 
 Study 2 addresses aim 2. This was a cohort study among sputum smear-positive 
pulmonary TB patients. The exposure was hyperglycaemia, measured by glycated 
haemoglobin. The outcome was TB treatment outcome, measured by two different 
recognised surrogate biomarkers: time to sputum culture positivity and time to 
sputum culture conversion. A subset of cases from study 1 were recruited to study 2 
using stratified selection based on random blood glucose concentration, aiming to 
optimise study power. 
 Study 3 addresses aims 3 and 4: This was a study of diagnostic accuracy. All 
participants of study 2 were also recruited to study 3, along with a further subset of 
study 1 participants. Stratified selection based on random blood glucose concentration 
was again used to increase the power of the study. A reference standard test for 
diabetes diagnosis was performed to distinguish between diabetes and stress-induced 
hyperglycaemia. This reference standard test was fasting blood glucose concentration 
measured after stabilisation of TB disease (3 months after TB treatment initiation). 
Three different tests for diabetes diagnosis taken at the time of TB diagnosis (the index 
tests) were each compared to the reference standard test, to determine which most 
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accurately diagnoses diabetes at the time of TB diagnosis. The three index tests used 
were random blood glucose, fasting blood glucose and glycated haemoglobin. 
 A pictorial overview of the studies and how they connect to each other is shown in Figure. 
Figure 1: Schematic diagram to show participant flow through the connected studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ZAMSTAR = The Zambia South Africa TB and AIDS Reduction study 
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2 Conceptual Framework 
To aid understanding of potential confounding factors, a conceptual framework to link study 
exposures to outcomes was drawn. This is shown in Figure 2. 
For study 1, the exposure was hyperglycaemia and the outcome was diagnosed active 
tuberculosis disease. Potential measureable confounding factors in this setting were age, sex, 
household socio-economic position, education and HIV status. HIV status was also considered 
to be a potential effect modifier. For study 2, the exposure was degree of hyperglycaemia and 
the outcome was tuberculosis treatment outcome, measured by two different recognised 
surrogate biomarkers: time to sputum culture positivity and time to sputum culture 
conversion. The potential confounders are the same as for study 1. Study 3 explores the 
immediate ancestors to hyperglycaemia, diabetes mellitus and stress-induced hyperglycaemia. 
This latter ancestor provides a route for reverse causality for the association between 
hyperglycaemia and tuberculosis. Body habitus has a unique relationship with TB and diabetes. 
Low body habitus has a causal association with TB incidence and is also an effect of TB disease. 
Low body habitus is a risk factor for poor TB outcome, but is also a consequence of severe TB 
disease which is independently a risk factor for poor TB outcome. High body habitus 
(particularly central/truncal obesity) has a causal association with insulin resistance and 
diabetes, and thus secondarily with hyperglycaemia, but low body habitus can be an effect of 
hyperglycaemia from uncontrolled diabetes. Conceptualising body habitus as a potential 
confounding factor is therefore not satisfactory but was measured in order to explore these 
associations. 
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Figure 2: Conceptual framework for studies  
 
Key 
exposure  outcome ancestor of exposure   ancestor of exposure and 
outcome 
      causal path   reverse causality path        potentially biasing path 
3 Design and methods: study 1 
3.1 Study design 
Study 1 was an unmatched case-control study. This design provided a cost-effective and time-
efficient method for addressing aim 1, to determine if HIV modifies the association between 
hyperglycaemia and diagnosed active tuberculosis disease. 
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3.2 Study population 
The study took place in Lusaka, Zambia from September 2013 until September 2015, among 
adults (≥18 years of age) living in the compounds of Chawama, George and Kanyama. These 
are three areas of the city that have a high incidence of tuberculosis and a high prevalence of 
HIV. The health centre TB clinics in these three areas collectively receive around 4,000 newly-
diagnosed TB patients per year, around 65% of whom are HIV positive. 
3.3 Sample size calculations 
The sample size calculations for study 1 (table 1) assumed the following: a hyperglycaemia 
prevalence of 3.2% in the non-TB control population (calculated from the ZAMSTAR prevalence 
survey data, defined as a random blood glucose (RBG) concentration of ≥11.1, Appendix I); a 
hyperglycaemia prevalence of between 2 and 3 times this among the active TB population (as 
suggested by systematic review of prior published studies); an HIV prevalence among incident 
TB cases of 65% (estimates from TB clinic routine data in Chawama, George and Kanyama, 
unpublished data), and an odds ratio between HIV strata of between 2 and 3 (taken to be the 
minimum difference deemed to be clinically important, given that no data existed at the time 
to guide this estimate). 
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Table 1: Sample size calculations for study 1, for the range of hyperglycaemia prevalence 
anticipated to be in the active TB population 
1 – 
α 
Power Hyperglycaemia 
prevalence in 
controls 
Hyperglycaemia 
prevalence in 
cases 
Sample size 
required to 
test primary 
association* 
Odds 
ratio 
between 
HIV 
strata 
Sample size 
required for 
effect 
modification* 
0.95 0.9 3.2% 6.4% 998 2 3992 
0.95 0.9 3.2% 8% 521 2.5 2084 
0.95 0.9 3.2% 9.6% 336 3 1344 
 
0.95 0.8 3.2% 6.4% 761 2 3044 
0.95 0.8 3.2% 8% 400 2.5 1600 
0.95 0.8 3.2% 9.6% 259 3 1036 
α = probability of a Type I error; *minimum sample size required for each group (cases and controls); rounded up to 
be conservative 
The above estimates were based on sample size equations for the primary association using 
Stata version 12 and the rule of multiplication by 4 for testing for interaction. Estimates 
determined by simulation of expected data were comparable, using Stata version 12 to create 
the simulation followed by repeated sampling from the simulated data, testing for interaction 
and finally counting the proportion of p-values for interaction that fell below the level of 
significance. 
These sample size estimates, using disease prevalence and anticipated odds ratios, are 
relevant for standard case-control analysis with exposure and outcome data in binary 
categories. Given that hyperglycaemia was defined here by a single RBG concentration, it was 
possible to undertake additional analyses with glycaemia in ordered categories or as a 
continuous variable. This was valuable for interpretation and clinical applicability. Sample size 
calculations performed for these scenarios resulted in smaller sample size estimates. As 
studies of effect modification are frequently underpowered the most conservative estimates 
(largest sample sizes) were chosen. 
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Therefore, recruitment of 4,000 participants to each group was anticipated to give >90% 
power to detect effect modification at the 5% level of significance. The final number of 
participants was 3,843 cases and 6,977 controls. The prevalence of hyperglycaemia, defined as 
a random blood glucose concentration ≥11.1mmol/L, was 1.4% among cases and 1.5% among 
controls, substantially lower than predicted. However, the difference in odds ratios between 
HIV strata was larger than anticipated (among individuals with HIV, the adjusted odds of TB 
was 5.47 times higher in those with RBG ≥11.1mmol/L compared to those with RBG 
<11.1mmol/L; among individuals without HIV this odds ratio was 1.17) and so the study still 
resulted in sufficient power to detect effect modification.  
3.4 Subjects: selection and definitions 
Cases for study 1 were adults with diagnosed TB attending the TB clinic at either Chawama, 
George or Kanyama health centre who had not yet started TB treatment or were within 2 days 
of starting TB treatment. All eligible potential participants were identified in the TB clinic and 
invited to participate during a routine clinic attendance. Recruitment ceased when the sample 
size had been reached. A TB case was defined as any person presenting to a TB clinic with a 
clinical diagnosis of TB (pulmonary or extra-pulmonary) with or without microbiological 
confirmation of TB and prescribed a full course of antitubercular chemotherapy, based on the 
World Health Organization (WHO) TB diagnostic criteria (Appendix III). This is the definition 
used for TB diagnosis in the study clinics as well as elsewhere in Zambia and much of sub-
Saharan Africa and so will facilitate translation of the study results to the clinical setting. It also 
facilitated recruitment of sputum smear negative and extra-pulmonary tuberculosis cases that 
did not have microbiological confirmation, but at the same time allowed for sub-group analysis 
of bacteriologically confirmed (smear or Xpert MTB/RIF positive) cases. 
 Inclusion criteria for cases: Newly-diagnosed case of tuberculosis due to commence on 
a full course of antitubercular chemotherapy. 
 Exclusion criteria for cases: <18 years of age, commenced TB treatment >2 days ago. 
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4,000 new TB patients per year are expected to attend the clinics in Chawama, George and 
Kanyama, but allowing for 5% who meet the exclusion criteria, 10% who are unwilling to 
participate, and time for investigator leave, it was anticipated to take up to 21 months to reach 
the required sample of 4,000. It actually took 24 months to reach the required sample size. 
Unmatched controls were adults without TB sampled randomly from all adults living in the 
clinic catchment area (the compounds of Chawama, George and Kanyama). A cross-sectional 
survey had recently been conducted comprising approximately 35,000 participants from 16 
communities throughout Zambia, including from the Lusaka compounds of Chawama, George 
and Kanyama, to measure the primary endpoint of prevalent TB in a large cluster randomised 
trial (total population 1.2 million; the ZAMSTAR study). Along with laboratory diagnosed TB 
and HIV data, participants have data on RBG concentration. These data have been used to 
describe the prevalence of hyperglycaemia in Zambia and to quantify the relationship between 
hyperglycaemia and prevalent TB, as discussed in Chapters 3 and 4. These data were used to 
provide population controls for study 1. There was therefore no need to repeat data collection 
among members of the local community. Participants of the ZAMSTAR prevalence survey were 
randomly sampled within each community using a 2-stage cluster sampling technique. Each 
community was divided into enumeration areas each containing roughly 1,000 adults. 
Enumeration areas were randomly selected until 4,000 participants were enumerated. All 
households of all enumeration areas were eligible and all adults within all households were 
eligible. Any adult who spent the preceding 24 hours with a household (defined as a group of 
people who usually eat together and sleep in the same dwelling) were defined as living in the 
household and were eligible for inclusion. 
 Inclusion criteria for controls: ZAMSTAR prevalence survey participants who live in the 
compounds of Chawama, George or Kanyama. 
 Exclusion criteria for controls: <18 years of age; diagnosed prevalent TB at the time of 
prevalence survey (culture positive sputum for mycobacterium tuberculosis); 
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diagnosed incident TB at the time of prevalence survey (self-report); previous TB 
within the year preceding study data collection (self-report). 
3.5 Activities 
Day 1 of enrolment 
1. Newly diagnosed tuberculosis patients attending Chawama, George and Kanyama 
clinics identified through consultation with clinic staff and clinic records.  
2. Individual written informed consent obtained from those meeting inclusion criteria 
and willing to participate. 
3. Structured questionnaire administered. 
4. Height, weight and waist circumference measured. 
5. Random blood glucose concentration measured. 
6. HIV status recorded. If no documented current HIV status available, an HIV test with 
pre- and post-test counselling as per national guidelines was performed.  
7. For HIV +ve participants, CD4 count recorded. If no documented current CD4 count 
available, CD4 count measured. 
3.6 Data collection methods: definitions and measurement 
The exposure, hyperglycaemia, was measured by a single capillary RBG concentration using an 
Optium Xceed point-of-care glucometer for controls and an Accu-Chek Aviva point-of-care 
glucometer for cases. Manufacture of the Optium Xceed glucometer had been discontinued 
between the start of data collection for controls and cases. The Accu-Chek Aviva was identified 
as being a similar and well-performing point-of-care glucometer and was therefore chosen for 
use instead.1-4 Measuring an RBG concentration is simple, quick, inexpensive, minimises 
participant inconvenience (the test requires one finger-prick drop of blood) and enables use of 
available ZAMSTAR data for the controls. It is not as sensitive for diabetes diagnosis as other 
measures of glycaemia, such as fasting blood glucose (FBG) or glycated haemoglobin (HbA1c) 
concentrations, but analysing the data with glycaemia as an ordered categorical or continuous 
variable will enable assessment of any shift in mean and cumulative proportion of glucose 
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concentration between cases and controls, rather than having a cut-off definition for 
hyperglycaemia.  Avoiding analysis solely by using a cut-off definition removes potential 
misclassification error that could exist with the use of this less sensitive measurement.  
All research staff were trained on the use of the glucometers and were required to undergo 
proficiency testing. Standardised control solution was used for performance checks on test 
strips and meters. The time of last oral intake (excluding water) was recorded. RBG 
concentration was measured during daylight hours and throughout the year for both cases and 
controls, so spanning all seasons. For the Accu-Chek Aviva glucometer, intra- and inter-
operator variability was measured to assess the validity of glucose measurement. All research 
assistants contributed to the assessment, using known normoglycaemic volunteers and a 
standard hyperglycaemic specimen. For intra-operator variability each research assistant 
repeated the test 5 consecutive times on a combined total of 13 subjects/specimens. For inter-
operator variability research assistants each performed the test on a single subject/specimen 
in the same place at the same time for 7 subjects/specimens. 
The potential effect modifier, HIV status, was taken from documented results in TB clinic 
records. As part of the Zambian National Tuberculosis Control Programme, this was routinely 
measured in all new-TB cases at the time of TB diagnosis. If no test has been performed since 
their TB diagnosis (unless already known to be HIV positive) this was measured using point-of-
care rapid blood-based kits. DetermineTM HIV-1/2 was used as the first line test and Uni-GoldTM 
HIV as a confirmatory test for individuals with a positive Determine test. Pre- and post-test 
counselling was offered. Participants who were positive on both tests were referred to the 
local HIV clinic for management in existing HIV services. Participants who tested HIV negative 
were counselled and advised to repeat the test as per national guidelines. 
In order to adjust for potential confounding factors, a structured questionnaire was 
administered to all cases by a member of the research team to obtain information on age, sex, 
household socio-economic position and education level. This information was entered directly 
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onto a pre-programmed personal digital assistant (PDA) by the researcher. Principal 
components analysis was used to create a measure of household socio-economic position 
using the following information: main type of dwelling; main type of flooring; main type of 
household toilet; main source of household drinking water, and presence of household assets 
including radio, television, refrigerator, bicycle, motorcycle, car, domestic worker and mobile 
phone. 
Data on baseline characteristics and potential confounding factors for control participants was 
taken from the ZAMSTAR questionnaire data. All questions, measurement tools (HIV testing 
kits but not glucometers) and test standard operating procedures were identical for cases and 
controls. 
To allow for sub-group analyses, the type of TB diagnosis (smear positive, smear negative 
pulmonary or non-pulmonary) was recorded. 
Research staff were trained by the principal investigator (PI) on all aspects of data collection 
and were required to follow standard operating procedures for glucose, HIV and CD4 testing 
and for measurement of anthropometrics. Research staff were monitored weekly initially and 
then monthly by the PI for quality control through repetition of non-invasive data collection on 
2 randomly selected participants, and observation of invasive sample collection in another 2 
randomly selected participants. A pilot study was performed on the first 10 participants 
recruited to test all data collection tools and procedures. 
3.7 Data management and statistical analysis 
All point-of-care measurements, test results and questionnaire data were entered directly 
onto a PDA by research staff. Pre-programmed software was used to ensure that only valid 
data could be entered and that all data points had an appropriate entry. 
With glycaemia as a binary exposure variable, logistic regression was used to quantify the 
magnitude and strength of association between hyperglycaemia and active tuberculosis. 
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Interaction terms were used to assess for effect modification by HIV. In addition to defining 
participants as hyperglycaemic or normoglycaemic, a shift in proportions of glycaemia over the 
range measured was assessed. Using the binary variable of active tuberculosis as the outcome 
and an ordered categorical variable of random blood glucose concentration as the exposure, 
logistic regression was used to further explore the association between hyperglycaemia and 
active tuberculosis. Interaction terms were again used to assess for effect modification by HIV, 
classified as a binary variable. We intended to repeat this using hyperglycaemia as a 
continuous variable if the analysis showed no departure from linear trend. Crude and adjusted 
odds ratios were calculated. Results are presented in table format in Chapter 7. 
In addition to stratification by HIV status, pre-specified sub-group analyses were: stratification 
by CD4 count, stratification by use of antiretroviral medication (as a proxy for viral load), 
stratification by type of tuberculosis (smear positive, smear negative pulmonary or non-
pulmonary, and also as a binary pulmonary/non-pulmonary variable) and restriction of the 
outcome definition to microbiologically-confirmed tuberculosis only. The CD4 count sub-
groups have been grouped into 4 groups: HIV –ve, CD4>350, CD4 200-350, CD4<200. The use 
of antiretroviral medication is a binary variable. Aside from stratification by HIV status, sub-
group analyses do not have sufficient power for hypothesis testing, but rather are analysed for 
the purposes of hypothesis generation. 
Potential bias was assessed using chi-squared tests of association of glycaemia with time of 
last oral intake before measurement and time of day of measurement of RBG concentration. 
Intra- and inter-operator variability were assessed for absolute agreement using a two-way 
mixed-effects model to calculate intraclass correlations (ICCs). 
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4 Design and methods: study 2 
4.1 Study design 
A prospective cohort study allowing for longitudinal follow-up addressed aim 2, to determine 
whether a dose-response relationship exists between hyperglycaemia and tuberculosis 
treatment outcome. Hyperglycaemia was determined by glycated haemoglobin level. 
Tuberculosis treatment outcome was assessed using two surrogate biomarkers: time to initial 
sputum culture positivity (TTP) and time to sputum culture conversion (TTC). 
4.2 Study population 
The study took place from September 2013 to December 2015 among smear-positive 
pulmonary tuberculosis cases who were about to be (or were newly) commenced on 
antitubercular therapy attending Chawama, George or Kanyama TB clinic in Lusaka, Zambia. 
4.3 Sample size calculations 
Table 3 gives the predicted sample sizes required for assessing the effect of glycaemia on the 
surrogate biomarker for tuberculosis treatment outcome of time to initial sputum culture 
positivity for a range of differences in mean time to culture positivity between the ordered 
categorical glycaemia groups, assuming a mean time to culture positivity of 7 days (standard 
deviation 5 days).52 The differences chosen were the minimum differences deemed to be 
clinically important.  
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Table 2: Sample size estimates for study 2: estimates required for analysis of the effect of 
glycaemia (as an ordered categorical variable) on time to initial sputum culture positivity 
1 – 
α 
Power Mean 
time to 
culture 
positivity 
(days) 
Standard 
deviation 
from mean 
time to 
culture 
positivity 
(days) 
Difference 
in means 
between 
groups 
(days) 
Sample 
size 
required 
for group 
1* 
Sample 
size 
required 
for group 
2* 
Sample 
size 
required 
for group 
3* 
0.95 0.9 7 5 3 59 59 59 
0.95 0.9 7 5 4 33 33 33 
0.95 0.9 7 5 5 22 22 22 
 
0.95 0.8 7 5 3 44 44 44 
0.95 0.8 7 5 4 25 25 25 
0.95 0.8 7 5 5 16 16 16 
α=probability of a Type I error; *rounded up to be conservative; group 1=HbA1c<6.5%, group 2=HbA1c 6.5-9%, group 
3=HbA1c ≥9% 
Therefore, assuming that 10% were lost to follow-up and 5% were smear positive but culture 
negative, it was predicted that 70 participants from each group (210 in total) would need to be 
recruited to give 90% power to detect the minimum clinically important difference at the 5% 
level of significance. Sample size estimates calculated for survival analysis using a cox 
proportional hazards model to assess the effect of glycaemia on time to initial sputum culture 
positivity achieved comparable numbers. 
Table 4 gives the sample sizes required for assessing the effect of glycaemia on the surrogate 
biomarker for tuberculosis treatment outcome of time to culture conversion for a range of 
differences in mean time to culture conversion between the ordered categorical glycaemia 
groups, assuming a mean time to culture conversion of 32 days (standard deviation 12 days).52 
The differences chosen were the minimum differences deemed to be clinically significant. 
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Table 3: Sample size estimates for study 2: estimates required for analysis of the effect of 
glycaemia (as an ordered categorical variable) on time to sputum culture conversion 
1 – 
α 
Power Mean time 
to culture 
conversion 
(days) 
Standard 
deviation from 
mean time to 
culture 
conversion (days) 
Difference 
in means 
between 
groups 
(days) 
Sample 
size 
required 
for group 
1* 
Sample 
size 
required 
for group 
2* 
Sample 
size 
required 
for group 
3* 
0.95 0.9 32 12 6 85 85 85 
0.95 0.9 32 12 7 62 62 62 
0.95 0.9 32 12 8 48 48 48 
  
0.95 0.8 32 12 6 63 63 63 
0.95 0.8 32 12 7 47 47 47 
0.95 0.8 32 12 8 36 36 36 
α=probability of a Type I error; *rounded up to be conservative; group 1=HbA1c<6.5%, group 2=HbA1c 6.5-9%, group 
3=HbA1c ≥9% 
Therefore, assuming that 10% were lost to follow-up and 5% were smear positive but culture 
negative, it was predicted that 100 participants from each group (300 in total) would need to 
be recruited to give 90% power to detect the minimum clinically important difference at the 
5% level of significance. Sample size estimates calculated for survival analysis using a cox 
proportional hazards model to assess the effect of glycaemia on time to sputum culture 
conversion achieved comparable numbers. 
The final number of participants was 173, though 12 had missing data for random blood 
glucose concentration and 13 had missing data for baseline glycated haemoglobin. As the 
prevalence of hyperglycaemia was much lower than anticipated in the population from where 
the participants were coming, there were only 10 participants with HbA1c ≥6.5, of whom 4 had 
HbA1c ≥9.0.  
The overall mean time to culture positivity of the initial sputum sample was 7.1 days (standard 
deviation, sd, 3.9 days). Individuals with HbA1c <6.5 had a mean time to culture positivity of 7.3 
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days days (sd 4.0 days). For individuals with HbA1c 6.5-9.0, this value was 6.5 days (sd 3.9 days), 
and for individuals with HbA1c ≥9.0 this was 6.0 days (sd 0.9 days). The overall mean time to 
culture conversion was 30.9 days (sd 18.5 days). Individuals with HbA1c <6.5 had a mean time 
to culture conversion of 30.8 days (sd 18.3 days). For individuals with HbA1c 6.5-9.0, this value 
was 25.2 days (sd 24.0 days), and for individuals with HbA1c ≥9.0 this was 47.3 days (sd 15.5 
days). As the number of participants with hyperglycaemia was so low, this study lacked power 
to detect any true difference between groups, even when the groups were re-categorised to 
have larger numbers in each group. 
4.4 Subjects: selection and definitions 
Participants were recruited from among the cases of study 1. All eligible potential participants 
were identified in the TB clinic and invited to participate during a routine clinic attendance. 
Recruitment ceased when study 1 ceased, regardless of whether or not the number of 
participants had reached the required size. 
 Inclusion criteria were: study 1 participant, smear-positive pulmonary tuberculosis 
case within 2 days of starting anti-tuberculosis therapy. 
 Exclusion criteria were: <18 years of age, smear-negative pulmonary tuberculosis, non-
pulmonary tuberculosis 
A stratified sampling technique was used to recruit participants from across the glycaemic 
range. The level of glycated haemoglobin was our glycaemic exposure of interest, as this best 
reflects the average blood glucose concentration over the time period of interest. However, 
there are no suitable point-of-care devices to measure HbA1c, and so we were unable to 
determine participants’ HbA1c level at the time of recruitment. For this reason we used RBG 
concentration as a proxy to HbA1c level to aid recruitment and attempt to recruit participants 
from across the glycaemic range. We aimed to achieve roughly equal numbers of participants 
with HbA1c <6.5, 6.5-9.0 and ≥9.0. We therefore based recruitment on RBG concentrations 
<7.0mmol/L, 7.0-9.0mmol/L and >9.0mmol/L. The first 91 participants with RBG<7mmol/L who 
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were eligible and willing to be enrolled were recruited. All 42 participants with RBG 7-9mmol/L 
and all 28 participants with RBG >9mmol/L were recruited. 
4.5 Activities 
Day 1 of enrolment 
1. Written informed consent obtained from consecutive eligible study 1 participants 
within the three strata of RBG concentration who were willing to participate.  
2. Venous blood sample taken for measurement of HbA1c concentration.  
3. Sputum specimen collected. 
Weekly for 8 weeks post-enrolment 
4. Sputum specimen collected. 
Week 12 post-enrolment 
5. Second venous blood sample taken for measurement of HbA1c concentration. 
6 months post-enrolment (or earlier if appropriate) 
6. TB register reviewed to determine final TB treatment outcome. 
4.6 Data collection methods: definitions and measurement 
The exposure, glycaemic control, was measured by HbA1c level, a continuous variable. This was 
measured at baseline and 12 weeks later. 
The outcome, tuberculosis treatment outcome, was assessed using two surrogate biomarkers: 
time to initial sputum culture positivity (TTP) and time to sputum culture conversion (TTC). TTC 
is a longstanding recognised and validated surrogate marker for tuberculosis relapse6; TTP, 
which reflects bacterial load and therefore degree of sputum smear positivity, has more 
recently been validated to predict 2-month sputum culture conversion and relapse.7, 8 
Results from the first sputum sample were used to determine TTP; results from the 
subsequent eight sputa determined TTC. For tuberculosis treatment outcome measured by 
TTP, the HbA1c concentration measured at the time of enrolment (at the time of tuberculosis 
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treatment commencement) was used to assess exposure status. This best reflects glycaemic 
concentration leading up to collection of the initial sputum sample. For tuberculosis treatment 
outcome measured by TTC, the HbA1c concentration measured at 12 weeks into tuberculosis 
treatment was used to assess exposure status. This reflects glycaemic concentration over the 
time that TTC was measured.  
Data on baseline characteristics and potential confounders were taken from the questionnaire 
administered in study 1. Potential confounding factors included age, sex, household socio-
economic position, and education level attained. 
Pin-prick capillary blood was taken for fasting blood glucose measurement and analysed using 
a point-of-care glucometer (Accu-Chek Aviva). Research staff performed all tests within the TB 
clinics. 
Research staff took a venous blood sample for HbA1c tests. These samples were transported by 
research staff daily to the ZAMBART laboratory for processing. The samples were processed by 
Zambart laboratory staff using an Abbott Architect i system. 
Sputum samples were collected at the TB clinics at the time of enrolment and then weekly for 
8 weeks. Research staff were trained to instruct participants on adequate expectoration to 
achieve a lower rather than upper airways sample. The samples were transported daily in a 
cooler box with cold packs to the laboratory and then processed daily using automated 
mycobacterial culture on liquid media. Each sample was decontaminated using the 
NaOH/NALC method (final concentration of NaOH = 1.5%), concentrated and then inoculated 
on to two BD MGIT (Mycobacteria Growth Indicator Tube) culture tubes. MGIT tubes were 
incubated in the BACTEC MGIT 960 instrument until the instrument detected growth. If the 
instrument had not declared them to be positive after 42 days the cultures were manually 
inspected for growth. Any showing growth such as cloudy or crumby particles were treated as 
a positive sample. Cultures with no visible growth were classified as negative. For MGIT 
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cultures with growth, a Ziehl-Neelsen stain for acid-fast bacilli (AFB) was performed. Samples 
with AFB negative stains were classified as contaminated. Samples with AFB positive stains 
were further identified using the Capilia TB-Neo assay, a rapid immunochromatographic test 
that confirms the presence of MTB-Complex in the culture supernatant. Capilia positive 
samples were classified as Myocbacterium tuberculosis (MTB). Capilia negative samples were 
classified as non-tuberculous mycobacteria (NTM). For these participants, the Hain GenoType 
Mycobacterium CM line-probe assay was used to confirm the presence/absence of MTB-
Complex and the presence/absence of an NTM, and to identify the NTM species, if possible.  If 
the CM assay could not identify the NTM species, the Hain GenoType Mycobacterium AS line-
probe assay was used. 
All contact with study participants took place during routine TB clinic attendances. 
Standard operating procedures were followed by field and laboratory staff for collection and 
processing of all specimens (Appendices IV). Research staff were trained by the PI on all 
aspects of data collection and were monitored by the PI for quality control. A pilot study was 
conducted on the first 10 participants recruited to test all data collection tools and procedures. 
4.7 Data management and statistical analysis 
As per study 1, all point-of-care test results were entered directly onto pre-programmed PDAs 
by research staff. Laboratory staff entered laboratory results directly into a database using a 
laboratory data management system. 
Cox-proportional hazards models were used to analyse both outcome measures, with HbA1c 
data in predefined categorical groups (<6.5, 6.5-9.0, >9.0mmol/L; based on clinically relevant 
categories) and as a linear variable. Results are presented in table and line graph format in 
Chapter 8. 
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Stratification by HIV status is the only pre-specified sub-group analysis, and as per study 1 is 
used for purposes of hypothesis generation rather than hypothesis testing due to insufficient 
study power for sub-group analyses. 
5 Design and methods: study 3 
5.1 Study design 
A study of diagnostic accuracy addressed aims 3 and 4, to distinguish between DM and stress-
induced hyperglycaemia and evaluate the accuracy for DM of measures of glycaemia at the 
time of tuberculosis diagnosis. 
5.2 Study population 
This study took place from September 2013 until December 2015 among newly-diagnosed 
adult cases of tuberculosis (pulmonary and non-pulmonary) who were about to be (or had 
newly been) commenced on antitubercular therapy at Chawama, George and Kanyama TB 
clinics in Lusaka, Zambia. 
5.3 Sample size calculations 
The sample size calculations for study 3 were based on simple estimates of precision for a 
calculated proportion, using the formula  𝑛 =
(1.962𝑝(1−𝑝))
𝑑2
  where n=sample size, p=proportion 
and d=precision. The proportions of interest were measures of index test accuracy (sensitivity, 
specificity, positive and negative predictive values) as determined by the reference standard. 
Table 4 shows sample size estimates for a range of anticipated test sensitivities assuming an 
acceptable level of precision of 0.05. 
  
122 
 
Table 4: Sample size estimates for study 3 
Precision Index test 
sensitivity+ 
Sample size required to 
calculate proportion* 
Total sample size 
required*# 
0.05 0.80 246 492 
0.05 0.85 196 392 
0.05 0.9 139 278 
0.05 0.95 73 146 
0.05 0.99 16 32 
+Estimates apply equally to other measures of test accuracy (specificity, positive predictive value or negative 
predictive value); *rounded up to be conservative; #double that required to calculate proportion as stratified 
sampling aims to recruit roughly half of participants with diabetes mellitus and half without. 
Therefore, assuming that 10% were lost to follow-up, it was predicted that 547 participants 
would need to be recruited to measure the sensitivity (or other measure of test accuracy) of 
each index test to within a precision of +/-5%. The final number of participants was 490; 205 
had a RBG <7.0mmol/L, 179 had a RBG 7.0-8.9mmol/L and 106 had a RBG ≥9.0mmol/L. 
However, only 8 participants were confirmed to have diabetes mellitus and so this study had 
poor precision for determining test sensitivity and positive predictive values but good precision 
for determining test specificity and negative predictive values. 
5.4 Subjects: selection and definitions 
Participants were recruited from studies 1 and 2.  
 Inclusion criteria were: study 1 or 2 participant, tuberculosis case within 2 days of 
starting antitubercular therapy. 
 Exclusion criteria are: <18 years of age 
The diagnosis of a case of tuberculosis was again based on WHO guidelines (Appendix II). 
Pulmonary and non-pulmonary cases of TB were eligible, with or without microbiological 
confirmation.  
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As studies 2 and 3 share some of the same activities, participants of study 2 were 
simultaneously recruited to study 3 when recruited to study 2: the 173 participants recruited 
to study 2 were included in study 3, with a further 317 recruited directly from study 1. 
To simplify recruitment and aim for roughly similar numbers of participants with and without 
true diabetes, the same stratified sampling technique was implemented for study 3 as for 
study 2. Therefore, the first 205 willing participants from study 1 with a RBG concentration of 
<7mmol/L were recruited to study 3; all 179 participants from study 1 with a RBG 
concentration of 7-9mmol/L and all 106 with a RBG concentration >9mmol/L were recruited. 
5.5 Activities 
Day 1 of enrolment 
1. Potential participants identified 
2. Individual written informed consent obtained from potential participants who were 
willing to be recruited 
3. Venous blood sample taken for measurement of HbA1c concentration 
4. Participants informed of procedures for fasting blood glucose measurement 
Day 2 following enrolment 
5. Fasting blood glucose concentration measured 
Week 12 post-enrolment 
6. FBG measurement repeated 
5.6 Data collection methods: definitions and measurement 
The index tests were RBG, FBG and HbA1c concentration measured at the time of TB diagnosis. 
The reference standard test for definitive diabetes diagnosis was FBG concentration measured 
after stabilisation of TB disease. 
Study 2 subjects followed all procedures necessary for both studies 2 and 3 without duplicating 
procedures (measurement of HbA1c concentration) that were required for both. Participants 
who were recruited directly from study 1 completed all procedures. 
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Standard operating procedures based on WHO guidelines were followed for measurement of 
fasting blood glucose. Capillary blood was sampled and glucose concentration measured using 
a point-of-care glucometer (Accu-Check Aviva). 
The same procedures as for study 2 were followed for measurement of HbA1c concentration. 
The reference standard test was measured at 3 months post-treatment commencement, by 
which time it was anticipated that the participants’ acute TB disease should have stabilised. 
The diabetes diagnostic criteria for the reference standard test, fasting blood glucose 
measured after stabilisation of tuberculosis disease, followed the WHO guidelines (Appendix 
III) i.e. a FBG concentration ≥7.0mmol/L was classified as diabetes. 
5.7 Data management and statistical analysis 
Analysis for aim 3 required descriptive frequency and percentage statistics only, to give the 
proportions of hyperglycaemic newly-diagnosed tuberculosis cases (measured separately by 
RBG, FBG and HbA1c) who truly have diabetes mellitus (measured by FBG after stabilisation of 
TB disease) rather than stress-induced hyperglycaemia secondary to infection (or other 
tuberculosis/non-diabetes cause of initial hyperglycaemia). 
Analysis for aim 4 required calculation of measures of test accuracy as determined by the 
reference standard test. Four measures were calculated for each index test: sensitivity, 
specificity, positive predictive value and negative predictive value.  
Results are presented in tabular format in Chapter 9. 
6 Project Management 
6.1 Personnel – functions and roles 
The PI developed all study forms (patient information sheets, informed consent forms, the 
questionnaire, all SOPs, participant referral letter, diabetes fact sheet); developed the PDA 
programme for real-time data entry; coordinated submission for ethics approval; recruited and 
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managed research nurses; oversaw all study activities and data collection; instigated quality 
control measures; analysed all data, and reported all study findings. Six research assistants 
recruited participants, administered questionnaire, conducted all point-of-care tests and 
organised collection of blood and sputum specimens for transport to the laboratory. Ministry 
of Health employed TB nurses based in the government TB clinics performed phlebotomy to 
collect the blood samples. Zambart drivers transported specimens from the clinics to the 
laboratory. Zambart laboratory staff processed specimens and inputted laboratory results to 
the database. The primary supervisor oversaw study development and execution and provided 
local liaison to facilitate running of the studies. The associate supervisors provided advice on 
aspects of the study design and logistics when required. The statistician provided advice on 
study design, sample size calculations and final data analyses. 
6.2 Follow-up procedures 
Follow-up of participants was necessary for studies 2 and 3. Follow-up either took place during 
routine TB clinic visits or through consultation with participant TB clinic records, except for 
collection of the initial FBG sample. For this attendance, therefore, participants were 
reimbursed for the cost of their travel to the clinic. For participants who did not attend the 
clinic for their routine visits and therefore missed their follow up appointments, attempts were 
made to contact them and request they attend for follow up. Repeated attempts were made 
via mobile telephone until the participant re-attended or advised that they were unable to re-
attend. Participants who did not return to the clinic after exhausting all options for contacting 
them and encouraging them to return were classified as lost-to-follow-up. 
7 Ethical Considerations 
The principles of the Helsinki Declaration were taken into account and were followed. The 
quality of the technical aspects of these studies was assured through rigorous planning and 
through adopting realistic and achievable methods and goals. Standard operating procedures 
were used to ensure safe and correct collection of all biological specimens from participants. 
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Ethics approval was secured prior to study commencement from the University of Zambia 
Biomedical Research Ethics Committee and the London School of Hygiene and Tropical 
Medicine Ethics Committee. 
Participants may have experienced mild bruising and discomfort associated with capillary and 
venous blood sampling. Routine safety and comfort measures were incorporated into the 
SOPs. There were no other hazards resulting from these studies.  
All participants who were identified to have an abnormal fasting blood glucose concentration 
as per WHO guidelines (≥7.0mmol/L; Appendix III; whether at time of TB diagnosis or after TB 
disease stabilisation) were referred to Chawama/George/Kanyama health centre for further 
assessment and management. Referral consisted of a participant letter with details of their 
glucose test results and a diabetes fact sheet for the participant to keep. Close liaison between 
research and clinic staff facilitated referral of each participant. For participants of study 1 only 
– who had only a random blood glucose concentration measured – individuals with a 
RBG≥7.0mmol/L were offered a subsequent FBG and referral following the same procedures if 
the subsequent FBG was ≥7.0mmol/L. 
HIV and CD4 count tests are a routine part of TB management in Lusaka, Zambia. We only 
performed these tests on participants who had not completed routine TB management 
procedures. Participant results for these were therefore reported to the TB clinic staff for 
continuation of management through existing TB and HIV care services, with verbal consent 
from participants. 
The study investigators give assurance that the participants’ interests were and will always be 
prioritised over those of science or society. Formal consent was required of every participant. 
Each participant received an information sheet detailing the aims and methods of the study 
and asking if they would like to be included in the study. If they responded favourably they 
were formally consented and were required to sign two copies of a consent form, one of which 
127 
 
they retained, in order to participate. There was no coercion of those not inclined to 
participate. Strict confidentiality was maintained throughout the study. 
The funding body (the Wellcome Trust) and all investigators have no conflicts of interest to 
declare. 
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Abstract 
Background: HIV and hyperglycaemia are independently associated with an increased risk of 
active tuberculosis. However, the dual effect of HIV and hyperglycaemia on the risk of 
developing tuberculosis disease is unclear. Systematic review identified only two prior studies 
investigating this. In these studies the effect of HIV on the association between 
hyperglycaemia and tuberculosis varied depending on the method used to measure 
hyperglycaemia and on the analysis strategy. Understanding these associations better will help 
us to respond appropriately to coexistent diabetes mellitus and tuberculosis in countries with 
a high prevalence of HIV.  Therefore, this study aims to determine how HIV modifies or not the 
association between hyperglycaemia and active tuberculosis in Lusaka, Zambia. 
Methods: This is a case-control study among newly-diagnosed adult tuberculosis cases and 
population controls in three areas of Lusaka. The individual character of interest is 
hyperglycaemia, determined by random blood glucose (RBG) concentration, measured at the 
time of recruitment. The outcome of interest is active tuberculosis disease, with cases 
determined by clinical diagnosis at a National Tuberculosis Programme government clinic. HIV 
status is determined by serological result. Multivariable logistic regression is used to explore 
the primary association and effect modification by HIV.  
Results: The prevalence of RBG concentration ≥11.1mmol/L among 3,843 tuberculosis cases 
was 1.4% and among 6,977 controls was 1.5%. Overall, the adjusted odds of active tuberculosis 
was 1.60 (95%CI 0.91-2.82) times higher among those with RBG concentration ≥11.1mmol/L 
compared to those with RBG concentration <11.1mmol/L. The corresponding adjusted odds 
ratio among those with HIV was 5.47 (95%CI 1.29-23.21) and among those without HIV was 
1.17 (95%CI 0.61-2.27). The p-value for effect modification by HIV was 0.042. On subgroup 
analysis, the adjusted odds of smear/Xpert-positive tuberculosis was 2.97 (95%CI 1.49-5.90) 
times higher among individuals with RBG concentration ≥11.1mmol/L compared to those with 
RBG concentration <11.1mmol/L. There was no evidence of association when the outcome 
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was restricted to smear/Xpert-negative or extrapulmonary tuberculosis (ORs 1.27 (95%CI 0.61-
2.63) and 1.88 (95%CI 0.58-6.13) respectively). 
Conclusions: Overall, no evidence of association between hyperglycaemia and active 
tuberculosis was found in this study population, though among those with HIV and/or 
smear/Xpert-positive tuberculosis there was statistical evidence of an association. 
Differentiation of hyperglycaemia caused by diabetes mellitus and stress-induced 
hyperglycaemia secondary to tuberculosis infection is important for a better understanding of 
these findings. 
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Keywords: Diabetes mellitus, Africa, Epidemiology 
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Background 
HIV and hyperglycaemia are independently associated with an increased risk of active 
tuberculosis (TB).1, 2 However, the dual effect of HIV and hyperglycaemia on the risk of 
developing TB disease is unclear. It could be that the contribution of hyperglycaemia to TB risk 
is relatively small in HIV-positive individuals compared with its contribution to TB risk in HIV-
negative individuals, as the greatly increased risk of TB among HIV-positive individuals could 
diminish any additional increased risk from hyperglycaemia. On the other hand, the effect of 
hyperglycaemia might be exacerbated in the presence of HIV infection if the contributions of 
each to increased TB risk are synergistic.  
Systematic review identifies only two prior studies investigating the effect of HIV on the 
association between hyperglycaemia or diabetes mellitus (DM) and tuberculosis.3, 4 Both 
studies were located in Tanzania and investigated the age- and sex-adjusted association 
between hyperglycaemia/DM and tuberculosis, stratified by HIV. The effect of HIV on the 
association varied depending on the analysis strategy used and on the method used to 
measure hyperglycaemia. Faurholt-Jepsen et al found no evidence of effect modification by 
HIV except for when adjusting the analysis for the acute phase reactant alpha-1-acid 
glycoprotein, in which case they found a stronger association between DM and active TB 
among HIV uninfected individuals than among those infected with HIV (p-value for interaction 
= 0.01).3 Boillat-Blanco et al found no evidence of effect modification by HIV except for when 
DM was determined by glycated haemoglobin, in which case again HIV uninfected individuals 
had the stronger association (p-value for interaction = 0.048).4 However, the stratified 
associations reverted to the null when measurement of diabetes was repeated five months 
after TB treatment initiation. 
Global guidelines exist for the care and control of co-existing diabetes mellitus and 
tuberculosis, but these were developed using evidence from studies largely based in non-
African populations and so had little contribution from high HIV prevalence settings.2, 5, 6 If HIV 
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does modify the association, this could lead to a different overall association in areas of high 
HIV prevalence. This is important to understand so that location-specific guidelines can be 
developed and implemented, to enable the most appropriate use of available resources to 
optimise the care and control of DM and TB. 
Therefore, this study aims to determine how HIV modifies or not the association between 
hyperglycaemia and active TB in Lusaka, Zambia. 
Methods 
Study design and setting 
This unmatched case-control study took place among adults in three urban communities in 
Lusaka, Zambia. Each community has a high incidence of TB and a high prevalence of HIV. The 
exposure of interest was hyperglycaemia and the outcome was diagnosed active TB disease.  
Cases 
Consecutive newly-diagnosed TB cases who had not yet started TB treatment or were within 2 
days of starting TB treatment were recruited from National TB Programme government clinics 
between September 2013 and September 2015. A TB case was defined as any person 
presenting to a TB clinic with a clinical diagnosis of TB (pulmonary or extra-pulmonary) with or 
without microbiological confirmation of TB and prescribed a full course of antitubercular 
chemotherapy, based on the World Health Organization (WHO) TB diagnostic criteria.7 This is 
the definition used for TB diagnosis in the study clinics as well as elsewhere in Zambia and 
much of sub-Saharan Africa and so use of this definition aimed to facilitate translation of the 
study results to the clinical setting. At the time of data collection the study clinics were using 
either sputum smear, Xpert MTB/RIF or both as microbiological tools to diagnose TB, 
depending on the availability of reagents and equipment. Exclusion criteria for cases were <18 
years of age, commenced TB treatment >2 days prior to recruitment or inability to give 
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consent due to disability/incapacitation. All eligible cases were identified in the TB clinic and 
invited to participate during a routine clinic attendance. 
Controls 
Unmatched controls were recruited between January and December 2010 as part of a cross-
sectional survey that measured prevalent TB for a large cluster randomised trial (the ZAMSTAR 
study).8, 9 The control participants were adults without prevalent TB and who were not on TB 
treatment on the date they were recruited to the cross-sectional survey. They were sampled 
randomly from all adults living in the catchment areas of the clinics, using a 2-stage cluster 
sampling technique within each community. Exclusion criteria for controls were <18 years of 
age, refusal to submit a respiratory sample, diagnosed TB at the time of the cross-sectional 
survey (culture positive sputum for mycobacterium tuberculosis), currently on treatment for TB 
at the time of the cross-sectional survey (self-report), inability to give consent due to 
disability/incapacitation or any persons living in institutional settings. All eligible controls were 
recruited in their homes. 
Data collection 
Glycaemia was determined by random capillary blood glucose sampling measured at the time 
of recruitment. An Optium Xceed point-of-care glucometer was used for controls and an Accu-
Chek Aviva point-of-care glucometer was used for cases. Manufacture of the Optium Xceed 
glucometer had been discontinued between the start of data collection for controls and cases. 
The Accu-Chek Aviva was identified as being a similar and well-performing point-of-care 
glucometer and was therefore chosen for use instead. The time of last oral intake (excluding 
water) was recorded. RBG concentration was measured during daylight hours and throughout 
the year for both cases and controls, so spanning all seasons. All research staff were trained on 
the use of the glucometers and were required to undergo proficiency testing. Standardised 
control solution was used for performance checks on test strips and meters. For the Accu-Chek 
Aviva glucometer, intra- and inter-operator variability was measured to assess the validity of 
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glucose measurement. All research assistants contributed to the assessment, using known 
normoglycaemic volunteers and a standard hyperglycaemic specimen. For intra-operator 
variability each research assistant repeated the test 5 consecutive times on a combined total 
of 13 subjects/specimens. For inter-operator variability research assistants each performed the 
test on a single subject/specimen in the same place at the same time for 7 subjects/specimens. 
For a subset of cases, fasting blood glucose (FBG) concentration was measured within 3 days of 
commencement of TB treatment and again 3 months later, to indicate if the hyperglycaemia 
was transient or persistent. A stratified sampling technique was used to select this subset to 
give participants with RBG concentrations across the glycaemic range.  
The potential effect modifier, HIV, was measured using point-of-care rapid blood-based kits. 
DetermineTM HIV-1/2 was used as the first line test and Uni-GoldTM HIV as a confirmatory test 
for individuals with a positive Determine test. Pre- and post-test counselling was offered. 
Participants who tested positive were referred to the local HIV clinic for management in 
existing HIV services, unless they were already integrated within a service. Self-reported use of 
antiretroviral therapy (ART) was recorded for individuals who were already known to be 
infected with HIV. 
In order to adjust for potential confounding factors, a structured questionnaire was used to 
obtain information on age, sex, smoking history, household socio-economic position and 
education level. Height, weight and waist circumference were measured using standardised 
methods. 
Data were electronically entered directly onto personal digital assistants by research assistants 
at the time of data collection, using pre-programmed questionnaires and result sheets with 
error and range checks. All data were downloaded into a SQL (structured query language) 
database and exported into Stata. 
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All questions, measurement tools (HIV testing kits but not glucometers) and test standard 
operating procedures were identical for cases and controls. 
Ethics 
Each participant was required to give written informed consent. Ethics approval was granted 
from the London School of Hygiene and Tropical Medicine Ethics Committee and the University 
of Zambia Biomedical Research Ethics Committee. 
Statistical analysis 
The sample size for this study was calculated to give sufficient power for determination of 
effect modification by HIV. Principal components analysis was used to create a measure of 
household socio-economic position. Hyperglycaemia was initially examined with RBG 
concentration as an ordered categorical variable. We then used the RBG cut-off 11.1mmol/L to 
explore hyperglycaemia as a binary variable. 
Unadjusted and adjusted odds ratios of the association between hyperglycaemia and active TB 
were estimated using logistic regression analysis. Interaction terms were used to assess for 
effect modification by HIV, adjusting for age, sex, socio-economic position, education, body 
mass index, smoking history and community. 
In addition to effect modification by HIV, restriction of the outcome definition separately to 
sputum smear-positive or Xpert MTB/RIF positive tuberculosis, smear-negative and Xpert 
MTB/RIF negative pulmonary TB, and extrapulmonary TB were identified a priori for sub-group 
analyses, as was exploration of the impact of ART use on HIV as an effect modifier. 
Potential bias was assessed using chi-squared tests of association of glycaemia with time of 
last oral intake before measurement and time of day of measurement of RBG concentration, 
each comparing cases to controls. Intra- and inter-operator variability were assessed for 
absolute agreement using a one-way random-effects model and a two-way random-effects 
model respectively, to calculate intraclass correlations (ICCs).10 
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Results 
There were 3,909 eligible TB cases identified, of which 3,843 (98.3%) consented to participate. 
There were 11,271 adults randomly selected from the three study communities and enrolled in 
the ZAMSTAR cross-sectional survey, of which 6,977 (61.9%) were eligible to be control 
participants for this case-control study (Figure 1).  
The characteristics of cases and controls are shown in Table 1. Cases were on average older 
than controls (p<0.001) and more frequently male (p<0.001). Among cases and controls, 12.9% 
and 16.2% respectively had a RBG concentration ≥7.0mmol/L, and 1.4% and 1.5% respectively 
had a RBG concentration ≥11.1mmol/L (Table 1). 65% of cases were living with HIV, compared 
to 18% of controls.  
On unadjusted analysis, there was no evidence of association between hyperglycaemia and 
tuberculosis with glycaemia as a binary variable. When analysed with RBG concentration as an 
ordered categorical variable, there was evidence of an association between hyperglycaemia 
and tuberculosis, but there was strong evidence that the association did not follow a linear 
trend. We therefore did not examine the association with RBG concentration as a continuous 
variable. Comparing participants with RBG ≥11.1mmol/L to those with RBG <11.1mmol/L, the 
unadjusted odds ratio of TB was 0.91 (95% CI 0.65-1.28). The unadjusted odds of TB was 8.74 
(95% CI 7.93-9.64) times higher in participants infected with HIV than in uninfected individuals. 
On unadjusted analysis there was no evidence to suggest that the odds of TB for the effect of 
hyperglycaemia differed between individuals infected and uninfected with HIV (Table 1). 
On adjusting for the effect of age, gender, education, socioeconomic position, body mass 
index, smoking history and community, there remained no evidence of association between 
hyperglycaemia and tuberculosis with RBG concentration as a binary variable. As a categorical 
variable there remained strong evidence of a non-linear association (test for departure from 
linear trend p<0.001); individuals with RBG concentration 7.0-8.9 mmol/L had a lower odds of 
TB than individuals in all other categories. This analysis was repeated separately for men and 
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women: for women the same non-linear direction of association was seen, for men no 
association was seen. The adjusted odds of TB was 1.60 times higher in those with RBG 
≥11.1mmol/L compared to those with RBG <11.1mmol/L (95% CI 0.91-2.82). However, there 
was evidence that the adjusted association between hyperglycaemia and tuberculosis was 
different between individuals uninfected and infected with HIV. Among individuals with HIV, 
the adjusted odds of TB was 5.47 times higher in those with RBG ≥11.1mmol/L compared to 
those with RBG <11.1mmol/L (95% CI 1.29-23.21). Among individuals without HIV, the 
adjusted odds of TB was 1.17 times higher for the same comparison (95% CI 0.61-2.27). The p-
value for interaction was 0.042. The main confounding factors were age, sex and body mass 
index. Interaction by age and gender was also seen, after adjusting for HIV, BMI, education, 
socioeconomic position, smoking history and community. For men aged 25-50 years the 
adjusted odds of TB was between 4.4 and 6.5 times higher than in men aged 18-25 years. For 
women aged 25-50 years the adjusted odds of TB was between 1.7 and 3.2 times higher than 
in women aged 18-25 years (p-value for interaction <0.001). 
Of all TB cases, 1,557 (40.9%) had sputum smear or Xpert positive TB, 1,929 (50.6%) had smear 
or Xpert negative pulmonary TB and 324 (8.5%) had extrapulmonary TB. When the analysis 
was restricted to these separate categories of TB, there was evidence of association between 
hyperglycaemia and sputum smear/Xpert-positive tuberculosis (adjusted odds ratio = 2.97, 
95% CI 1.49-5.90), and this association was stronger in individuals infected with HIV than in 
uninfected individuals (p-value for interaction = 0.028, Table 2). There remained no evidence 
of association between hyperglycaemia and tuberculosis for smear/Xpert-negative TB and 
extrapulmonary TB, both for the overall association and stratified by HIV (Table 2), though the 
direction of association was the same for all three categories of TB. 
Among individuals infected with HIV, 36.7% of cases and 21.2% of controls were taking ART. 
When HIV as a variable was re-categorised to include use of ART, there was evidence of 
association between hyperglycaemia and active tuberculosis among individuals who were HIV 
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positive and not currently taking ART, but not among individuals who were HIV-positive and 
taking ART (Table 3). 
FBG concentration was measured in 232 participants with TB at baseline and 3 months later. 
Nine participants had hyperglycaemia at baseline (FBG ≥7.0 mmol/L) and 4 (44.4%) of these 
had persistent hyperglycaemia 3 months later. Three (75%) of the participants with persistent 
hyperglycaemia were uninfected with HIV. Four (80%) of the participants with transient 
hyperglycaemia were infected with HIV. 
Participants reported the time of last oral intake prior to measurement of RBG concentration 
to be a mean of 4.9 hours (standard deviation 4.6 hours). This included all food and drink 
except water. There was no evidence of a difference in time (< or ≥6 hours) of last oral intake 
between participants with RBG <11.1 mmol/L and those with RBG ≥ 11.1 mmol/L (p=0.815), 
nor between individuals with and without TB (p=0.793). All cases had their RBG concentration 
measured in the morning, between the hours of 7am and 12pm. There was no evidence of a 
difference in the hour of measurement between participants with RBG <11.1 mmol/L and 
those with RBG ≥ 11.1 mmol/L (p=0.832). 
Assessment of the validity of the Accu-Chek Aviva glucometer measurements gave an 
intraclass correlation of 0.996 (95% CI 0.991-0.999) for intra-operator variability and 0.983 
(95% CI 0.954-0.995) for inter-operator variability. 
Discussion 
In this case-control study in Lusaka, Zambia, we found no evidence of association between 
hyperglycaemia and active tuberculosis, except for when TB was restricted to individuals with 
smear/Xpert-positive pulmonary TB only. There was evidence of effect modification by HIV for 
the association between hyperglycaemia and active TB. When adjusted for confounding 
factors, the association was stronger among individuals infected with HIV than among 
uninfected individuals. 
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When analysed as an ordered categorical variable with pre-defined categories, there was 
evidence of a non-linear association between hyperglycaemia and tuberculosis in our study 
population, as individuals with RBG concentration 7.0-8.9 mmol/L had a lower odds of TB than 
individuals with lower or higher RBG concentration (p<0.001). This was an unexpected finding 
and may be due to chance as there is no biological reason to explain this pattern. Aside from 
this, our primary association findings are in keeping with other studies that investigated the 
association between hyperglycaemia and tuberculosis in Africa. Haraldsdottir et al found no 
association between DM and active tuberculosis in a case-control study in Guinea-Bissau 
measuring diabetes in newly-diagnosed TB cases (adjusted odds ratio (OR) of TB for the effect 
of DM = 0.88, 95% CI [0.17-4.58]).11 Boillat-Blanco et al found a positive association between 
hyperglycaemia and tuberculosis in Tanzania when hyperglycaemia was measured around the 
time of TB treatment initiation, but the association disappeared when measurement of 
diabetes was repeated five months after TB treatment initiation, suggesting that the initial 
positive association was due to an increase in stress-induced hyperglycaemia among TB cases 
secondary to acute TB infection rather than due to DM.4  
Our findings of a stronger association among HIV infected than uninfected individuals could 
suggest that HIV and hyperglycaemia work synergistically to increase an individual’s risk of TB. 
Another possible explanation is an increase in stress-induced hyperglycaemia among newly-
diagnosed TB cases, as seen in Boillat-Blanco’s study. It is plausible that the most unwell newly 
diagnosed TB cases, and therefore the most likely to have stress-induced hyperglycaemia, 
could be found among individuals with HIV and with smear/Xpert-positive pulmonary TB. This 
would explain the positive associations seen in our study, and is in keeping with our findings 
from the subset of cases who had measurement of baseline and follow-up FBG concentration.  
This study used a single random blood glucose concentration to measure hyperglycaemia. This 
method is simple, quick, and minimises participant inconvenience as it requires only one 
finger-prick drop of blood. It is therefore ideal for use in a large community-based study, 
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facilitating measurement of glycaemia in control participants in their homes. It is not as 
sensitive for diabetes diagnosis as other measures of glycaemia, such as fasting blood glucose, 
2-hour blood glucose following an oral glucose tolerance test or glycated haemoglobin 
concentration, and so has likely led to an underestimate of the prevalence of hyperglycaemia. 
Each of the more sensitive methods would have been challenging to perform on a large scale 
in the community and could have led to selection bias if they were considered to be 
unacceptable to healthy control participants. An alternative could have been the use of a 
clinic-based control population as a proxy to community controls, but this too could have led 
to selection bias. Our choice to use community controls, measure RBG concentration and 
analyse the data with glycaemia as an ordered categorical variable has enabled assessment of 
shifts in proportions of glucose concentration between cases and controls.  Avoiding analysis 
solely by using a binary cut-off definition of hyperglycaemia has limited potential 
misclassification error that could exist with the use of this less sensitive measurement. 
Our definition of hyperglycaemia did not incorporate individuals with previously diagnosed 
(known) diabetes mellitus who were not hyperglycaemic at the time of measuring their RBG. 
This was an explicit decision resulting from our prior experience of discussing diabetes with 
groups and individuals in the community as well as health care workers. It became clear that 
there is high level of misclassification of known diabetes due to a low level of understanding of 
diabetes among all groups, and therefore it is difficult to reliably ascertain prior diagnoses of 
diabetes in our study setting. We therefore chose to focus on a biological measure of 
hyperglycaemia alone. This could have led to an underestimate of the association between 
long-term hyperglycaemia and active TB. 
Our assessment of intra- and inter-operator variability suggests that measurement of point-of-
care random blood glucose among cases in this study was consistent and valid. Additionally to 
this we explored the possibility of undertaking laboratory validation of glucose measurements 
by comparing glucometer results to results from laboratory processed venous blood samples 
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taken simultaneously. This proved not to be possible in our setting, as point-of-care glucose 
measurement is the principal method for measuring glycaemia, both in the community and 
centrally. The laboratory alternatives were therefore not equipped to offer a reliable 
benchmark. 
The temporal space between recruitment of controls and cases is another potential source of 
bias, though the three communities in this study have relatively stable populations and to our 
knowledge there were no major changes in the prevalence of hyperglycaemia or diabetes, the 
incidence of TB or the prevalence of HIV during the study period. The use of ART among 
individuals infected with HIV could feasibly have changed between recruitment of controls and 
cases: use of ART among the control population would most likely have increased over time. 
Exploration of the impact of ART on the associations studied showed an association only 
among individuals with HIV who were not taking ART, and not among individuals taking ART. 
An increase in use of ART among cases could therefore reduce the overall association seen 
among individuals with HIV, but an increase in use of ART among controls is unlikely to change 
the overall association. Further, this pattern fits with our hypothesis that the associations seen 
in this study could be due to stress-induced hyperglycaemia rather than diabetes. The 
recruitment gap is therefore unlikely to have introduced bias. However, an unforeseen 
consequence of the gap was the discontinuation of the initial glucometer model used for 
control participants. It was therefore necessary to use a different model for case participants. 
We attempted to choose a similar model to minimise any potential variability between the 
models, and so any difference in measurement of glycaemia is likely to be small rather than 
large. All other study procedures were identical for cases and controls. 
Control participants are representative of the general population within each community as 
they were randomly selected from the community. Case participants are representative of TB 
cases in each community as they were consecutively selected and defined using the same 
criteria used in the clinical setting. The findings from this study are therefore generalizable to 
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the study communities and are likely also generalizable to communities elsewhere in Zambia 
and much of sub-Saharan Africa with similar high incidence of TB and high prevalence of HIV. 
Conclusions 
Overall, no evidence of association between hyperglycaemia and active tuberculosis was found 
in this study population, though among those with HIV and those with smear/Xpert-positive 
pulmonary TB there was evidence of an association. Differentiation of hyperglycaemia caused 
by diabetes mellitus and stress-induced hyperglycaemia secondary to tuberculosis infection is 
important to understand these data further. 
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Figure 1: Number and flow of cases and controls 
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Table 1: Logistic regression estimates of the unadjusted and adjusted odds ratios of 
tuberculosis, stratified by HIV status 
Characteristic Cases 
n (%) 
Controls 
 n (%) 
Unadjusted OR 
(95% CI) 
P-value Adjusted OR (95% 
CI) 
P-value 
Overall 3,843 (100) 6,977 (100) - - - - 
Glucose 
concentration 
(mmol/L)* 
<5.6 2,255 (58.8) 3,069 (52.3) 1 <0.001 
TFT: 
<0.001 
DFT: 
<0.001 
1 <0.001 
TFT: 
0.051 
DFT: 
<0.001 
5.6-6.9 1,089 (28.4) 1,845 (31.5) 0.80 (0.73-0.88) 0.86 (0.74-1.00) 
7.0-8.9 352 (9.2) 755 (12.9) 0.63 (0.55-0.73) 0.62 (0.50-0.77) 
9.0-11.0 89 (2.3) 109 (1.9) 1.11 (0.84-1.48) 1.36 (0.84-2.21) 
>11.0 53 (1.4) 89 (1.5) 0.81 (0.57-1.14) 1.46 (0.83-2.58) 
HIV status* Uninfected 1,287 (34.8) 4,320 (82.4) 1 <0.001 1 <0.001 
Infected 2,412 (65.2) 926 (17.7) 8.74 (7.93-9.64) 9.35 (8.07-10.85) 
HIV uninfected <5.6 803 (62.4) 2,258 (53.6) 1 - 1 - 
5.6-6.9 330 (25.7) 1,297 (30.8) 0.72 (0.62-0.83) <0.001 0.86 (0.71-1.04) 0.125 
7.0-8.9 106 (8.2) 520 (12.3) 0.57 (0.46-0.72) <0.001 0.63 (0.47-0.85) 0.002 
9.0-11.0 24 (1.9) 71 (1.7) 0.95 (0.59-1.52) 0.832 1.33 (0.71-2.49) 0.372 
>11.0 23 (1.8) 71 (1.7) 0.91 (0.57-1.47) 0.701 1.08 (0.56-2.09) 0.826 
HIV infected <5.6 1,365 (56.6) 447 (49.2) 1 - 1 - 
5.6-6.9 727 (30.2) 316 (34.8) 0.75 (0.64-0.89) 0.001 0.86 (0.68-1.09) 0.209 
7.0-8.9 232 (9.6) 125 (13.8) 0.61 (0.48-0.77) <0.001 0.61 (0.43-0.85) 0.004 
9.0-11.0 60 (2.5) 16 (1.8) 1.23 (0.70-2.15) 0.474 1.41 (0.66-3.02) 0.371 
>11.0 27 (1.1) 5 (0.6) 1.77 (0.68-4.62) 0.245 4.94 (1.16-21.02) 0.031 
Glucose <5.6 
mmol/L 
HIV uninfected 803 (37.0) 2,258 (83.5) 1 <0.001 1 <0.001 
HIV infected 1,365 (63.0) 447 (16.5) 8.59 (7.51-9.82) 9.26 (7.67-11.19) 
Glucose 5.6-6.9 
mmol/L 
HIV uninfected 330 (31.2) 1,297 (80.4) 1 <0.001 1 <0.001 
HIV infected 727 (68.8) 316 (19.6) 9.04 (7.56-10.81) 9.26 (7.18-11.95) 
Glucose 7.0-8.9 
mmol/L 
HIV uninfected 106 (31.4) 520 (80.6) 1 <0.001 1 <0.001 
HIV infected 232 (68.6) 125 (19.4) 9.10 (6.73-12.31) 8.86 (5.85-13.44) 
Glucose 9.0-
11.0 mmol/L 
HIV uninfected 24 (28.6) 71 (81.6) 1 <0.001 1 <0.001 
HIV infected 60 (71.4) 16 (18.4) 11.09 (5.40-22.79) 9.84 (3.73-25.93) 
Glucose >11.0 
mmol/L 
HIV uninfected 23 (46.0) 71 (93.4) 1 <0.001 1 <0.001 
HIV infected 27 (54.0) 5 (6.6) 16.67 (5.75-48.30) 42.48 (8.74-206.50) 
Age (years) 18-24 555 (14.4) 2,771 (40.3) 1 <0.001 1 <0.001 
25-29 751 (19.5) 1,222 (17.8) 3.07 (2.70-3.49) 2.68 (2.20-3.26) 
30-34 861 (22.4) 813 (11.8) 5.29 (4.63-6.04) 3.46 (2.80-4.28) 
35-39 755 (19.7) 573 (8.3) 6.58 (5.71-7.58) 4.52 (3.59-5.68) 
40-49 612 (15.9) 727 (10.6) 4.20 (3.65-4.84) 2.96 (2.34-3.74) 
50+ 309 (8.0) 770 (11.2) 2.00 (1.71-2.35) 2.13 (1.66-2.74) 
Sex Male 2,605 (67.8) 1,955 (28.0) 1 <0.001 1 <0.001 
Female 1,238 (32.2) 5,022 (72.0) 0.19 (0.17-0.20) 0.19 (0.16-0.22) 
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Highest level of 
education 
None 387 (10.1) 446 (6.4) 1 <0.001 1 <0.001 
Grade 1-7 1,388 (36.2) 2,474 (35.5) 0.65 (0.56-0.75) 0.42 (0.32-0.56) 
Grade 8-12 1,969 (51.3) 3,645 (52.2) 0.62 (0.54-0.72) 0.31 (0.24-0.41) 
College/ 
University 
91 (2.4) 412 (5.9) 0.25 (0.2-0.33) 0.10 (0.07-0.16) 
Smoking 
history 
Never smoked 2,863 (74.6) 6,188 (88.7) 1 <0.001 1 0.326 
Current or ex-
smoker 
976 (25.4) 789 (11.3) 2.67 (2.41-2.97) 1.10 (0.91-1.32) 
Body Mass 
Index  
(weight(kg)/ 
height2(m)) 
Healthy weight 
(18.5-24.9) 
1,985 (51.9) 4,106 (62.5) 1 <0.001 1 <0.001 
Underweight 
(<18.5) 
1,659 (43.4) 541 (8.2) 6.34 (5.68-7.09) 6.49 (5.49-7.68) 
Overweight (25-
29.9) 
129 (3.4) 1,265 (19.3) 0.21 (0.17-0.25) 0.24 (0.19-0.31) 
Obese (≥30) 53 (1.4) 655 (10.0) 0.17 (0.13-0.22) 0.23 (0.16-0.34) 
OR=odds ratio; CI=confidence interval; TFT = test for linear trend; DFT = test for departure from linear trend; 
*Estimates from model with no interaction. All other estimates taken from model with HIV interaction; Adjusted 
analyses adjusted for all variables shown, plus household socioeconomic position and community; 167 cases & 2,179 
controls excluded from adjusted analyses due to missing data; p-value for interaction, unadjusted analysis = 0.707; 
p-value for interaction, adjusted analysis = 0.390; 
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Table 2: Logistic regression estimates of the unadjusted and adjusted odds ratios of 
smear/Xpert-positive, smear/Xpert-negative and extrapulmonary tuberculosis, stratified by 
HIV status 
Characteristic Cases 
n (%) 
Controls 
n (%) 
Unadjusted OR 
(95% CI) 
P-value Adjusted OR (95% 
CI) 
P-value 
Sputum smear/Xpert-positive tuberculosis 
RBG concentration 
(mmol/L)* 
<11.1 1,533 (98.5) 5,778 (98.5) 1 0.911 1 0.003 
≥11.1 23 (1.5) 89 (1.5) 0.97 (0.61-1.55) 2.97 (1.49-5.90) 
HIV uninfected RBG<11.1 588 (98.3) 4,146 (98.3) 1 0.984 1 0.153 
RBG≥11.1 10 (1.7) 71 (1.7) 0.99 (0.51-1.94) 1.87 (0.79-4.39) 
HIV infected RBG<11.1 879 (98.8) 904 (99.5) 1 0.132 1 0.001 
RBG≥11.1 11 (1.2) 5 (0.6) 2.26 (0.78-6.54) 12.43 (2.63-58.69) 
Sputum smear/Xpert-negative tuberculosis 
RBG concentration 
(mmol/L)* 
<11.1 1,903 (98.7) 5,778 (98.5) 1 0.593 1 0.518 
≥11.1 26 (1.4) 89 (1.5) 0.89 (0.57-1.38) 1.27 (0.61-2.63) 
HIV uninfected RBG<11.1 592 (98.2) 4,146 (98.3) 1 0.803 1 0.949 
RBG≥11.1 11 (1.8) 71 (1.7) 1.09 (0.57-2.06) 0.97 (0.42-2.27) 
HIV infected RBG<11.1 1,260 (98.9) 904 (99.5) 1 0.182 1 0.153 
RBG≥11.1 14 (1.1) 5 (0.6) 2.01 (0.72-5.60) 3.55 (0.62-20.19) 
Extrapulmonary tuberculosis 
RBG concentration 
(mmol/L)* 
<11.1 320 (98.8) 5,778 (98.5) 1 0.675 1 0.324 
≥11.1 4 (1.2) 89 (1.5) 0.81 (0.30-2.22) 1.88 (0.58-6.13) 
HIV uninfected RBG<11.1 73 (97.3) 4,146 (98.3) 1 0.518 1 0.573 
RBG≥11.1 2 (2.7) 71 (1.7) 1.60 (0.39-6.65) 1.54 (0.34-6.92) 
HIV infected RBG<11.1 226 (99.1) 904 (99.5) 1 0.576 1 0.321 
RBG≥11.1 2 (0.9) 5 (0.6) 1.60 (0.31-8.30) 2.92 (0.35-24.26) 
OR=odds ratio; CI=confidence interval; *Estimates from model with no interaction; p-values for interaction: 
smear/Xpert-positive TB = 0.028, smear/Xpert-negative TB = 0.172, extrapulmonary TB = 0.628 
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Table 3: Logistic regression estimates of the unadjusted and adjusted odds ratios of 
tuberculosis, stratified by HIV status and use of antiretroviral therapy 
Characteristic Cases 
n (%) 
Controls 
n (%) 
Unadjusted OR 
(95% CI) 
P-
value 
Adjusted OR (95% 
CI) 
P-
value 
RBG concentration 
(mmol/L)* 
<11.1 3,785 (98.6) 5,778 (98.5) 1 0.584 1 0.104 
≥11.1 53 (1.4) 89 (1.5) 0.91 (0.65-1.28) 1.60 (0.91-2.82) 
HIV uninfected RBG<11.1 1,263 (98.2) 4,146 (98.3) 1 0.800 1 0.574 
RBG≥11.1 23 (1.8) 71 (1.7) 1.06 (0.66-1.71) 1.21 (0.62-2.34) 
HIV infected and 
currently taking ART 
RBG<11.1 878 (99.3) 193 (98.5) 1 0.248 1 0.885 
RBG≥11.1 6 (0.7) 3 (1.5) 0.44 (0.11-1.77) 0.85 (0.09-7.79) 
HIV infected and not 
currently taking ART 
RBG<11.1 1,506 (98.6) 711 (99.7) 1 0.031 1 0.013 
RBG≥11.1 21 (1.4) 2 (0.3) 4.96 (1.16-21.2) 16.79 (1.8-156.75) 
OR=odds ratio; CI=confidence interval; ART=antiretroviral therapy; *Estimates from model with no interaction. 
 
 
 
152 
 
Chapter 8: Study 2 paper: The effect of hyperglycaemia on 
tuberculosis treatment outcome in Lusaka, Zambia; a cohort study 
Bailey SL1,2, Floyd S1, Munkondya-Gondwe S2, Mwanza W2, Maluzi K2, Cheeba-Lengwe M2, 
Chiwele-Kangololo K2, Kaluba-Milimo D2, Kosloff B1,2, Yudkin JS3, Godfrey-Faussett P1, Ayles H1,2 
1LSHTM TB Centre and Department of Clinical Research, London School of Hygiene and Tropical 
Medicine, London, UK 
2Zambart Project, Lusaka, Zambia  
3Division of Medicine, University College London, London, UK 
Corresponding author: Dr Sarah Lou Bailey, slbailey@doctors.org.uk, +442081234489 
Word count: 4,179 
 
  
153 
 
Abstract 
Background: Hyperglycaemia in individuals with tuberculosis is a risk factor for poor 
tuberculosis treatment outcome. Diabetes mellitus and hyperglycaemia cause impaired 
immunity which is more severe for individuals with poor glycaemic control than for those with 
good glycaemic control. Therefore, we aimed to determine if a dose-response relationship 
exists between hyperglycaemia and tuberculosis treatment outcome. 
Methods: We conducted a prospective cohort study among smear-positive pulmonary 
tuberculosis cases who were starting antitubercular therapy at three clinics in Lusaka, Zambia. 
We used a stratified sampling technique to recruit individuals from across the glycaemic range, 
by screening all potential participants through measurement of their random blood glucose 
(RBG) concentration. The exposure of interest was glycated haemoglobin (HbA1c). Tuberculosis 
treatment outcome was assessed using two surrogate biomarkers: time to initial sputum 
culture positivity (TTP) and time to sputum culture conversion (TTC). Unadjusted and adjusted 
rate ratios of the association between glycaemia and tuberculosis treatment outcome were 
estimated using cox-proportional hazards models. 
Results: We screened 1,557 individuals with pulmonary tuberculosis, of whom 173 were 
recruited. Of these, 153 were confirmed on culture to have Mycobacterium tuberculosis and 
were included in the analysis, and 131 (86%) participated in follow up. We identified only 21 
individuals with a baseline HbA1c 6.0-6.4% and 9 with HbA1c ≥6.5%. On adjusted cox regression 
analysis with glycaemia as an ordered categorical variable we found no evidence of association 
between glycaemia and TTP (RR=1.75, 95%CI 0.73-4.18 comparing participants with HbA1c 
≥6.5% to those with HbA1c <6.0%), or between glycaemia and TTC (RR 0.73, 95%CI 0.20-2.60 
for the same comparison). We found weak evidence of a linear association between glycaemia 
and TTP (RR=0.97, 95% CI 0.63-1.49). Using a binary variable to compare individuals with HbA1c 
≥6.0% to those with a level <6.0%, there was no evidence of association between glycaemia 
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and TTP but weak evidence of association between glycaemia and TTC (RR 1.44, 95%CI 0.89-
2.33 and RR 0.54, 95%CI 0.27-1.09 respectively). 
Conclusions: We found no evidence that a relationship exists between glycaemia as an 
ordered categorical variable and tuberculosis treatment outcome, though the direction of 
trend was consistent with a faster time to initial sputum positivity and a slower time to sputum 
culture conversion for higher levels of glycaemia. We found a low prevalence of 
hyperglycaemia and so our study was underpowered to detect any true association. This does 
however suggests that hyperglycaemia is not a major challenge for TB control in this location. 
401 words 
Keywords: Glycaemic control; Diabetes mellitus; Transient hyperglycaemia; Africa. 
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Background 
Systematic review of the literature suggests that individuals with tuberculosis (TB) and 
coexistent diabetes mellitus have 1.89 (95% CI 1.36-2.12) times increased risk of death from 
tuberculosis and 3.89 (95% CI 2.43-6.23) times increased risk of tuberculosis relapse compared 
to individuals with tuberculosis alone.1 Transient hyperglycaemia at the time of tuberculosis 
diagnosis, which was found to normalise after five months of antituberculosis treatment, has 
also been identified as a risk factor for poor TB treatment outcome:2 in a study of 530 
Tanzanian individuals with tuberculosis, those with a fasting capillary glucose level of ≥6.1 
mmol/L at the time of TB diagnosis had 3.32 (95% CI 1.20-9.14) times the adjusted odds of TB 
treatment failure or death compared to individuals with a fasting capillary glucose of <6.1 
mmol/L at the time of TB diagnosis.2  
Diabetes mellitus causes impaired cell mediated immunity, including T-cell function, which is 
more severe for individuals with poor glycaemic control than for those with good glycaemic 
control.3-7 The differences in cellular cytokine responses to M. tuberculosis in TB patients with 
diabetes compared to TB patients without diabetes are even more marked for patients with 
poor glycaemic control.4 Effective cellular immunity is important for controlling growth of M. 
tuberculosis4, 8, 9 so we might expect to see a dose-response relationship between 
hyperglycaemia and TB treatment outcome. If this is the case, we could hypothesise that 
controlling glycaemia during TB treatment could help to improve TB treatment outcome. 
Diagnosing diabetes mellitus at the time of active TB infection can be troublesome, as it is 
difficult to distinguish diabetes from transient hyperglycaemia due to acute infection.2 In 
practice, at the time of TB diagnosis, we can distinguish hyperglycaemia from normoglycaemia, 
either through measurement of blood glucose concentration – reflecting glycaemia at the time 
the sample was taken – or through measurement of glycated haemoglobin – reflecting the 
average level of glycaemia over the preceding few weeks. Any hyperglycaemia identified 
through measurement of either of these could be due to underlying diabetes mellitus or could 
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be transient from factors such as stress hyperglycaemia from TB infection. We are not able to 
distinguish diabetes mellitus from transient hyperglycaemia until after resolution of active TB 
infection; after the window period for potential intervention. For this reason we have chosen 
to focus on hyperglycaemia at the time of active TB infection irrespective of underlying 
diagnosis, rather than having a restricted focus solely on diabetes mellitus. Moreover, as 
transient hyperglycaemia is itself associated with poor TB treatment outcome, the hypothesis 
that worsening hyperglycaemia could be associated with worsening TB treatment outcome is 
equally relevant to individuals with transient hyperglycaemia. 
We have identified four prior studies that have explored the association between glycaemic 
control or diabetes control and TB treatment outcome.10-13 Their findings are conflicting, all but 
one are retrospective, none are located in Africa and all either exclude participants who are 
infected with HIV or have a very low prevalence of HIV in their study population. Therefore, we 
aimed to contribute to the literature on this topic by conducting a prospective study to 
determine if a dose-response relationship exists between hyperglycaemia and tuberculosis 
treatment outcome in our study setting of Lusaka, Zambia. 
Tuberculosis treatment outcome can be defined in different ways. At the end of treatment, the 
outcome can be classified as successful, which includes individuals with evidence of 
microbiological cure and those who have completed treatment, or unsuccessful, which 
includes individuals with evidence of microbiological treatment failure, those who died, and 
those who did not complete treatment.14 Unsuccessful treatment outcome defined as 
tuberculosis relapse requires measurement at a time point beyond the end of TB treatment. 
TB treatment outcome can also be measured by numerous surrogate biomarkers at an earlier 
time point, the most common of which is sputum smear or culture conversion after two 
months of treatment among individuals with pulmonary tuberculosis.15-23 This can be 
measured as a binary variable or as a quantitative time to conversion. The time to sputum 
culture conversion (TTC) is a longstanding recognised and validated surrogate marker for 
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tuberculosis relapse as it is a quantifiable measure of response to tuberculosis treatment.24 
Time to initial sputum culture positivity (TTP) at the start of TB treatment reflects bacterial 
load and therefore degree of sputum smear positivity, so has more recently been validated to 
predict 2-month sputum culture conversion and relapse.15, 16 
The use of surrogate markers of TB treatment outcome are particularly useful for settings with 
low death and treatment failure rates from tuberculosis, such as in our Zambian study 
setting.25 
Methods 
We conducted a prospective cohort study among smear-positive pulmonary tuberculosis cases 
who were about to be (or had newly been) commenced on antitubercular therapy at three TB 
clinics in Lusaka, Zambia. Recruitment took place from September 2013 until September 2015. 
Participants were followed up for 3 months; data collection finished in December 2015. 
Participants 
All eligible potential participants were identified in the TB clinics and invited to participate 
during a routine clinic attendance. Eligible participants were newly-diagnosed cases of smear- 
or Xpert MTB/RIF-positive tuberculosis due to commence on a full course of antitubercular 
chemotherapy. Exclusion criteria were <18 years of age, commenced TB treatment >2 days 
ago, smear/Xpert-negative pulmonary tuberculosis and non-pulmonary tuberculosis. A 
stratified sampling technique was used to recruit participants from across the glycaemic range. 
The level of glycated haemoglobin was our glycaemic exposure of interest, as this best reflects 
the average blood glucose concentration over the time period of interest. However, the only 
reliable method of measuring glycated haemoglobin in our study setting was a laboratory 
method, not through use of a point-of-care device, and so we were unable to determine 
glycated haemoglobin level in potential participants at the time of recruitment. For this reason 
we used RBG concentration as a proxy to glycated haemoglobin to aid recruitment, as we were 
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able to determine this at the time of recruitment through use of a point-of-care device. We 
screened all eligible and willing participants with a random blood glucose (RBG) concentration 
using an Accu-Chek Aviva glucometer and based stratified recruitment on RBG concentrations 
<7.0mmol/L and ≥7.0mmol/L. The first 90 participants with RBG <7.0mmol/L and all 
participants with RBG ≥7.0mmol/L were recruited. Participants were followed up in the TB 
clinic during routine clinic visits. Sample size calculations were based on estimates for survival 
analysis using a cox proportional hazards model to assess the effect of glycaemia on both time 
to initial sputum culture positivity and time to culture conversion. We had aimed to recruit a 
minimum of 85 participants in each group to give sufficient power to detect the minimum 
difference deemed to be clinically significant between groups. 
The exposure 
The exposure, hyperglycaemia, was determined by glycated haemoglobin (HbA1c). Venous 
blood samples were drawn for HbA1c tests at the time of enrolment and 3 months after 
commencement of TB treatment. These samples were transported daily from the clinics to the 
laboratory for storage at 2-8oC before being processed in weekly batches using an Abbott 
Architect i2000SR analyser. For TB treatment outcome measured by time to initial sputum 
culture positivity, the HbA1c level measured at the time of enrolment (at the time of 
tuberculosis treatment commencement) was used to assess exposure status. This best reflects 
glycaemic concentration leading up to collection of the initial sputum sample. For TB 
treatment outcome measured by time to sputum culture conversion, the HbA1c level measured 
at 3 months into tuberculosis treatment was used to assess exposure status. This reflects 
glycaemic concentration over the time that culture conversion was measured.  
All participants who had glycaemia in the diabetes range (HbA1c ≥6.5%) on either test were 
referred to local health care facilities for follow-up and management. 
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The outcome 
The outcome of interest, tuberculosis treatment outcome, was assessed using two surrogate 
biomarkers: time to initial sputum culture positivity (TTP) and time to sputum culture 
conversion (TTC).  
Sputum samples were collected at the TB clinics at the time of enrolment and then weekly for 
8 weeks. Research staff were trained to instruct participants on adequate expectoration to 
achieve a lower rather than upper airways sample. The samples were transported daily in a 
cooler box with cold packs to the laboratory and then processed daily using automated 
mycobacterial culture on liquid media. Each sample was decontaminated using the 
NaOH/NALC method (final concentration of NaOH = 1.5%), concentrated and then inoculated 
on to two BD MGIT (Mycobacteria Growth Indicator Tube) culture tubes. MGIT tubes were 
incubated in the BACTEC MGIT 960 instrument until the instrument detected growth. If the 
instrument had not declared them to be positive after 42 days the cultures were manually 
inspected for growth. Any showing growth such as cloudy or crumby particles were treated as 
a positive sample. Cultures with no visible growth were classified as negative. For MGIT 
cultures with growth, a Ziehl-Neelsen stain for acid-fast bacilli (AFB) was performed. Samples 
with AFB negative stains were classified as contaminated. Samples with AFB positive stains 
were further identified using the Capilia TB-Neo assay, a rapid immunochromatographic test 
that confirms the presence of MTB-Complex in the culture supernatant. Capilia positive 
samples were classified as Myocbacterium tuberculosis (MTB). Capilia negative samples were 
classified as non-tuberculous mycobacteria (NTM). For these participants, the Hain GenoType 
Mycobacterium CM line-probe assay was used to confirm the presence/absence of MTB-
Complex and the presence/absence of an NTM, and to identify the NTM species, if possible.  If 
the CM assay could not identify the NTM species, the Hain GenoType Mycobacterium AS line-
probe assay was used. 
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Results from the baseline sputum sample were used to determine TTP; results from the 
subsequent seven sputa were used to determine TTC.  
Mitigating for potential bias 
Data on baseline characteristics and potential confounders were collected through use of a 
questionnaire, including information on age, sex, household socio-economic position and HIV 
status. 
All data collection methods were identical for all exposure groups. Standard operating 
procedures were followed by field and laboratory staff for collection and processing of all 
specimens. Research staff were trained by the PI on all aspects of data collection and were 
monitored for quality control. All questionnaire data and point-of-care test results were 
entered at the time of data collection by research staff, directly onto pre-programmed 
personal digital assistants with error and range checks. Data were downloaded into a SQL 
(structured query language) database and exported into Stata. Laboratory staff entered 
laboratory results directly into a database using a laboratory data management system. 
Ethics 
Each participant was required to give written informed consent. Ethics approval was granted 
from the London School of Hygiene and Tropical Medicine Ethics Committee and the University 
of Zambia Biomedical Research Ethics Committee. 
Statistical analysis 
The exposure variable, glycated haemoglobin, was grouped into predefined categorical groups 
using clinically relevant cut points (<6.0%, 6.0-6.4% and ≥6.5%). Participants were recruited 
based on the smear/Xpert result of the sputum sample taken and processed for routine 
diagnostic purposes in the TB clinics. For analysis, however, each participant was re-classified 
as having TB, NTM or no mycobacterial disease based on the results of sputum samples 
collected for this study and processed in our research laboratory. Participants were classified 
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as having TB if any study sputum sample either at baseline or follow-up was culture positive 
for M. tuberculosis as defined by being AFB positive and Capilia TB positive. Participants were 
classified as having NTM if any study sputum sample was culture positive for mycobacteria 
other than tuberculosis as defined by being AFB positive but Capilia TB negative, with 
subsequent confirmation by the molecular test. Participants were classified as having no 
mycobacterial disease if all study samples were either MGIT negative, or MGIT positive and 
AFB negative, indicating sample contamination. Participants with NTM or no mycobacterial 
disease were excluded from all analyses. For the participants included in the study, each 
sputum sample was classified as being positive for TB if either or both MGIT cultures were 
classified as positive for TB, by being AFB and Capilia TB positive. If only one culture was TB 
positive the TTP for this culture was used in the analysis. If both cultures were positive for TB 
the mean TTP was calculated and used in the analysis. Sputum samples were classified as 
negative if both MGIT cultures were classified as negative, or if they were MGIT positive and 
AFB/Capilia negative. The week of culture conversion was classified as the first week with a 
negative sputum sample with all subsequent samples remaining negative. 
Principal components analysis was used to create a measure of household socio-economic 
position. Median days to initial sputum culture positivity and median weeks to sputum culture 
conversion were calculated along with inter-quartile ranges (IQRs). Unadjusted and adjusted 
rate ratios of the association between glycaemic control and tuberculosis treatment outcome 
were estimated using cox-proportional hazards models. Potential confounding factors were 
controlled for through adjusting the survival analysis estimates for age, sex, socio-economic 
position, community and HIV. Sub-group and interaction analyses were not performed due to 
insufficient power for these analyses. 
Results 
There were 1,557 sequential smear-positive TB cases who were screened for eligibility to this 
cohort study: 173 participants were found to be eligible. All consented for recruitment. After 
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recruitment, 13 participants had sputum cultures that were persistently negative for 
mycobacteria and 7 participants were confirmed to have non-tuberculous mycobacterial 
disease rather than TB. These participants were therefore excluded from the analysis, leaving 
153 participants included in the analysis. Of these, 81 (53%) participants had RBG<7mmol/L, 61 
(40%) had RBG ≥7mmol/L and 11 (7%) had missing data for RBG concentration. There were 
140 (92%) participants who completed the baseline HbA1c test and 88 (56%) who completed 
the follow-up HbA1c test at 12 weeks. There were 131 (86%) participants who participated in 
follow up of sputum samples, 97 (63%) completed sputum submission to 7 weeks and 43 (28%) 
completed sputum submission to 8 weeks. The flow of study participants through recruitment 
and follow-up is shown in Figure 1. 
The median follow-up time for sputum collection was 3 weeks (IQR 1-6 weeks). The combined 
total follow-up time for all participants submitting sputum samples was 746 weeks. There was 
no evidence to suggest that participants who completed all follow-up data collection differed 
in terms of baseline characteristics from individuals with incomplete follow-up data (Table 1). 
The participants had a median age of 33 years (IQR 28-38 years). More than two-thirds were 
male (68.3%) and nearly two-thirds were infected with HIV (62.2%). Of all participants with a 
baseline HbA1c test, 110 (78.6%) had HbA1c <6.0%, 21 (15.0%) had HbA1c 6.0-6.4% and 9 (6.4%) 
had HbA1c ≥6.5%. For the follow up HbA1c test, these values were 64 (72.7%), 18 (20.5%) and 6 
(6.8%). Two participants reported a prior diagnosis of diabetes mellitus. Neither were on 
diabetes treatment and both had a baseline HbA1c ≥6.5%. 
The median time to positivity of the baseline sputum sample was 6.8 days (IQR 4.9-9.4 days) 
for participants with a baseline HbA1c <6.0%, 6.0 days (IQR 4.1-8.1 days) for participants with 
baseline HbA1c 6.0-6.4% and 5.9 days (IQR 4.9-7.1 days) for participants with baseline HbA1c 
≥6.5%. Of all participants, 94 (61.4%) achieved documented sputum conversion within the 
follow-up time. Of the 43 participants who completed sputum submission to 8 weeks, 33 
(76.7%) achieved sputum conversion. The median time to sputum culture conversion for 
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participants with follow-up HbA1c <6.0%, 6.0-6.4% and ≥6.5% was 5 weeks (IQR 4-7 weeks), 
6weeks (IQR 3-7 weeks) and 6 weeks (IQR 5-6 weeks) respectively. 
On unadjusted cox regression analysis of the baseline data, the rate ratio point estimates for 
the time to sputum culture positivity of the initial sputum sample collected at the time of TB 
treatment initiation increase with increasing levels of glycated haemoglobin. However, the 
confidence intervals are wide and no evidence is seen for an association (p=0.285, Table 2). On 
unadjusted analysis of the follow-up data there was no evidence of association between 
glycated haemoglobin level and time to sputum culture conversion (p=0.427, Table 3). Figures 
2 and 3 show unadjusted Kaplan-Meier estimates of the time to sputum culture positivity and 
the time to sputum culture conversion respectively, by glycated haemoglobin level. 
Tables 2 and 3 show the cox regression adjusted analyses of the baseline and follow-up data 
respectively, adjusted for age, sex, socioeconomic position, HIV status and community. The 
negative confounding factors were age and socioeconomic position. HIV status was a positive 
confounding factor. There remained no evidence of association between glycated 
haemoglobin level as a categorical variable and time to sputum culture positivity for the 
baseline sputum sample (p=0.309), nor between glycated haemoglobin level as a categorical 
variable and time to sputum culture conversion (p=0.181). The direction of trend was 
consistent with an association: there was a faster time to initial sputum positivity and a slower 
time to sputum culture conversion for higher levels of glycaemia, though the RR and p-value 
for a linear association between glycaemia and time to initial sputum culture positivity showed 
only weak evidence of a linear association (adjusted RR=0.97 95% CI [0.63-1.49], p=0.125). 
Using a binary exposure variable, comparing individuals with glycated haemoglobin ≥6.0% to 
those with a level <6.0%, there was no evidence of association between glycaemia and TTP of 
the baseline sputum sample but weak evidence of association between glycaemia and TTC (RR 
1.44 95%CI [0.89-2.33], p=0.149 and RR 0.54 95%CI [0.27-1.09], p=0.076 respectively; Tables 2 
and 3). 
164 
 
During data collection for this study, 2 participants died, both of whom had a baseline HbA1c 
<6.0%. 
Subgroup analyses were not explored as the number of participants with hyperglycaemia, the 
risk factor of interest, was low. 
Discussion 
In this cohort study in Lusaka, Zambia, we found no evidence of association between 
hyperglycaemia as an ordered categorical variable and two surrogate markers of tuberculosis 
treatment outcome. Although the direction of trend was consistent with a faster time to initial 
sputum positivity and a slower time to sputum culture conversion for higher levels of 
glycaemia, there was weak evidence to support a dose-response relationship between 
hyperglycaemia and tuberculosis treatment outcome. 
However, despite screening over 1,500 smear-positive TB cases we found only 30 individuals 
with a baseline HbA1c ≥6.0 and only 24 individuals with a follow-up HbA1c ≥6.0. As these were 
our exposures of interest the study was underpowered to detect an association with TB 
treatment outcome. Nonetheless these findings suggest that hyperglycaemia is not a major 
challenge for TB control in our study location. 
As our findings do not support the hypothesis that increasing levels of hyperglycaemia are 
associated with worse TB treatment outcome, they consequently do not support the 
hypothesis that controlling glycaemia during treatment of tuberculosis could improve TB 
treatment outcome. As the number of participants with hyperglycaemia was low, however, 
our findings also do not invalidate these hypotheses; confidence intervals in our study were 
wide and so we are 95% confident that the rate ratio for association between glycaemia and 
TTP, comparing participants with HbA1c ≥6.5% to those with HbA1c <6.0%, lies between 0.73 
and 4.18. We are 95% confident that the rate ratio for association between glycaemia and TTC 
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lies between 0.20 and 2.60, also comparing participants with HbA1c ≥6.5% to those with HbA1c 
<6.0%. 
The four prior studies that have explored the association between glycaemic or diabetes 
control and TB treatment outcome show conflicting results. A retrospective cohort study in 
South Korea examined the rate of sputum culture conversion at two months for 214 culture-
confirmed pulmonary tuberculosis patients.12 Individuals infected with HIV were excluded. Of 
28 participants with uncontrolled diabetes (HbA1c≥7%) 6 had a positive culture at 2 months. 
Compared to non-diabetics, uncontrolled diabetes was found to be a significant risk factor for 
a positive sputum culture at 2 months (OR 4.3, 95% CI 1.3-14.3, p=0.017). A retrospective 
record review in Kerala State, India, reviewed TB treatment outcome at the end of TB 
treatment for 3,116 patients.10 Diabetes status was recorded for 90%, of which, 137 TB cases 
had uncontrolled diabetes. The prevalence of HIV among study participants was 1.5%. Poor 
glycaemic control was found to be weakly associated with unfavourable TB treatment 
outcome (RR 2.00, 95% CI 0.97-4.13). A retrospective review of notification data and medical 
records for 1,473 TB cases in Taiwan found 276 individuals with uncontrolled diabetes.13 The 
prevalence of HIV was 0.3%. Uncontrolled diabetes was found to be associated with improved 
TB treatment outcome at the end of TB treatment compared to TB cases with well controlled 
diabetes (5.8% of participants with HbA1c >9% died compared to 13.8% for HbA1c 7-9% and 
18.3% for HbA1c <7%; p<0.001). A prospective cohort study in South Korea determined sputum 
culture positivity at two months of treatment for 661 individuals with pulmonary TB.11 
Individuals with HIV infection were excluded. 108 participants had uncontrolled diabetes. 
Uncontrolled diabetes compared to no diabetes was found to be an independent risk factor for 
a positive sputum culture after two months of treatment (OR 2.11, 95% CI 1.03-4.31, p=0.042) 
and also for treatment failure or death (OR 4.11, 95% CI 1.23-13.78) p=0.027). No intervention 
studies to optimise glycaemic control in individuals with hyperglycaemia during TB treatment 
have yet taken place.26 Our study is the first to be located in Africa and in a setting with a high 
prevalence of HIV. 
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The main limitation of our study is the low prevalence of hyperglycaemia found among TB 
patients in these study communities, particularly severe hyperglycaemia. It is possible that our 
study methods of using a single random blood glucose concentration to screen for 
hyperglycaemia contributed to this low prevalence of hyperglycaemia because of the low 
sensitivity of this test. There were too few individuals with hyperglycaemia to detect any 
potential true association between increasing levels of glycaemia and TB treatment outcome. 
In particular, it would have been favourable to explore the association among individuals with 
higher levels of glycaemia than we were able to in our study. Nonetheless, it is clear that 
hyperglycaemia is not a major driver of poor TB treatment outcome in our study population. 
Another potential source of bias was the lack of obtaining complete follow up data for all 
participants. Although we collected all follow-up data during routine TB clinic attendances, 
aiming to minimise inconvenience to participants and therefore maximise follow-up, we found 
that many participants would send relatives to collect their TB medication on their behalf 
rather than attend the clinic themselves. This was the main cause of missing follow-up data. 
Whilst this has further led to loss of study power, it is unlikely to have introduced additional 
bias as there was no evidence to suggest that loss of follow-up data was associated with 
hyperglycaemia, the exposure of interest. Participant death was a very small contributor to 
loss of follow-up data as very few participants died during the study and so there is also no 
reason to suggest that loss of follow-up data might be associated with TB treatment outcome, 
the outcome of interest. 
Rather than measure TB treatment outcome at the end of or beyond TB treatment, we used 
surrogate markers at an earlier time point. The use of surrogate markers is particularly useful 
for settings such as ours that have a low prevalence of unsuccessful TB treatment. Without the 
use of surrogate markers the study would otherwise have been logistically challenging due to 
the high sample size requirement for a rare outcome. However, contrary to our expectation, 
many participants did not achieve documented sputum conversion within the follow-up time. 
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The proportion of participants who did not convert was lower when the analysis was restricted 
to only those who completed sputum submission to 8 weeks, so the low proportion of 
participants with documented sputum conversion is likely due, at least in part, to missing data. 
A strength of our study was the use of automated liquid culture to process sputum specimens. 
We were able to determine quantitative time to sputum culture positivity accurately without 
the potential introduction of human error. 
As described above, we have focused on hyperglycaemia rather than diabetes mellitus, so that 
we also encompass transient stress-induced hyperglycaemia. This reflects the situation in 
practice, as it is not possible to distinguish between these diagnoses at the time of active TB 
infection. A consequence of this, however, it was possible that we would not capture 
individuals with previously diagnosed (known) diabetes mellitus who were not hyperglycaemic 
at the time of measuring glycaemia. In fact this did not result as a potential source of bias 
because there were only two individuals in this study who reported a prior diagnosis of 
diabetes and both were hyperglycaemic at baseline. 
The findings from this study are generalizable to the study communities as participants were 
consecutively selected within glycaemia strata. They are likely also generalizable to 
communities elsewhere in Zambia and much of sub-Saharan Africa with similar high incidence 
of TB and low prevalence of hyperglycaemia. However, the findings are less likely to be 
generalizable to locations with a medium or high prevalence of hyperglycaemia and so 
repeating this study in other locations would be valuable. 
Conclusions 
In this cohort study of culture-confirmed pulmonary tuberculosis cases we found no evidence 
that a dose-response relationship exists between glycaemia as an ordered categorical variable 
and tuberculosis treatment outcome, though the direction of trend was consistent with a 
faster time to initial sputum positivity and a slower time to sputum culture conversion for 
168 
 
higher levels of glycaemia. We found weak evidence that a linear dose-response relationship 
exists between glycaemia and time to initial sputum culture positivity, and weak evidence of 
association between glycaemia as a binary variable and time to sputum culture conversion. We 
found a low prevalence of hyperglycaemia in our study population in Lusaka, Zambia and so 
the study was underpowered to detect any true association. This does however suggest that 
hyperglycaemia is not a major challenge for TB control in this location. Repeating this study in 
locations with higher hyperglycaemia prevalence is necessary to determine the impact of 
hyperglycaemia to TB control in settings with a medium or high prevalence of hyperglycaemia.  
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Figure 2: Kaplan-Meier estimates of the time to initial sputum culture positivity by level of 
glycated haemoglobin 
 
 
Figure 3: Kaplan-Meier estimates of the time to sputum culture conversion by level of 
glycated haemoglobin 
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Table 1: Baseline characteristics of participants, comparing individuals with complete and 
incomplete follow-up data 
Characteristic Participants 
with complete 
follow-up data* 
n (%) 
Participants with 
incomplete follow-
up data** 
 n (%) 
p-value 
Overall 36 (23.5) 117 (76.5) - 
Baseline glycated 
haemoglobin 
concentration (%) 
<6.0 26 (72.2) 84 (80.8) 0.106 
6.0-6.4 9 (25.0) 12 (11.5) 
≥6.5 1 (2.8) 8 (7.7) 
HIV status Uninfected 12 (33.3) 39 (39.4) 0.521 
Infected 24 (66.7) 60 (60.6) 
Age (years) 18-24 4 (11.1) 18 (17.0) 0.211 
25-34 13 (36.1) 53 (50.0) 
35-44 14 (38.9) 25 (23.6) 
≥45 5 (13.9) 10 (9.4) 
Sex Male 24 (66.7) 73 (68.9) 0.806 
Female 12 (33.3) 33 (31.1) 
Household 
socioeconomic 
position 
Very low 6 (16.7) 15 (14.2) 0.557 
Low 16 (44.4) 59 (55.7) 
Medium 13 (36.1) 27 (25.5) 
High 1 (2.8) 5 (4.7) 
P-values derived from chi-squared tests; *Defined as having data for baseline HbA1c, follow-up HbA1c and sputum 
culture at 8 weeks after initiation of TB treatment.; **Defined as missing data for any or all of baseline HbA1c, 
follow-up HbA1c and sputum culture at 8 weeks after initiation of TB treatment. 
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Table 2: The median time to sputum culture positivity of the baseline sputum sample taken 
at the time of TB treatment initiation, with corresponding unadjusted and adjusted rate 
ratios estimated by cox regression 
Characteristic Number of 
participants 
(%) 
Median days 
to sputum 
culture 
positivity 
(IQR) 
Unadjusted RR 
(95% CI) 
p-value+ Adjusted RR** 
(95% CI) 
p-value+ 
Overall 151 (100) 6.4 (4.8-8.8) - - - - 
Glycated 
haemoglobin 
concentration 
(%)* 
<6.0 109 (79.0) 6.8 (4.9-9.4) 1 0.285  
(TFT 
RR=1.27 
(0.95-
1.71), 
p=0.126) 
1 0.309 
(TFT 
aRR=0.97 
(0.63-
1.49), 
p=0.125) 
6.0-6.4 20 (14.5) 6.0 (4.1-8.1) 1.39 (0.84-2.30) 1.34 (0.76-2.35) 
≥6.5 9 (6.5) 5.9 (4.9-7.1) 1.51 (0.76-3.01) 1.75 (0.73-4.18) 
Glycated 
haemoglobin 
concentration 
(%)* 
<6.0 109 (79.0) 6.8 (4.9-9.4) 1 0.117 1 0.149 
≥6.0 29 (21.0) 6.0 (4.5-8.1) 1.43 (0.93-2.19) 1.44 (0.89-2.33) 
HIV status Un-
infected 
50 (37.6) 6.0 (4.6-7.7) 1 0.021 1 0.227 
Infected 83 (62.4) 7.5 (5.3-9.5) 0.65 (0.45-0.93) 0.76 (0.49-1.18) 
Age (years) 18-24 22 (15.7) 6.9 (6.0-8.7) 1 0.072 1 0.027 
25-34 65 (46.4) 6.3 (4.6-8.2) 1.14 (0.69-1.87) 1.28 (0.74-2.23) 
35-44 39 (27.9) 6.2 (4.7-9.5) 1.09 (0.64-1.86) 1.13 (0.63-2.03) 
45+ 14 (10.0) 9.3 (5.2-11.9) 0.53 (0.26-1.10) 0.48 (0.22-1.07) 
Sex Male 97 (69.3) 6.2 (4.8-8.4) 1 0.122 1 0.905 
Female 43 (30.7) 7.5 (5.3-10.3) 0.75 (0.52-1.08) 0.97 (0.62-1.53) 
Household 
socio-
economic 
position 
Very low 20 (14.3) 7.9 (6.5-10.9) 1 0.496 1 0.676 
Low 74 (52.9) 6.6 (4.7-8.6) 1.30 (0.79-2.14) 1.06 (0.63-1.78) 
Medium 40 (28.6) 5.9 (4.8-7.5) 1.40 (0.81-2.42) 1.31 (0.71-2.42) 
High 6 (4.3) 9.0 (8.7-10.3) 0.87 (0.32-2.32) 0.76 (0.25-2.34) 
IQR=inter-quartile range; RR=rate ratio; aRR=adjusted rate ratio; CI=confidence interval; *Measured at time of 
tuberculosis diagnosis; TFT=likelihood ratio test for trend with exposure as a linear variable; +Likelihood ratio tests; 
**131 participants included in analysis, adjusted for all variables shown plus community, separately for each 
categorisation of glycated haemoglobin concentration; Missing data: 11 for age, sex, socioeconomic position and 
community, 18 for HIV status, 13 for HbA1c concentration and 2 for baseline sputum sample. 
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Table 3: The median time to sputum culture conversion, with corresponding unadjusted and 
adjusted rate ratios estimated by cox regression 
Characteristic Number of 
participants 
(%) 
Median 
weeks to 
sputum 
culture 
conversion 
(IQR) 
Unadjusted RR 
(95% CI) 
p-
value+ 
Adjusted RR** 
(95% CI) 
p-
value+ 
Overall 153 (100) 6 (3-7) - - - - 
Glycated 
haemoglobin 
concentration 
(%)* 
<6.0 64 (72.7) 5 (4-7) 1 0.427 1 0.181 
6.0-6.4 18 (20.5) 6 (3-7) 0.65 (0.33-1.29) 0.50 (0.23-1.08) 
≥6.5 6 (6.8) 6 (5-6) 0.83 (0.30-2.30) 0.73 (0.20-2.60) 
Glycated 
haemoglobin 
concentration 
(%)* 
<6.0 64 (72.7) 5 (4-7) 1 0.228 1 0.076 
≥6.0 24 (27.3) 6 (4-6) 0.70 (0.39-1.26) 0.54 (0.27-1.09) 
HIV status Un-
infected 
51 (37.8) 6 (4-6) 1 0.687 1 0.811 
Infected 84 (62.2) 5 (3-7) 0.91 (0.59-1.42) 1.08 (0.58-2.01) 
Age (years) 18-24 22 (15.5) 6 (4-7) 1 0.845 1 0.754 
25-34 66 (46.5) 5.5 (3-7) 0.98 (0.55-1.75) 1.66 (0.60-4.59) 
35-44 39 (27.5) 5 (3-6) 0.79 (0.42-1.50) 1.70 (0.60-4.82) 
≥45 15 (10.6) 6 (3-7) 0.89 (0.40-1.98) 1.45 (0.44-4.79) 
Sex Male 97 (68.3) 6 (4-7) 1 0.655 1 0.712 
Female 45 (31.7) 4 (3-6) 1.11 (0.71-1.72) 0.88 (0.46-1.70) 
Household 
socio-
economic 
position 
Very low 21 (14.8) 6 (3-6.5) 1 0.109 1 0.134 
Low 75 (52.8) 5 (3-6) 1.62 (0.85-3.10) 1.79 (0.84-3.82) 
Medium 40 (28.2) 6.5 (4-7) 1.20 (0.60-2.40) 1.04 (0.42-2.58) 
High 6 (4.2) 5 (2-6) 3.53 (1.23-10.16) 3.97 (0.65-24.16) 
IQR=inter-quartile range; RR=rate ratio; CI=confidence interval; *Measured at 2 months post -tuberculosis diagnosis; 
+Likelihood ratio tests; **83 participants included in analysis, adjusted for all variables shown plus community, 
separately for each categorisation of glycated haemoglobin concentration; Missing data: 11 for age, sex, 
socioeconomic position and community, 18 for HIV status, 65 for HbA1c concentration and 32 for sputum samples. 
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Abstract 
Background: A positive association between diabetes mellitus and tuberculosis has been 
established. When testing for diabetes in individuals with tuberculosis, most prior studies have 
measured glycaemia at the time of tuberculosis diagnosis. Acute TB disease could also cause 
hyperglycaemia, because of physiological stress from the infection, and this could lead to false 
positive test results for diabetes. Therefore, we aimed to distinguish between transient 
hyperglycaemia, which most likely represents stress hyperglycaemia, and persistent 
hyperglycaemia, which is indicative of diabetes mellitus, and evaluate the accuracy of 
measures of glycaemia at the time of tuberculosis diagnosis for the diagnosis of diabetes 
mellitus. 
Methods: In this diagnostic accuracy study we compared three index tests to a reference 
standard test. Index tests were random blood glucose (RBG) concentration, fasting blood 
glucose (FBG) concentration and glycated haemoglobin (HbA1c), measured at the time of 
tuberculosis diagnosis. The reference standard test for diabetes mellitus was a FBG 
concentration measured 3 months after commencement of tuberculosis treatment, when 
acute TB disease had stabilised. Participants were newly-diagnosed tuberculosis patients in 
three health care centres in Lusaka, Zambia. Recruitment was stratified by RBG concentration. 
Test sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
were calculated for each index test. Subgroup analyses stratified test accuracy by HIV status. 
Results: Of 490 participants recruited, 71 (14.5%) had hyperglycaemia on at least one index 
test. The reference standard test was performed in 242 (49.4%) participants, of whom 8 (3.3%) 
had diabetes. Of participants who had hyperglycaemia on the index RBG, FBG and HbA1c tests, 
6 (33%), 4 (44%) and 7 (39%) participants respectively had diabetes. All index tests had similar 
test accuracy, with overlapping confidence intervals. The specificity and NPV were ≥95% with 
narrow confidence intervals for all index tests. The sensitivity ranged from 57%-88% and the 
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PPV ranged from 33%-44%, all with wide confidence intervals. Among participants infected 
and uninfected with HIV, the PPV ranged from 17%-22% and 50%-100% respectively. 
Conclusions: In individuals with tuberculosis, a low proportion of hyperglycaemia measured at 
the time of tuberculosis diagnosis was due to diabetes mellitus, particularly among individuals 
co-infected with HIV. There was no evidence that glycated haemoglobin had greater test 
accuracy for diabetes diagnosis at the time of tuberculosis diagnosis than FBG or RBG. When 
testing for diabetes in individuals with tuberculosis, repeat testing after resolution of acute 
tuberculosis disease should be considered before a diagnosis of diabetes is made. 
399 words 
Keywords: Stress-induced hyperglycaemia, transient hyperglycaemia, southern Africa 
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Background 
A positive association between diabetes mellitus (DM) and tuberculosis (TB) has been 
established. Individuals with DM are around three times more likely to develop active TB 
disease than individuals without DM. This is thought to be due to the negative effect of 
diabetes on cell mediated immunity, including altered T-cell function, reduced chemotaxis and 
reduced oxidative killing potential,1-6 all of which could impair the control of M. tuberculosis.2, 7, 
8 
When testing for diabetes in individuals with tuberculosis, most prior studies have measured 
glycaemia at the time of tuberculosis diagnosis. However, acute TB disease prior to adequate 
treatment could also cause hyperglycaemia, because of physiological stress from the infection, 
and this could lead to false positive test results for diabetes. Stress hyperglycaemia is a well-
documented clinical feature of sepsis and critical illness such as acute myocardial infarction, 
resulting from the interference of stress hormones and cytokines with normal carbohydrate 
metabolism.9-11 It is possible that this is also a feature of severe TB disease, and differentiation 
of this from diabetes mellitus could help to ensure appropriate management of individuals and 
appropriate organisation of health services.  
If stress hyperglycaemia is a common condition among individuals who have untreated TB 
disease, it would be useful to be able to distinguish this from diabetes mellitus at the time of 
TB diagnosis, in order to ensure appropriate management for individuals. The World Health 
Organisation has approved multiple different methods of measuring glycaemia in the diagnosis 
of diabetes.12 Most measure an individual’s blood glucose concentration at the time of testing, 
but measurement of glycated haemoglobin quantifies the average blood glucose concentration 
over the preceding 2-3 months. Consequently, it is possible that this measure is better than 
others at predicting persistent hyperglycaemia and therefore diabetes, without also giving 
false positives from transient stress hyperglycaemia. 
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Therefore, firstly, we aimed to determine the proportion of hyperglycaemia among newly-
diagnosed tuberculosis cases that is persistent after resolution of acute TB disease and is thus 
indicative of diabetes mellitus rather than stress-induced hyperglycaemia. Secondly, we aimed 
to evaluate the accuracy of random blood glucose (RBG) concentration, fasting blood glucose 
(FBG) concentration and glycated haemoglobin (HbA1c) measured at the time of tuberculosis 
diagnosis for predicting diabetes mellitus, as determined by the reference standard of fasting 
blood glucose concentration measured after stabilisation of tuberculosis disease. 
Methods 
Study design and participants 
We conducted a prospective study of diagnostic accuracy from September 2013 until 
December 2015 in three tuberculosis clinics in Lusaka, Zambia. Study participants were newly-
diagnosed tuberculosis cases who were ≥18 years of age and had commenced TB treatment ≤2 
days ago or had not yet started TB treatment. The study was linked to a case-control study 
which investigated the association between DM and TB in Lusaka, comparing TB cases to non-
TB controls. All TB cases of the case-control study were assessed for eligibility for this study of 
diagnostic accuracy. 
A TB case was defined as any person presenting to one of the TB clinics with a clinical diagnosis 
of pulmonary or extra-pulmonary TB with or without microbiological confirmation of TB and 
prescribed a full course of antitubercular chemotherapy, based on the World Health 
Organization TB diagnostic criteria.13 This is the definition used for TB diagnosis in the study 
clinics as well as elsewhere in Zambia and much of sub-Saharan Africa and so use of this 
definition aimed to facilitate translation of the study results to the clinical setting. All 
potentially eligible participants were identified in the TB clinics and invited to participate 
during a routine clinic attendance. 
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A stratified sampling technique was used to recruit adequate numbers of participants with and 
without diabetes mellitus. As it was not possible to determine the status of diabetes at the 
time of recruitment we instead based recruitment on the participants’ initial random blood 
glucose (RBG) concentration. We used three strata to facilitate recruitment of participants 
from across the glycaemic range: RBG <7mmol/L, RBG 7-9mmol/L and RBG >9mmol/L. Within 
each stratum, consecutive TB cases who were eligible and willing were recruited. Recruitment 
to a stratum ceased if the target sample size was met before the end of study recruitment. 
The eligibility criteria for this study were therefore: age ≥18 years; newly-diagnosed case of TB 
due to commence on a full course of antitubercular chemotherapy; commenced TB treatment 
≤2 days ago if already commenced TB treatment, and RBG concentration within the required 
stratum. 
Test methods 
We evaluated three index tests: RBG, FBG and HbA1c concentration measured at the time of TB 
diagnosis. We compared each of these tests to a reference standard test for diabetes mellitus, 
which we defined as a repeat FBG concentration measured 3 months after commencement of 
TB treatment, by which time we expect the TB to have stabilised and only persistent 
hyperglycaemia to remain. 
RBG concentration was measured at the time of recruitment. FBG concentration for the initial 
index test was measured the day following recruitment or as soon as possible after this, after 
at least a 6 hour overnight fast of all food and drink except water. Capillary blood was sampled 
using an auto-lancet and an Accu-Chek Aviva point-of-care glucometer was used to measure 
the glucose concentration. These point-of-care tests were performed by the research 
assistants who were also recruiting and interviewing the participants, and so they were aware 
of demographic and clinical information of each participant at the time of undertaking the 
index tests. 
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Venous blood was sampled at the time of recruitment for measurement of HbA1c. The blood 
samples were transported daily to the laboratory to be stored for up to a week at 5oC. Samples 
were analysed weekly using an Abbott Architect i system. Laboratory staff who processed the 
samples were unaware of any participant demographic or clinical information. 
The repeat reference standard FBG followed the same procedures as the initial index FBG, but 
was measured 3 months post-treatment commencement. Research assistants undertaking this 
point-of-care test again had access to clinical information and index test results for each 
participant. If participants were taking hypoglycaemic medication they were asked to omit 
their morning dose until after measurement of FBG concentration. 
All test positivity cut-offs for the index and reference standard tests were pre-specified and 
followed the WHO guidelines for diabetes diagnostic criteria, as follows: RBG concentration 
≥11.1mmol/L; FBG concentration (index or reference standard) ≥7.0mmol/L; HbA1c ≥6.5%.12, 14 
All participants who had glycaemia in the diabetes range on any test were referred to local 
health care facilities for follow-up and management. 
A structured questionnaire was used to record participant characteristics and clinical 
information, including age, sex, household socioeconomic position, education level and details 
of any prior diabetes diagnosis. Height and weight were measured. This information was 
entered directly onto a pre-programmed personal digital assistant (PDA) by the researcher, 
using pre-programmed questionnaires and result sheets with error and range checks. To 
enable sub-group analyses, HIV status was determined using point-of-care rapid blood-based 
kits. DetermineTM HIV-1/2 was used as the first line test and Uni-GoldTM HIV as a confirmatory 
test for individuals with a positive Determine test (following the Zambia national algorithm for 
HIV diagnosis). 
Research staff were trained and monitored on all aspects of data collection and were required 
to follow standard operating procedures for measurement of glucose, HbA1c, anthropometrics 
and for HIV tests. All research staff were required to undergo proficiency testing for measuring 
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capillary blood glucose. Standardised control solution was used for glucometer and test strip 
performance checks. Intra- and inter-operator variability was measured to assess the validity 
of glucose measurement using the Accu-Chek Aviva glucometer. All research assistants 
contributed to the assessment, using known normoglycaemic volunteers and a standard 
hyperglycaemic specimen. For intra-operator variability each research assistant repeated the 
test 5 consecutive times on a combined total of 13 subjects/specimens. For inter-operator 
variability research assistants each performed the test on a single subject/specimen in the 
same place at the same time for 15 subjects/specimens. A two-way mixed-effects model 
assessing for absolute agreement was used to calculate intraclass correlations (ICCs): the ICC 
for intra-operator variability was 0.983 (95% CI 0.954-0.995) and for inter-operator variability 
was 0.997 (95% CI 0.990-0.999). 
Laboratory performance evaluation was undertaken for measurement of HbA1c concentration 
using the Abbot Architect i system: performance evaluation gave a score of 100% for 
acceptable results.  
Analysis 
Baseline characteristics of participants with and without hyperglycaemia, and with and without 
follow-up data, were compared using chi-squared tests. Descriptive frequency and percentage 
statistics were used to give the proportions of hyperglycaemic newly-diagnosed tuberculosis 
cases, measured separately by RBG, FBG and HbA1c, who have diabetes mellitus rather than 
transient hyperglycaemia. To determine test accuracy, the test sensitivity, specificity, positive 
predictive value and negative predictive value were calculated for each index test, along with 
95% confidence intervals. Participants with missing data on either the index or the reference 
standard test were excluded from the analysis. 
Stratification by HIV status was specified a priori for subgroup analysis. 
Additionally, for purposes of hypothesis generation, predictors of transient hyperglycaemia 
among all participants who were hyperglycaemic on any index test were explored using 
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unadjusted and adjusted logistic regression analysis. The potential predictors explored were 
age, sex, socioeconomic position, HIV status and body mass index. 
Ethics 
Each participant was required to give written informed consent. Ethics approval was granted 
from the London School of Hygiene and Tropical Medicine Ethics Committee and the University 
of Zambia Biomedical Research Ethics Committee. 
Results 
The case-control study linked to this study recruited 3,843 TB cases. All were assessed for 
eligibility to this diagnostic accuracy study. Of these, 490 were eligible for recruitment: 205 had 
a RBG <7.0mmol/L, 179 had a RBG 7.0-8.9mmol/L and 106 had a RBG ≥9.0mmol/L. The flow of 
study participants is shown in Figure 1. No participant had missing data for the index RBG test. 
95 (19.4%) participants had missing data for the index FBG test, 86 (17.6%) participants had 
missing data for the index HbA1c test and 248 (50.6%) participants had missing data for the 3-
month follow-up reference standard test. We were able to obtain outcome data for 163 
(65.7%) participants who were lost to follow-up for the reference standard test. Of these, 13 
(8.0%) died, 9 (5.5%) defaulted on their TB treatment and 10 (6.1%) had their TB treatment 
transferred out to another clinic. Individuals who were lost to follow-up for the reference 
standard test were similar to participants with reference standard test data in terms of index 
test results and all baseline characteristics except for HIV status and community. Individuals 
who were infected with HIV and from community 1 were more likely to be lost to follow-up 
(supplementary Table 1). 
426 (87.1%) participants were recruited on the same day as starting TB treatment. Index RBG 
tests were all measured at the time of recruitment. Index FBG tests were measured a median 
of 1 day after recruitment (interquartile range, IQR = 1-3 days). The mean length of fast prior 
to measurement of the index FBG concentration was 12.2 hours (standard deviation 2.7 
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hours). Samples for index HbA1c tests were taken at the time of recruitment and processed in 
the laboratory a median of 3 days later (IQR = 1-6 days). Reference standard FBG tests were 
measured a median of 90 days after recruitment (IQR = 83-98 days). The mean length of fast 
prior to measurement of the reference standard FBG concentration was 12.3 hours (standard 
deviation 1.7 hours). 
Table 1 shows the baseline characteristics of study participants, stratified by the absence or 
presence of hyperglycaemia on index tests and the reference standard test. Participants with 
and without hyperglycaemia on index tests were similar in terms of age, sex, education, 
smoking history, body mass index and HIV status. There was weak evidence that individuals 
with hyperglycaemia on index tests were of a higher socioeconomic position and had a higher 
body mass index than individuals without hyperglycaemia on index tests. There was evidence 
of a difference between communities. Participants with and without hyperglycaemia on the 
reference standard test had no evidence of a difference in baseline characteristics except for 
HIV status: there was evidence that individuals with hyperglycaemia were less likely to be HIV-
infected than individuals without hyperglycaemia. 
Tables 2a, 2b and 2c show cross tabulation of each of the index test results by the reference 
standard test results. The proportion of participants with hyperglycaemia at the time of TB 
diagnosis determined by RBG, FBG and HbA1c tests respectively was 9.0%, 4.8% and 9.2%. The 
proportion of participants with hyperglycaemia after an average of 90 days on TB treatment, 
determined by the reference standard FBG test, was 3.3%. Persistent hyperglycaemia, and 
therefore diabetes, was found in 6 (33%) participants who had hyperglycaemia on the index 
RBG test, 4 (44%) participants who had hyperglycaemia on the index FBG test and 7 (39%) 
participants with hyperglycaemia on the index HbA1c tests. 
At the time of recruitment 12 (2.5%) participants had been given a prior diagnosis of DM. Of 
these, 6 were taking hypoglycaemic medication: 2 participants were taking oral hypoglycaemic 
agents (glibenclamide and metformin) and 4 participants were taking insulin. A further 2 
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participants were commenced on oral hypoglycaemic agents by local health care practitioners 
following the index test results. All participants on diabetes treatment who were followed up 
with a reference standard test had a result in the diabetes range. 
The measures of test accuracy for each index test, overall and stratified by HIV status, are 
shown in Table 3. The specificity and negative predictive value were high (>93%) for all index 
tests, overall and within HIV strata. Overall, the sensitivity of index tests ranged from 57% to 
88% but with wide confidence intervals for all tests due to the low number of individuals with 
hyperglycaemia in our study. Overall, the positive predictive value was low for all tests, ranging 
from 33% to 44%, again with wide confidence intervals. No test emerged as being more 
accurate than the others for diagnosing diabetes mellitus at the time of TB diagnosis; 
confidence intervals of the three tests overlapped for all measures of test accuracy. 
When stratified by HIV, the point estimate of the positive predictive value (PPV) was lower 
among individuals infected with HIV compared to those uninfected for all index tests, though 
confidence intervals were wide and overlapping (Table 3). 
There were 21 participants who had transient hyperglycaemia on at least one index test. On 
unadjusted logistic regression analysis of predictors of transient hyperglycaemia, there was 
evidence that being infected with HIV or being male were associated with transient rather 
than persistent hyperglycaemia (p=0.046 and 0.022 respectively). There was no evidence of 
association between age, socioeconomic position or body mass index and transient 
hyperglycaemia. On adjusted logistic regression analysis, the adjusted odds of transient 
hyperglycaemia was 12.87 (95% CI 0.63-264.91) times higher among those infected with HIV 
than those uninfected (p=0.061). The adjusted odds ratio for stress hyperglycaemia comparing 
women to men was 0.23 (95% CI 0.02-3.26; p=0.166). The main positive confounding factor for 
HIV as a risk factor was body mass index and the main negative confounding factor was 
socioeconomic position. The main positive confounding factor for sex as a risk factor for 
transient hyperglycaemia was HIV. 
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There were no adverse events from performing any of the index tests or the reference 
standard test. 
Discussion 
In our Zambian study setting we found that a low proportion of hyperglycaemia measured at 
the time of TB diagnosis was due to diabetes mellitus. Most hyperglycaemia was transient, 
which likely represents stress hyperglycaemia secondary to acute TB disease. Contrary to our 
expectation and to the pattern seen in individuals with acute myocardial infarction,9, 11 
glycated haemoglobin showed no greater test accuracy for diabetes diagnosis at the time of TB 
diagnosis than FBG or RBG tests. This could reflect prolonged hyperglycaemia among 
individuals in our population with stress hyperglycaemia prior to their TB diagnosis, in addition 
to prolonged hyperglycaemia among individuals with diabetes. This is in keeping with the 
typical onset of TB disease, which is slow and gradual, in contrast to the rapid onset of illness 
seen with acute myocardial infarction. 
An alternative explanation of the transient hyperglycaemia seen is a previously described 
phenomenon with glucose similar to “white coat hypertension”,15 though this is less plausible 
than stress hyperglycaemia. Individuals with HIV had a greater proportion of transient 
hyperglycaemia and a lower test accuracy for diabetes than individuals without HIV. This is in 
keeping with the idea that transient hyperglycaemia represents stress hyperglycaemia, as 
individuals who are infected with HIV more commonly have severe TB16-18 and therefore may 
be more likely to have stress hyperglycaemia than individuals who are uninfected with HIV. 
However, this study was not powered for sub-group analyses and so these analyses should be 
seen as hypothesis generating rather than hypothesis testing. 
Our findings are in keeping with the few existing studies that have differentiated between 
transient and persistent hyperglycaemia in individuals with TB. In 1990 Oluboyo performed 
sequential OGTTs on 54 Nigerian patients with active pulmonary TB. Only one of eight patients 
with initial impaired glucose tolerance remained with persisting glucose intolerance after 3 
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months of TB treatment.19 In a more recent larger cohort of Tanzanian TB patients, Boillat-
Blanco et al found that a high proportion of hyperglycaemia was transient.20 At the time of 
active TB diagnosis, 4.5%, 6.8% and 9.3% had hyperglycaemia measured by FBG, oral glucose 
tolerance test (OGTT) and HbA1c respectively. After 5 months of receiving TB treatment and 
exclusion of patients with previously known DM, 75%, 64% and 71% of these initially 
hyperglycaemic participants were no longer hyperglycaemic on follow-up FBG, OGTT and 
HbA1c tests respectively. A high proportion of transient hyperglycaemia in TB patients has 
similarly been described in Indonesia21, Iran22, Pakistan23, Turkey24 and India25. 
Our study was limited by the low proportion of participants with diabetes mellitus. This was 
despite recruiting participants from a pool of nearly 4,000 TB patients over 2 years, and 
reflects the low prevalence of diabetes in the general population in Lusaka. It is possible that 
our screening method of using a random blood glucose concentration to detect potential 
participants with hyperglycaemia has contributed to this low proportion as the method lacks 
sensitivity for the diagnosis of diabetes. As a result of the low proportion of participants with 
diabetes, estimates of sensitivity and positive predictive value have wide confidence intervals. 
Repeating this study in a population with a high prevalence of diabetes would be valuable to 
give more precise estimates of sensitivity and PPV. 
To maximise follow-up of participants we opted to undertake only FBG as the follow-up test 
for diabetes and not to also measure repeat RBG concentration and HbA1c. Consequently we 
needed to follow-up the participants just once after the recruitment procedures, and perform 
only a finger-prick blood test rather than undertake repeat venous blood sampling. The latter 
was much less acceptable to our participants. Even so, it was a challenge to follow-up some 
participants, even aside from those who had died, defaulted on TB treatment or been 
transferred out to another clinic for treatment. The main reason for this was the common 
practice of patients sending relatives to the TB clinic to collect medication on their behalf, 
coupled with a low proportion of participants having a personal mobile phone number that 
190 
 
remained unchanged during the study. It was therefore difficult to gain direct access to the 
participants to remind and encourage them to attend the clinic for follow-up. This was 
particularly a challenge in clinic 1 and has led to a loss of study power and precision. However, 
aside from clinic and HIV status, the participants who were lost to follow-up were similar to 
those who were followed-up in terms of baseline characteristics and index test results and so 
our low retention rate is unlikely to have caused systematic bias to our study findings. Any 
potential bias resulting from the disproportionate number of HIV infected participants lost to 
follow-up is mitigated by stratifying the results by HIV status. Other than the further loss of 
study power, it is unlikely that the lack of follow-up RBG and HbA1c tests would have changed 
the study conclusions, as the comparison of like to like index FBG to follow-up FBG gave the 
same overall conclusions as comparing index RBG and HbA1c tests to the follow-up FBG test. 
In this study we used point of care tests using capillary blood samples for random and fasting 
blood glucose tests. As well as being more acceptable to participants than venous blood 
sampling, point of care tests are logistically less challenging and less expensive to undertake. 
Our assessment of intra- and inter-operator variability suggests that measurement of random 
blood glucose among cases in this study was consistent and valid. Additionally, we explored 
the possibility of undertaking laboratory validation of glucose measurements by comparing 
glucometer results to results from laboratory processed venous blood samples taken 
simultaneously. This proved to be not possible in our setting, as point-of-care glucose 
measurement is the principal method for measuring glycaemia, both in the community and 
centrally. The laboratory alternatives were therefore not equipped to offer a reliable 
benchmark. 
For hypothesis generating purposes we explored predictors of transient hyperglycaemia. The 
number of participants with hyperglycaemia was small and confidence intervals were wide so 
no definitive predictors were identified. Further exploration of this with greater study power 
would be valuable. 
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The definition of TB used in this study is the same definition used clinically in the study setting 
and so the results are applicable to the clinical setting in Lusaka. As the participants were 
randomly selected the results are also likely generalizable to other settings in Zambia and 
surrounding southern African countries with a similar high prevalence of HIV. 
Conclusions 
In individuals with tuberculosis, a low proportion of hyperglycaemia measured at the time of 
tuberculosis diagnosis was persistent and therefore due to diabetes mellitus, particularly 
among individuals infected with HIV. The majority of hyperglycaemia measured at the time of 
tuberculosis diagnosis was transient and therefore most likely represents stress-induced 
hyperglycaemia rather than underlying diabetes mellitus. This was particularly the case for 
individuals co-infected with HIV. There was no evidence that glycated haemoglobin had 
greater test accuracy for diabetes diagnosis at the time of TB diagnosis than FBG or RBG. When 
testing for diabetes in individuals with tuberculosis, repeat testing after resolution of acute TB 
disease should be considered before a diagnosis of diabetes is made. 
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Figure 1: Flow of study participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RBG=random blood glucose; FBG=fasting blood glucose; HbA1c=glycated haemoglobin; RS=reference standard; 
DM=diabetes mellitus; LTFU=lost to follow-up  
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Table 1: Participant characteristics 
Characteristic Total 
n (%) 
Hyper-
glycaemia 
absent on 
all index 
testsa 
n (%) 
Hyper-
glycaemia 
present on 
at least one 
index testb 
 n (%) 
p-
value 
Hyper-
glycaemia 
absent on 
reference 
standard 
testc 
n (%) 
Hyper-
glycaemia 
present 
on 
reference 
standard 
testd 
n (%) 
p-
value 
Overall 490 (100.0) 419 (100.0) 71 (100.0) - 234 (100.0) 8 (100.0) - 
Age (years) 18-24 58 (11.8) 51 (12.2) 7 (9.9) 0.139 27 (11.5) 2 (25.0) 0.290 
25-29 83 (16.9) 77 (18.4) 6 (8.5) 37 (15.8) 1 (12.5) 
30-34 108 (22.0) 92 (22.0) 16 (22.5) 52 (22.2) 1 (12.5) 
35-39 109 (22.2) 94 (22.4) 15 (21.1) 51 (21.8) 0 (0.0) 
40-49 86 (17.6) 70 (16.7) 16 (22.5) 49 (20.9) 2 (25.0) 
50+ 46 (9.4) 35 (8.4) 11 (15.5) 18 (7.7) 2 (25.0) 
Sex Male 337 (68.8) 290 (69.2) 47 (66.2) 0.612 163 (69.7) 4 (50.0) 0.237 
Female 153 (31.2) 129 (30.8) 24 (33.8) 71 (30.3) 4 (50.0) 
Household 
socio-
economic 
position 
Very low 78 (16.0) 70 (16.8) 8 (11.3) 0.058 38 (16.3) 1 (12.5) 0.899 
Low 212 (43.4) 185 (44.3) 27 (38.0) 101 (43.4) 3 (37.5) 
Medium 164 (33.5) 138 (33.0) 26 (36.6) 79 (33.9) 3 (37.5) 
High 35 (7.2) 25 (6.0) 10 (14.1) 15 (6.4) 1 (12.5) 
Highest 
level of 
education 
None 39 (8.0) 34 (8.1) 5 (7.0) 0.877 13 (5.6) 0 (0.0) 0.191 
Grade 1-7 194 (39.7) 163 (39.0) 31 (43.7) 87 (37.3) 6 (75.0) 
Grade 8-12 246 (50.3) 212 (50.7) 34 (47.9) 128 (54.9) 2 (25.0) 
College/ 
University 
10 (2.0) 9 (2.2) 1 (1.4) 5 (2.2) 0 (0.0) 
Smoking 
history 
Never smoked 357 (72.9) 305 (72.8) 52 (73.2) 0.938 171 (73.1) 5 (62.5) 0.509 
Current or ex-
smoker 
133 (27.1) 114 (27.2) 19 (26.8) 63 (26.9) 3 (37.5) 
Body Mass 
Index  
(weight(kg)
/ 
height2(m)) 
Healthy 
weight (18.5-
24.9) 
251 (51.3) 209 (50.0) 42 (59.2) 0.064 126 (54.1) 5 (62.5) 0.810 
Underweight 
(<18.5) 
217 (44.4) 193 (46.2) 24 (33.8) 99 (42.5) 3 (37.5) 
Overweight 
(25-29.9) 
17 (3.5) 14 (3.4) 3 (4.2) 8 (3.4) 0 (0.0) 
Obese (≥30) 4 (0.8) 2 (0.5) 2 (2.8) 0 (0.0) 0 (0.0) 
HIV status Uninfected 141 (29.9) 119 (29.4) 22 (32.8) 0.567 73 (32.7) 6 (75.0) 0.013 
Infected 331 (70.1) 286 (70.6) 45 (67.2) 150 (67.3) 2 (25.0) 
TB clinic 1 217 (44.3) 175 (41.8) 42 (59.2) 0.013 78 (33.3) 4 (50.0) 0.578 
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2 105 (21.4) 97 (23.2) 8 (11.3) 55 (23.5) 1 (12.5) 
3 168 (34.3) 147 (35.1) 21 (29.6) 101 (43.2) 3 (37.5) 
aIndex RBG <11.1mmol/L and index FBG <7.0mmol/L and index HbA1c <6.5%; bIndex RBG ≥11.1mmol/L or index FBG 
≥7.0mmol/L or index HbA1c ≥6.5%; cReference standard FBG <7.0mmol/L; dReference standard FBG ≥7.0mmol/L; 
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Table 2: Cross tabulation of the results of each index test by the reference standard results 
(a) 
  Reference standard: follow-up FBG 
≥7.0 
mmol/L 
<7.0 
mmol/L 
Total 
RBG at 
time of 
TB 
diagnosis 
≥11.1 mmol/L 6 12 18 
<11.1 mmol/L 2 222 224 
Total 8 234 242 
 
(b) 
  Reference standard: follow-up FBG 
≥7.0 mmol/L <7.0 mmol/L Total 
FBG at 
time of TB 
diagnosis 
≥7.0 mmol/L 4 5 9 
<7.0 mmol/L 3 220 223 
Total 7 225 232 
 
(c) 
  Reference standard: follow-up FBG 
≥7.0 mmol/L <7.0 mmol/L Total 
HbA1c at 
time of TB 
diagnosis 
≥6.5% 7 11 18 
<6.5% 1 192 193 
Total 8 203 211 
 
RBG=random blood glucose; FBG=fasting blood glucose; HbA1c=glycated haemoglobin; TB=tuberculosis   
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Table 3: Estimates of diagnostic accuracy and precision for each index test, overall and 
stratified by HIV status 
Measure of test accuracy for 
diabetes diagnosis 
RBG concentration FBG concentration HbA1c concentration 
All participants 
Sensitivity % (95% CI) 75.0 (34.9-96.8) 57.1 (18.4-90.1) 87.5 (47.4-99.7) 
Specificity % (95% CI) 94.9 (91.2-97.3) 97.8 (94.9-99.3) 94.6 (90.5-97.3) 
Positive predictive value % (95% CI) 33.3 (13.3-59.0) 44.4 (13.7-78.8) 38.9 (17.3-64.3) 
Negative predictive value % (95% CI) 99.1 (96.8-100.0) 98.7 (96.1-99.7) 99.5 (97.2-100.0) 
Participants uninfected with HIV 
Sensitivity % (95% CI) 83.3 (35.9-99.6) 60.0 (14.7-94.7) 83.3 (35.8-99.6) 
Specificity % (95% CI) 93.2 (84.7-97.7) 100.0 (94.9-100.0) 96.8 (89.0-99.6) 
Positive predictive value % (95% CI) 50.0 (18.7-81.3) 100.0 (29.2-100.0) 71.4 (29.0-96.3) 
Negative predictive value % (95% CI) 98.6 (92.2-100.0) 97.3 (90.5-99.7) 98.4 (91.3-100.0) 
Participants infected with HIV 
Sensitivity % (95% CI) 50.0 (1.3-98.7) 50.0 (1.3-98.7) 100.0 (15.8-100.0) 
Specificity % (95% CI) 96.7 (92.4-98.9) 97.2 (93.0-99.2) 94.6 (89.2-97.8) 
Positive predictive value % (95% CI) 16.7 (0.4-64.1) 20.0 (0.5-71.6) 22.2 (2.8-60.0) 
Negative predictive value % (95% CI) 99.3 (96.2-100.0) 99.3 (96.1-100.0) 100.0 (97.1-100.0) 
RBG=random blood glucose; FBG=fasting blood glucose; HbA1c=glycated haemoglobin; CI=confidence interval 
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Supplementary Table 1: Baseline characteristics of participants, comparing individuals with 
and without reference standard test follow-up data 
Characteristic Participants 
with follow-up 
data 
n (%) 
Participants 
without follow-up 
data 
 n (%) 
p-value 
Overall 242 (100) 248 (100) - 
Index RBG <11.1mmol/L 224 (92.6) 222 (89.5) 0.238 
≥11.1 mmol/L 18 (7.4) 26 (10.5) 
Index FBG <7.0 mmol/L 223 (96.1) 153 (93.9) 0.302 
≥7.0 mmol/L 9 (3.9) 10 (6.1) 
Index HbA1c <6.5% 193 (91.5) 174 (90.2) 0.647 
≥6.5% 18 (8.5) 19 (9.8) 
Age (years) 18-24 29 (12.0) 29 (11.7) 0.445 
25-29 38 (15.7) 45 (18.2) 
30-34 53 (21.9) 55 (22.2) 
35-39 51 (21.1) 58 (23.4) 
40-49 51 (21.1) 35 (14.1) 
50+ 20 (8.3) 26 (10.5) 
Sex Male 167 (69.0) 170 (68.6) 0.913 
Female 75 (31.0) 78 (31.5) 
Household 
socioeconomic 
position 
Very low 39 (16.2) 39 (15.7) 0.972 
 Low 104 (43.2) 108 (43.6) 
Medium 82 (34.0) 82 (33.1) 
High 16 (6.6) 10 (7.7) 
Highest level of 
education 
None 13 (5.4) 26 (10.5) 0.147 
Grade 1-7 93 (38.6) 101 (40.7) 
Grade 8-12 130 (53.9) 116 (46.8) 
College/ 
University 
5 (2.1) 5 (2.0) 
Smoking history Never smoked 176 (72.7) 181 (73.0) 0.949 
Current or ex-
smoker 
66 (27.3) 67 (27.0) 
Body Mass 
Index  
(weight(kg)/ 
height2(m)) 
Healthy weight 
(18.5-24.9) 
131 (54.4) 120 (48.4) 0.156 
Underweight 
(<18.5) 
102 (42.3) 115 (46.4) 
Overweight 
(25-29.9) 
8 (3.3) 9 (3.6) 
Obese (≥30) 0 (0.0) 4 (1.6) 
HIV status Uninfected 79 (34.2) 62 (25.7) 0.044 
201 
 
Infected 152 (65.8) 179 (74.3) 
TB clinic 1 82 (33.9) 135 (54.4) <0.001 
2 56 (23.1) 49 (19.8) 
3 104 (43.0) 64 (25.8) 
RBG=random blood glucose; FBG=fasting blood glucose; HbA1c =glycated haemoglobin; p-values derived from chi-
squared tests. 
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Chapter 10: Overall discussion and conclusions 
1 Summary of research findings 
The research findings are presented in Chapters 7, 8 and 9, and so here I summarise the main 
findings relating to each PhD study question. 
1.1 Study question 1: Does HIV modify the association between hyperglycaemia and active 
tuberculosis? 
In our case-control study we found no evidence of an overall association between 
hyperglycaemia and active tuberculosis, though we did find evidence of effect modification by 
HIV for the association between hyperglycaemia and active TB: we found statistical evidence 
of a positive association among individuals infected with HIV, but no evidence of an association 
among individuals who were uninfected with HIV. 
These findings could suggest that HIV and hyperglycaemia work synergistically to increase an 
individual’s risk of active TB, or alternatively, the findings could be explained by an increased 
prevalence of transient stress hyperglycaemia among newly-diagnosed TB cases who are 
infected with HIV compared to individuals with newly-diagnosed TB but who are uninfected 
with HIV. 
1.2 Study question 2: Is there a dose-response relationship between hyperglycaemia and 
tuberculosis treatment outcome? 
In our cohort study we found no evidence of a dose-response relationship between glycaemia 
and tuberculosis treatment outcome, however, we found a low prevalence of hyperglycaemia 
in our study population and so our study was likely underpowered to detect any true 
association.  
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1.3 Study question 3: What proportion of hyperglycaemia among newly-diagnosed 
tuberculosis cases is due to diabetes mellitus rather than to stress-induced 
hyperglycaemia? 
In our study of diagnostic accuracy, we found that a low proportion of hyperglycaemia among 
newly-diagnosed tuberculosis cases was due to diabetes. Of participants who had 
hyperglycaemia on the index random blood glucose, fasting blood glucose and glycated 
haemoglobin tests, 6 (33%), 4 (44%) and 7 (39%) participants respectively were found to have 
diabetes on the follow-up reference standard test. The remainder of the initial hyperglycaemia 
was found to be transient hyperglycaemia. 
1.4 Study question 4: How accurate for the diagnosis of diabetes mellitus are measures of 
random blood glucose, fasting blood glucose and glycated haemoglobin concentrations 
measured at the time of tuberculosis diagnosis, compared to the reference standard of 
fasting blood glucose concentration measured after stabilisation of tuberculosis disease. 
In our study of diagnostic accuracy, we found the sensitivity for diabetes diagnosis of random 
blood glucose, fasting blood glucose and glycated haemoglobin concentrations to be 75% (95% 
CI 35-97%), 57% (95% CI 18-90%) and 88% (95% CI 47-99%) respectively. We found the positive 
predictive value for diabetes diagnosis to be 33% (95% CI 13-59%), 44% (95% CI 14-79%) and 
39% (95% CI 17-64%) respectively for RBG, FBG and HbA1c concentrations. Confidence intervals 
were wide and overlapping for both these measures of accuracy, reflecting the low prevalence 
of hyperglycaemia and diabetes found in our study population. The specificity and negative 
predictive value were ≥95% with narrow confidence intervals for all index tests. We found no 
evidence that any one measure of glycaemia had greater test accuracy than the others for 
diabetes diagnosis at the time of tuberculosis diagnosis. 
2 Study limitations 
The limitations of each study are discussed in detail in Chapters 7, 8 and 9 and so here I focus 
on the overall limitations of this PhD work. 
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2.1 Low prevalence of hyperglycaemia 
The main limitation of this work was the low prevalence of hyperglycaemia found in our study 
setting of Lusaka, Zambia. It was lower than the prevalence predicted from our preliminary 
background work, based on data from the ZAMSTAR study. The likely reason for this is the 
ZAMSTAR study was based in communities throughout Zambia, and so the prevalence of 
hyperglycaemia identified from the ZAMSTAR data was an average prevalence of 
hyperglycaemia among all the Zambian communities. Our PhD work was based only in Lusaka, 
in three low-income areas of the city. We found a lower prevalence of hyperglycaemia than we 
had anticipated. Whilst this is an important finding in itself, the consequence of low study 
power was seen in studies 2 and 3. 
As a consequence of the low prevalence of hyperglycaemia, we chose to re-categorise our 
glycaemia categories in study 2, to allow us to compare TB treatment outcomes across a lower 
range of glycaemia. This enabled us to still explore a dose-response relationship between 
glycaemia and TB treatment outcome, but as we had so few participants with higher levels of 
glycaemia, we were unable to explore this dose-response relationship across higher levels of 
glycaemia. This may well account for why we found no evidence of an association between 
glycaemia and TB treatment outcome. 
It is important to note that our own methods may have contributed to our finding of a low 
prevalence of hyperglycaemia, due to our use of a single random blood glucose level to screen 
for hyperglycaemia as discussed further in section 2.2. 
2.2 Measurement of glycaemia 
In these studies we focused on glycaemia as a continuous process in addition to a binary 
with/without disease entity, aiming to help us understand the shifts in glycaemic levels 
associated with TB (with or without HIV), whist simultaneously ensuring the studies were 
feasible to undertake. Ideally, if it was feasible and acceptable to participants, we would have 
had measures of oral glucose tolerance, fasting blood glucose and glycated haemoglobin at all 
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time points in all of our studies. But this would have been neither acceptable to participants 
nor feasible in just under 4,000 TB cases and 7,000 community controls. We therefore opted to 
choose the methods of glucose measurement that were feasible for each study, and then 
made certain that our subsequent interpretation of the findings reflected the methods used, 
and did not extrapolate to other methods of glucose measurement. 
The major concern with this approach is the potential for underestimating the prevalence of 
hyperglycaemia. We know that measures of random blood glucose lack sensitivity for the 
detection of hyperglycaemia or diabetes. For the few participants who were tested with both a 
random blood glucose and HbA1c in our study of diagnostic accuracy, we found that 12/80 
participants (15%) had a RBG <7mmol/L but went on to have a HbA1c ≥6.0%. It is likely 
therefore that for the many participants who only received a random blood glucose 
measurement we failed to detect some who were truly hyperglycaemic. We also found 42/60 
participants (70%) had a RBG ≥7.0mmol/L but a HbA1c <6.0%, which further highlights the 
failings of a single random blood glucose concentration as a measure of hyperglycaemia. 
We also chose not to incorporate prior diagnoses of diabetes within our definition of 
hyperglycaemia, partly because we were explicitly focusing on hyperglycaemia rather than 
diabetes, partly because of the likelihood of misclassification due to a low level of 
understanding of diabetes within our study communities, and partly because the prevalence of 
well-controlled diabetes in our study setting is very low. It was however possible for individuals 
with previously diagnosed (known) diabetes mellitus who were on treatment to be 
normoglycaemic at the time of measuring glycaemia even though they may be hyperglycaemic 
at other times. This could have led to an underestimate of the association between long term 
hyperglycaemia and acute TB but did not affect the association between hyperglycaemia and 
TB treatment outcomes because for that study there were only two individuals who reported a 
prior diagnosis of diabetes and both were hyperglycaemic at baseline.  
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2.3 Missing data 
We found a high proportion of missing data in our studies, particularly for follow-up data. A 
major cause of this was because we arranged to follow up participants in the TB clinics during 
routine appointments. However, we discovered during the studies that it is common practice 
in our study setting for TB patients to send relatives to represent them at the clinic, rather that 
the patients themselves attending. The relatives pick up medication and deliver any necessary 
specimens. We had neither the ethics approval nor the resources to visit participants in their 
homes to obtain follow-up data, and so we were unable to obtain high levels of follow-up data 
for all of our participants. We found no difference in baseline characteristics between 
individuals with and without missing data in our studies, so there is no reason to believe that 
this has introduced bias, but it did contribute to a lack of study power for our longitudinal 
studies. 
We also experienced difficulties obtaining CD4 count results for many of our HIV-infected 
participants. In Ministry of Health establishments in Zambia, CD4 testing is a routine part of 
the management of newly-diagnosed TB patients who are infected with HIV. In Lusaka, many 
clinics have capabilities to process CD4 tests in the clinic laboratory. We therefore planned to 
obtain the routine CD4 count result for our participants, whenever possible, rather than 
duplicate the process again ourselves. However, we experienced great difficulties obtaining a 
timely result. We found that there was often a long delay between TB diagnosis and CD4 count 
testing, leaving us with a result that was not applicable to the time of TB diagnosis. However, a 
bigger difficulty was obtaining any result, regardless of timing. The clinic systems are mostly 
paper-based rather than computerised, so physically finding the result, if one was available, 
was challenging. Further, many participants simply did not have their CD4 count tested due to 
various reasons including breakdown of laboratory machines and a lack of reagents. 
When planning these studies, we had intended to explore sub-group analyses for hypothesis 
generation purposes, including stratification of the case-control analysis by CD4 count. Given 
208 
 
the combined factors of a low prevalence of hyperglycaemia and a high proportion of missing 
data for CD4 count we were unable to explore this sub-group analysis. This was also the case 
for stratification by use of antiretroviral medication (as a proxy for viral load), though largely 
due to the low prevalence of hyperglycaemia rather than due to missing data. 
3 Overall conclusions 
The overall aim of this research was to determine how hyperglycaemia affects tuberculosis 
control in the sub-Saharan Africa context of high HIV prevalence and poor diabetes control. All 
studies conducted for this work found a low prevalence of hyperglycaemia, both in individuals 
with tuberculosis and in those without. We found no evidence of an overall association 
between hyperglycaemia and tuberculosis in our study population in Lusaka, Zambia. We 
found no evidence of a dose-response relationship between glycaemia and tuberculosis 
treatment outcome, and though our cohort study likely lacked power to determine any true 
association, it did so because of the low prevalence of hyperglycaemia found in our study 
population. Regardless, therefore, this suggests that hyperglycaemia is not a driver of poor 
tuberculosis treatment outcomes in our study setting. Combined, these studies suggest that 
hyperglycaemia is not a major threat to tuberculosis control in our study setting of Lusaka, 
Zambia. 
However, we did find evidence of association between hyperglycaemia and active tuberculosis 
among individuals infected with HIV, and we later found that a high proportion of 
hyperglycaemia measured at the time of TB diagnosis was transient rather than persistent. It is 
possible that the association seen in our population between hyperglycaemia and active 
tuberculosis among individuals with HIV reflects a higher proportion of transient stress 
hyperglycaemia among individuals infected with HIV than in uninfected individuals. We were 
unable to test this hypothesis formally due to the low numbers of individuals with 
hyperglycaemia recruited to our studies and the consequent lack of power for subgroup 
analyses, but we did see a higher point prevalence of transient hyperglycaemia in participants 
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infected with HIV than in uninfected participants. This was true for all three measures of 
glycaemia. 
We also found evidence of association between hyperglycaemia and active tuberculosis among 
individuals with sputum smear/Xpert-positive pulmonary TB. Transient hyperglycaemia could 
again be an explanation for this association, as it is plausible that the most unwell newly 
diagnosed pulmonary TB cases, and therefore the most likely to have stress hyperglycaemia, 
are found among individuals with smear-positive rather than smear-negative disease. Again, 
our studies were underpowered to test this hypothesis. 
We were not able to identify any test that was accurate for diabetes diagnosis at the time of 
tuberculosis diagnosis, and so, when testing for diabetes in individuals with tuberculosis, 
repeat testing after resolution of acute tuberculosis disease should be considered before a 
diagnosis of diabetes is made, as any initial hyperglycaemia identified could reflect transient 
hyperglycaemia. 
4 Future research 
Future work following on from this research would be best located in a setting with equally 
high tuberculosis incidence and HIV prevalence, but with a higher prevalence of 
hyperglycaemia than we found in Lusaka. This would ensure that it is feasible to obtain 
adequate study power. 
Further studies are needed to better understand the importance of transient hyperglycaemia 
in patients with tuberculosis.1 Studies to determine the prevalence of transient 
hyperglycaemia among hyperglycaemic individuals with TB in other settings around the world 
would be valuable, as would studies among subgroups, including individuals infected and 
uninfected with HIV. Studies to better understand the nature of transient hyperglycaemia 
would also be valuable – does this reflect stress hyperglycaemia due to acute tuberculosis 
disease or are there other causes of transient hyperglycaemia in individuals with tuberculosis? 
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Further studies are needed to assess the relationship between increasing levels of glycaemia 
and TB treatment outcome. If adequately powered studies find a dose-response relationship 
between rising levels of glycaemia and poor tuberculosis treatment outcome, as did Boillat-
Blanco et al’s study in Tanzania,2 a trial of interventions to improve glucose control among 
individuals with tuberculosis would be of value. Urban Tanzania has high rates of TB, HIV and 
hyperglycaemia2 and so would be ideal for such a trial.  
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Appendix II: World Health Organization definition of a 
tuberculosis case 
Taken from: Treatment of tuberculosis: guidelines – 4th edition. WHO/HTM/TB/2009.420. p23-
25. http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf  
The TB case definitions below are based on the level of certainty of the diagnosis and on 
whether or not laboratory confirmation is available.  
Definition of case of tuberculosis: A definite case of TB (defined below) or one in which a 
health worker (clinician or other medical practitioner) has diagnosed TB and has decided to 
treat the patient with a full course of TB treatment.  
Note. Any person given treatment for TB should be [considered] a case. Incomplete “trial” TB 
treatment should not be [considered] as a method for diagnosis. 
Definition of definite case of tuberculosis: A patient with Mycobacterium tuberculosis 
complex identified from a clinical specimen, either by culture or by a newer method such as 
molecular line probe assay. In countries that lack the laboratory capacity to routinely identify 
M. tuberculosis, a pulmonary case with one or more initial sputum smear examinations 
positive for acid-fast bacilli (AFB) is also considered to be a “definite” case, provided that there 
is a functional external quality assurance (EQA) system with blind rechecking. 
Pulmonary tuberculosis (PTB) refers to a case of TB (defined above) involving the lung 
parenchyma. Miliary tuberculosis is classified as pulmonary TB because there are lesions in the 
lungs. Tuberculous intrathoracic lymphadenopathy (mediastinal and/or hilar) or tuberculous 
pleural effusion, without radiographic abnormalities in the lungs, constitutes a case of 
extrapulmonary TB. A patient with both pulmonary and extrapulmonary TB should be 
classified as a case of pulmonary TB. 
Extrapulmonary tuberculosis (EPTB) refers to a case of TB (defined above) involving organs 
other than the lungs, e.g. pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and 
bones, meninges. Diagnosis should be based on at least one specimen with confirmed M. 
tuberculosis or histological or strong clinical evidence consistent with active EPTB, followed by 
a decision by a clinician to treat with a full course of tuberculosis chemotherapy. The case 
definition of an EPTB case with several sites affected depends on the site representing the 
most severe form of disease. Unless a case of EPTB is confirmed by culture as caused by M. 
tuberculosis, it cannot meet the “definite case” definition given above. 
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Appendix III: World Health Organization criteria for diabetes 
mellitus diagnosis 
Taken from: Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. 
Report of a WHO/IDF consultation. WHO Document Production Services, Geneva, Switzerland. 
2006. p3 
The following Table summarises the 2006 WHO recommendations for the diagnostic criteria 
for diabetes and intermediate hyperglycaemia. 
Diabetes  
Fasting plasma glucose ≥7.0mmol/l (126mg/dl) 
OR  
2–h plasma glucose* ≥11.1mmol/l (200mg/dl) 
  
  
Impaired Glucose Tolerance (IGT)  
Fasting plasma glucose <7.0mmol/l (126mg/dl) 
AND  
2–h plasma glucose* ≥7.8 and <11.1mmol/l (140mg/dl and 200mg/dl) 
  
  
Impaired Fasting Glucose (IFG)  
Fasting plasma glucose 6.1 to 6.9mmol/l (110mg/dl to 125mg/dl) 
AND (if measured)  
2–h plasma glucose* <7.8mmol/l (140mg/dl) 
* Venous plasma glucose 2–h after ingestion of 75g oral glucose load 
* If 2–h plasma glucose is not measured, status is uncertain as diabetes or IGT cannot be 
excluded 
 
In 2011 an addendum to the diagnostic criteria published in the 2006 WHO/IDF report was 
published, following a WHO expert consultation (Use of Glycated Haemoglobin (HbA1c) in the 
Diagnosis of Diabetes Mellitus. Report of a WHO Consultation. WHO Document Production 
Services, Geneva, Swizerland. 2011). The WHO consultation concluded that glycated 
haemoglobin can be used as a diagnostic test for diabetes, provided that stringent quality 
assurance tests are in place and assays are standardised to criteria aligned to the international 
reference values. An HbA1c of 6.5% is recommended as the cut point for diagnosing diabetes. 
There were no changes to the above 2006 recommendations on the use of plasma glucose 
measurements to diagnose diabetes.  
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Appendix IV: Participant Information 
Sheet 
 
 
INFORMATION FOR POTENTIAL PARTICIPANTS OF THE DIABETES-TB CONTROL STUDY 
You are invited to take part in a study to improve our understanding of how diabetes (sugar 
disease) affects tuberculosis and its control in Zambia. 2,000 people who are diagnosed with 
tuberculosis at ..................... clinic (fill in clinic name) will take part in this study. Another 2,000 
people who are diagnosed with tuberculosis in another clinic in Lusaka will also take part. 
Information on the study is supplied in this leaflet. A trained research nurse will be on hand to 
explain it and answer all your questions. Please check that you understand everything in this 
document. If you decide to take part, you will be asked to give written consent before you take 
part. 
Who is doing the study? 
This study is being performed by health workers from ZAMBART Project from the University of 
Zambia led by Dr Sarah Lou Bailey. Research assistants will be responsible for the day to day 
running of the study. ZAMBART Project is based at the Ridgeway Campus in Lusaka. The full 
contact details are: ZAMBART Project, P.O Box 50697, Lusaka Phone 021-1254710; Fax: 021-
1257215 Email: Info@zambart.org.zm. Your Local Research Assistant can be contacted at:  
……………………………………………………………..........................................................................................
.........(Name and Contact details of research assistant for each clinic here) 
This research protocol has been approved by the University of Zambia Research Ethics 
Committee: 
The Chairperson 
Research Ethics Committee 
University of Zambia 
Ridgeway Campus 
P.O Box 50110 
Lusaka, Zambia 
Tel/Fax 021-1250753 
Email: unzarec@zamtel.zm 
 
What is the purpose of the study? 
The main aim of this study is to improve our understanding of how diabetes affects 
tuberculosis (TB) and its control in Zambia. We know from other studies that have been done 
in other countries around the world, that people who have diabetes are more likely to develop 
tuberculosis than people who don’t have diabetes. We also know that once they have 
tuberculosis, the treatment for tuberculosis doesn’t work as well as it does in people who 
don’t have diabetes. But Zambia and other similar countries in Africa may be different to 
elsewhere in the world, and we want to know how diabetes affects tuberculosis here in 
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Zambia. This will in turn help to improve the way diabetes and tuberculosis are dealt with in 
our country. 
Diabetes causes abnormal sugar levels in the blood. If untreated, this can cause a person to 
lose weight and become very thirsty. Over months and years, abnormal sugar levels in the 
blood can cause many different problems in the body, including poor eye sight and blindness, 
damage to the kidneys, heart disease and stroke. It also affects a person’s ability to fight off 
infections, so a person with diabetes is more likely to get infections such as TB than a person 
without diabetes. To find out whether you have diabetes we will be asking you to provide a 
blood sample by means of a finger prick which will be screened immediately by a research 
nurse. The results can be available in just 5 minutes. You will be given your results and told 
what next step to take depending on the results. 
TB is an infectious disease caused by bacteria (germs), which are spread through droplets 
(coughing). TB infection mainly affects the lungs, but can also affect other parts of the body, 
such as the lining of the brain (meningitis), and glands. In spite of a good programme for 
tracing and treating people with active TB infection, many people in Zambia still develop TB 
disease each year. If we can understand better why some people get TB more than others 
(such as people with diabetes) then this could help up to improve identifying people who have 
TB at an early stage of their disease. 
We know that people with HIV, the virus that can cause AIDS, are also more likely to get TB 
than people without HIV. One thing that we’re particularly interested in in this study is what 
happens to tuberculosis if someone has both diabetes and HIV. Therefore, if you haven't had a 
recent HIV test, we will be asking you to provide a blood sample which we use to test for HIV. 
The results of the HIV test can be made available in 20 minutes. A trained counsellor will give 
you pre-test and post-test counselling and you will be referred to the clinic if you need any 
care. If you prefer, you can have the test but choose not to receive the results. 
We will ask you questions to get more details about yourself and your living conditions. This 
information will help us better understand how diabetes affects tuberculosis. 
Taking part in this study is voluntary. You are free to withdraw from this study at any stage, 
without any consequences for you. No financial reward will be given to any persons taking part 
in this study. 
Are there any risks for people who take part in this survey? 
Taking part in this study does not pose any risks to you or your family. However, you may feel 
worried about the results of the tests done. We will refer you for care and we will be in your 
TB clinic every day Monday – Friday so that if you have any questions later you can come and 
discuss them with us. It is possible that you may experience some mild discomfort or bruising 
when we take a finger prick or other blood sample from you. We will do our best to minimise 
any discomfort. The following will be required of all those taking part: 
1) You will be asked to sign two copies of a consent form after you have read and 
understood this information leaflet. You will be given an original copy of this leaflet 
and one of the copies of the consent form to keep. 
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2) You will be asked to answer questions about your health. The research nurse will ask 
you the questions and will record your answers on a computer copy of our 
questionnaire. She/he will write the answers directly onto a handheld computer. 
3) We will measure  your blood pressure, height, weight and the distance around your 
waist. 
4) You will be asked to provide a finger prick blood samples for diabetes testing. 
5) If you have not had a recent HIV test we will ask you if we can use some of this blood 
to also test for HIV. 
6) If you are HIV positive we will ask if you've had a recent CD4 test. This is something 
that should be checked when you are diagnosed with TB, but if it hasn't been done 
then we can do it for you.  
7) We will select some people in the study to follow-up to see how they get on over the 
first 2 months of their TB treatment. If we have selected you, we will ask you to cough 
up some phlegm once a week for two months, to see how quickly your tuberculosis is 
improving with treatment. We will also like to perform some more sophisticated tests 
for diabetes. One is called HbA1c, for which we will need a small blood sample. The 
other is called fasting blood glucose, which involves us taking another finger prick 
blood sample. For this test you must not have eaten or drank anything except water 
for the previous 6 hours, so it’s easiest if we do this first thing in the morning before 
you eat breakfast. As you won't have had breakfast we will give you a drink and a bun 
after the test. For this test, you may need to make an additional trip to the clinic, in 
which case we will pay for your travel to and from the clinic. 
8) Your blood samples and TB cultures will be kept in a sample bank with only a bar code 
on (not your name). These samples can be used in future for further tests on diabetes 
or TB. 
What is the benefit to you of taking part in this study? 
By taking part in this study you will be checked for diabetes and HIV. If you have either of these 
conditions you will be referred for treatment so that you can be kept healthy. We will also give 
you a health information/education leaflet about diabetes. The information gained from this 
study will be used to provide suggestions for improving health services. 
Blood Sugar and blood pressure Results 
If your blood sugar results are abnormal, you will be given an information sheet on diabetes 
and referred to the health centre for further screening and advice. We will also refer you to 
the health centre if your blood pressure is persistently high. 
What will happen if the HIV test is positive? 
If your HIV results are positive, we will refer you to your local clinic for you to access 
appropriate care for HIV. We will also inform your TB clinic so that they can offer you the best 
treatment for your tuberculosis. 
Quality assurance 
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As part of the process of collecting data, we will perform quality assurance on some of the 
data that will be collected. You may be asked some of the questions in the questionnaire a 
second time by a different member of the study team to check that we haven’t made any 
mistakes. 
Confidentiality of information and privacy of the participant 
All personal information obtained during this study will remain strictly confidential. Your 
questionnaire answers will be transferred directly to a computer, but your name will not be 
included. You will be identified by a coded number only. No information about any of your 
results will be released to any other parties but the research team, without your further 
consent. 
The information entered onto the computer will be stored on a central database which will be 
protected by a password. Your name and address will be stored on a separate database which 
will be protected by a separate password. No information regarding personal details which 
could identify individuals or individual households will be disclosed. However, there may be 
follow-up studies to this study. In this case personal details may be obtained only after further 
ethical approval and may only be made available to the principal investigator of any follow-up 
study to facilitate follow-up. 
Thank you for reading this information sheet. If you have any questions, please ask them 
now. The research nurse will be pleased to answer them. If you wish to take part, please 
read and sign the consent form. Please keep this information sheet in a safe place. 
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Appendix V: Participant Consent Form 
 
 
  
 
 
INFORMED CONSENT FORM FOR DIABETES-TB CONTROL STUDY (PERSONS AGED 18 YEARS 
AND OLDER) 
1. I confirm that I have read the information sheet, and that the information and procedures 
involved in my taking part in this study have been explained to me. 
2. I have been given time and opportunity to read the information carefully, to discuss it with 
others and to decide whether or not to take part in this study. 
3. I understand that my blood and sputum specimens will be kept in a sample bank for up to 
5 years with only a bar code on (not my name) and that these samples can be used in 
future for further tests relating to diabetes or TB. 
4. I understand that the results of this study will be published in scientific journals but that 
my name will not be used. 
5. I agree to take part in the study. 
Subject’s signature/fingerprint: __________________________________ Date ________ 
Subject’s name: ______________________________________ (please print) 
 
The person who obtains the informed consent discussion must also sign and date this form. 
Signature: ___________________________________________Date ________ 
Name: ______________________________________________ (please print) 
 
Signature of witness (if applicable) 
Signature of witness: ___________________________________Date_________ 
Witnessed by (print name): ______________________________ 
  
Participant study ID number 
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Appendix VI: Flow Charts of Participant Activities 
 
Flow Chart of Participant Activities:  
Study 1 Participants 
 
 
 
  
• Read the information sheet
• Read and sign the consent form
• Answer some questions that we ask you about you and your health
• We will measure your blood pressure, height, weight and the distance 
around your waist
• We will take a finger-prick drop of blood for a sugar test
• (If you haven’t had a recent HIV test we will also ask you if we can use 
some of this blood to test for HIV. If you have had a recent HIV test at 
the TB clinic then there’s no need to repeat this. If you already know 
that you are HIV positive we will ask if you have had a recent CD4 test. 
This is something that should be checked when you are diagnosed with 
TB, but if it hasn't been done then we can do it for you.)
Today
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Flow Chart of Participant Activities:  
Study 2 Participants 
 
 
  
• Read the information sheet
• Read and sign the consent form
• We will take a blood sample from you for a detailed sugar test (called HbA1c)
• Please give us a sputum sample by coughing up some phlegm into a 
collection pot
• You will need to fast overnight tonight to prepare for a sugar test tomorrow 
morning. Please don't eat or drink anything except water after you've gone 
to bed this evening
Today
• Please don't eat or drink anything except for water. Come straight to the 
clinic in the morning 
• We will take a finger-prick drop of blood for the fasting sugar test before you 
collect your medicines. As soon as this is done you can eat and drink 
whatever you like. We will give you a drink and a bun to eat for you comfort
Tomorrow morning
• When you come to the clinic to collect your medicines each week, please 
give us another sputum sample
Next week and then weekly for a total of 8 weeks
• We will repeat the fasting sugar test on a day that you are coming to the 
clinic to collect your medicines. When you wake up in the morning, again, 
please do not eat or drink anything except water. We will take another 
finger-prick drop of blood for the fasting sugar test. As soon as this is done 
you can eat and drink whatever you like. We will give you a drink and a bun 
to eat for your comfort
• We will also take another blood sample to repeat the detailed sugar test 
(HbA1c)
In three months
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Flow Chart of Participant Activities:  
Study 3 Participants 
 
 
  
• Read the information sheet
• Read and sign the consent form
• We will take a blood sample from you for a detailed sugar test (called HbA1c)
• You will need to fast overnight tonight to prepare for a sugar test tomorrow 
morning. Please don't eat or drink anything except water after you've gone to 
bed this evening
Today
• Please don't eat or drink anything except for water. Come straight to the clinic 
in the morning 
• We will take a finger-prick drop of blood for the fasting sugar test before you 
collect your medicines. As soon as this is done you can eat and drink whatever 
you like. We will give you a drink and a bun to eat for you comfort
Tomorrow morning
• We will repeat the fasting sugar test on a day that you are coming to the clinic 
to collect your medicines. When you wake up in the morning, again, please do 
not eat or drink anything except water. We will take another finger-prick drop 
of blood for the fasting sugar test. As soon as this is done you can eat and 
drink whatever you like. We will give you a drink and a bun to eat for your 
comfort
In three months
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Appendix VII: Daily Task List for Investigators 
For participants in studies 2 and 3 who were enrolled yesterday 
1. Measure fasting blood glucose concentration 
Initial procedures for study 1 participants 
2. Identify newly diagnosed tuberculosis patients attending Kanyama, Chawama and 
George clinics through consultation with clinic staff and clinic records 
3. Obtain individual written informed consent from those meeting inclusion criteria and 
willing to participate 
4. Administer structured questionnaire 
5. Measure blood pressure 
6. Measure weight, height and waist circumference 
7. Measure random blood glucose concentration 
8. Record HIV status. If no current HIV status available, perform an HIV test with pre- and 
post-test counselling 
9. For HIV +ve participants, record CD4 count. If no current CD4 count available, measure 
CD4 count 
10. Give a diabetes fact sheet to each participant 
Initial procedures for studies 2 and 3 participants 
11. Identify sputum-smear positive participants within the three strata of RBG 
concentration 
12. Take a venous blood sample for measurement of HbA1c concentration 
13. Collect a sputum specimen 
14. Inform participants of procedures for fasting blood glucose measurement 
Initial procedures for study 3 participants 
15. Identify sputum-smear negative participants within the three strata of RBG 
concentration 
16. Take a venous blood sample for measurement of HbA1c concentration 
17. Inform participants of procedures for fasting blood glucose measurement 
For study 2 participants returning weekly for 8 weeks post-enrolment 
18. Collect sputum specimens  
For study 2 participants at 12 weeks post-enrolment 
19. Repeat FBG measurement 
20. Take a second venous blood sample for measurement of HbA1c concentration 
For study 3 participants at 12 weeks post-enrolment 
21. Repeat FBG measurement 
For all participants at 6 months post-enrolment (or earlier if appropriate) 
22. Review TB clinic and laboratory records to determine if case has a microbiological 
confirmation of TB 
For all specimens collected during day 
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23. Transport to ZAMBART lab for processing or storage  
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Appendix VIII: Participant Questionnaire 
 
SECTION 1 
ALL QUESTIONS IN THIS SECTION MUST BE ANSWERED 
 
Q01_INC Interviewer’s code  
  
Q02_CLC Clinic's code    
  Chawama  1 
  George 2 
                  Kanyama 3 
 
Q03_DAT Date today  
D 
 
D 
 
M 
 
M 
 
Y 
 
Y 
 
Y 
 
Y   
        
Q04_IND Participant barcode number  
  
 
Q05_SEX Sex M F 
  1 2 
 
Q06_AGE Age   
  
 
Q07_DIS Disability?    
  No Disability 1 
  Sight(blind/ severe visual impairment) 2 
                  Hearing (deaf/ profoundly hard of  hearing) 3 
  Communication(speech impairment) 4 
  Physical(needs wheelchair/ crutches) 5 
  Mental disability 6 
  Unknown 7 
 
Q08_CON Consent No Yes Absent Excluded 
  0 1 2 3 
 
 
 
ONLY CONTINUE IF CONSENT IS GIVEN 
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SECTION 2 – FILL THIS AND SUBSEQUENT SECTIONS IN ONLY IF PERSON HAS GIVEN CONSENT 
  
Q09_DOB Date of Birth (01/01/1800 if 
unknown) 
 
D 
 
D 
 
M 
 
M 
 
Y 
 
Y 
 
Y 
 
Y 
 If not known, what was your age in 
 years at your last birthday? (999 if 
unknown) 
        
 
Q10_YLC How many years have you lived in this community?   
 Write down actual number, zero if less than one year   
 
Q11_RAC What is your race?    
 Select only one option Black 1 
  Coloured 2 
  Indian/Asian 3 
  White 4 
  Other 5 
 
Q12_COB What is your country of birth?    
 (Drop down menu with SADC countries and  few other 
Africa countries) 
  
 
Q13_CMS  What is your current marital Status?  
 Never married   1 
 Currently married or living as married 2 
                                                                                                                          Divorced or 
Separated 
3 
 Widowed 4 
If Married, Divorced or widowed, continue. If never married go to Q15 
 
Q14_AFM  Age at first marriage? (years)  
    
 
 
Q15_MOY What has been your main 
occupation during the past 
year?  
    
  Unemployed/working on own land 1 
  Occasional/seasonal employment 2 
  Employed (Formal employment or self employed 
making money) 
3 
  Unable  to work 4 
  Student 5 
  Housewife/ home-maker 6 
 
 
 
Q16_HES Have you ever been a smoker? No Yes 
 If no, jump to Q17_CDH 0 1 
 
I would like to ask you about your current drinking and smoking habits 
I would like to ask you some questions 
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Q16_1_HES How old were you when you first started regular cigarette 
smoking? 
Age Unk 
   -1 
 
Q16_2_HES If you have stopped smoking, how old were you when 
you stopped? 
Age Unk Not 
stopped 
   -1 -5 
 
Q16_3_HES On average over the entire time that you smoke(d), about how 
many cigarettes do (did) you smoke? 
Number per 
week 
Unk 
   -1 
 
Q16_4_HES On average over the entire time that you smoke(d), do (did) you primarily smoke 
manufactured or hand rolled cigarettes? 
 
                                                                                                                          Manufactured  1 
                                                                                                                          Hand rolled 2 
 
Q17_CDH How would you classify your drinking habits?     
  Have never drunk 1 
  Daily drinker 2 
  Occasional drinker 3 
  Ex-drinker 4 
 
 
 
Q18_HEA 
 
What is the highest level of education you 
have attained?   
    
  No Formal Education 0 
 Grade 1-12(Indicate actual grade)Note Grade 8-12 is also Form 1 –form 5  
  College 20 
  University 30 
If has attended school, continue. If no formal education go to Q20 
 
Q19_YES When was the last year you were  enrolled 
 in School/College/University? Enter 9999 if year is not known  
 
Y 
 
Y 
 
Y 
 
Y 
 
Q20_OCC What was your main 
occupation at age 15 
years? 
    
  Unemployed/ working on own land 1 
  Seasonal/Occasional employment 2 
  Employed (formal employment or self employed 
earning money) 
3 
  Unable to work 4 
  Student 5 
  Housewife/home-maker 6 
  Can’t remember 9 
 
 
 
  
Q21_DTS Date TB treatment started         
Now I will ask questions about your education  
I would like to ask you about your health. (Current TB questions)  
248 
 
  D D M M Y Y Y Y 
 
Q22_TTN TB treatment Number 
 
 
 
 
Q23_CAT
  
Category of TB?    
  Sputum  smear Positive 1 
  Sputum smear Negative 2 
  Extrapulmonary 3 
  Unknown/not recorded 4 
 
 
 
 
 Previous TB treatment 
Q24_TTB Have you ever been on TB treatment before? No Yes Unk 
  If yes continue, if no go to Q26 0 1 9 
 
Q25_HMT How many times?     
  Once 1 
  Twice 2 
  Three times 3 
  More than three times 4 
  Unknown 9 
 
 
 
Q26_CHC Do you currently have a cough? No Yes 
 If yes continue, if no go to Q28 0 1 
 
Q27_WBC How many weeks have you been coughing?  
Write number of weeks in box     
 
   
 
Q28_CPS Do you currently produce sputum No Yes 
  0 1 
 
Q29_CCB Do you currently cough up blood? No Yes 
  0 1 
 
Q30_CCP Do you currently have chest pains? No Yes 
  0 1 
 
Q31_CHF Do you currently have a fever? No Yes 
  0 1 
 
Q32_DNS Do you currently have drenching night sweats? No Yes 
  0 1 
 
Q33_LWU In the last month have you lost weight unintentionally? No Yes 
I would like to ask about your TB symptoms 
  Questions about previous TB treatment 
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  0 1 
 
Q34_DBB Do you currently have difficulty breathing or shortness of breath? No Yes 
  0 1 
 
 
 
Q35_THD Have you ever been told you have diabetes/blood sugar No Yes 
 If Yes continue, if No go to Q38 0 1 
 
Q35_1_THD
  
How long ago were you 
diagnosed with diabetes? 
  
  0-6 Months 1 
  7-12 Months 2 
  1-2 years 3 
  2-3 Years 4 
  >3 Years 5 
  Don't know/Refuse -1 
 
 
Q35_2_THD Was it diagnosed when you were a child? No Yes Unk 
 If male, skip to Q36_CAT 0 1 9 
 
Q35_3_THD Was it diagnosed during pregnancy? No Yes Unk 
  0 1 9 
 
Q35_4_THD Did it continue after pregnancy? No Yes Unk 
  0 1 9 
 
Q36_CAT Are you currently on any treatment for diabetes?  No Yes 
 If yes continue. If no go to Q37_1_TON 0 1 
                                   
Q37_TON What treatment are you on?     
  Dietary only 1 
  Tablets 2 
  Insulin injections 3 
Q37_1_TON What tablets are you on?     
  Metformin 1 
  Glibenclamide 2 
  Other 3 
Q37_2_TON If other, what medication?     
   
 
Q37_3_TON Why are you not on treatment for diabetes?     
  Health facility too far 1 
  Long queues 2 
  No medicine at Health facility 3 
  Symptoms not too bad 4 
  Have no money 5 
  No transport 6 
  Too sick to go to Health facility 7 
  Other 8 
Now I will ask questions about Diabetes and HIV 
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  Don't know/Refuse -1 
 
 
 
Q38_KHS Do you know your HIV status? No Yes 
  0 1 
 
Q39_DHS Are you willing to disclose your HIV status? No Yes 
 If yes continue, if not willing to discuss go to Q43 0 1 
 
Q40_HIV What was the result?   
  Negative 0 
  Positive 1 
 If HIV status is Positive, continue, if negative go to Q43 
 
Q41_ART Are  you on Antiretroviral treatment( ART) No Yes 
 If yes continue, if no go to Q43 0 1 
 
Q42_LAR How long have you been on ART?  Write down actual 
number of months 
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SECTION 3 
Now I will ask some questions about your home. 
Q43_HHH In your Household is there  No Yes 
 (Check every option) Electricity 0 1 
  A radio/radio cassette 0 1 
  A television 0 1 
  A refrigerator/freezer 0 1 
  A bicycle  0 1 
  A motorcycle 0 1 
  A car 0 1 
  
A domestic worker not related to 
household head 
0 1 
  A mobile phone 0 1 
  A landline (non mobile telephone) 0 1 
 
Q44_WOL Do members of your household work on their or the family’s agriculture 
land? 
 
No 
 
Yes 
  0 1 
 
Q45_WAT 
What is the main source of DRINKING 
WATER for this household (check only one 
option) 
  
  Piped water inside the residence  1 
  Piped water in the yard 2 
  Piped water from a public tap 3 
  Protected  well 4 
  Unprotected shallow well 5 
  Traditional well 6 
  Bore hole 7 
  River, stream, lake etc 8 
  Other 9 
 
Q46_TOI 
What is the main type of TOILET facility for this 
household? 
Private flush toilet 1 
 (Check only one option)  Shared flush toilet 2 
  Pit Latrine without ventilation 3 
  VIP Latrine  4 
  None- use bush/field 5 
  Bucket system 6 
  Chemical 7 
  Other 9 
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Q47_DWE 
Which of the following types best describes the main dwelling unit that this 
household occupies?  
 
  House/brick structure on own stand (single unit) 1 
  Townhouse/cluster/semidetached house (multiunit residence)  2 
  Traditional dwelling/hut/structure made from traditional material 3 
  Flat in block of flats 4 
  Brick house/flat/room in backyard 5 
  Informal dwelling or shack in backyard 6 
  
Informal dwelling or shack not in backyard (informal squatter 
settlement) 
7 
  Caravan/Tent 8 
  Worker’s hostel 9 
  Other 99 
 
 
Q48_FLO What is the main type of flooring for this household? Dirt/earth 1 
 (Check only one option) Wood, plank 2 
  Parquet, lino 3 
  Cement 4 
  Tile flooring 5 
  Other 9 
 
Q49_HEA 
What type of fuel does your household mainly use 
to keep warm inside the house during winter? 
  
 (Check only one option) Nothing 0 
  Electricity 1 
  Liquefied Petroleum Gas 2 
  Kerosene/Paraffin 3 
  Charcoal 4 
  Wood 5 
  Other  9 
Q50_FFC 
What type of fuel does your household mainly use 
for cooking? 
  
 (Check only one option)   No cooking is done 0 
  Electricity 1 
  Liquefied Petroleum Gas 2 
  Paraffin 3 
  Charcoal 4 
  Wood 5 
  Other  9 
          
Q51_ TOS What type of stove is usually used for cooking?   
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  Open fire 1 
  Surrounded fire 2 
  
Stove with combustion 
chamber 
3 
  Two or three pot stove 4 
  Sunken pot stove 5 
  Gas stove 6 
  Electric/gas range 7 
    
Q52_WCH Where does cooking mainly happen? Indoors in main house 1 
 (Check only one option) Indoors separate building 2 
  Outdoors 3 
 
 
 
Q53_RON Did your household have to rely on any of the following in the last 18 months? 
 (Each item must be answered) No Yes 
 Relief food, free food from government and other bodies 0 1 
 Reducing number of meals or food in-take 0 1 
 Borrowing cash (e.g. kaloba, borrowing from friends etc) 0 1 
 Sale of assets 0 1 
 Sending household members away 0 1 
 
Q54_HUN 
During the past three months, did it happen even once that you or any member of your 
family experienced hunger because you did not have any food to eat? 
  No 0 
  Yes 1 
  Unk 9 
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SECTION 4 
 
 
 
Q55_ABP Blood pressure?  
If not done, write 999/999 
   
/ 
   
mm/Hg 
 
Q56_WEI Weight? Record weight in Kilograms (one decimal 
point) 
If not done, write 999.9 
   
. 
 
Kg 
 
Q57_HEI Height? Record height in centimetres  
If not done, write 999 
   
cm 
 
Q58_ABC Abdominal Circumference? Record in centimeters  
If not done, write 999 
   
cm 
 
 
 
 
Q59_BLG Blood Glucose. Write actual Results below 
    
. 
 
 
Q60_LAG When did you last have anything to eat or 
drink (except water)? 
Write Number of hours ago 
      
 
 
Q61_HIV_DET HIV Test result (Determine).   
  Negative 0 
  Positive 1 
  Not Done 9 
 
Q62_HIV_UNI Confirmatory HIV Test result (Unigold)   
  Negative 0 
  Positive 1 
  Not Done 9 
 
Q63_KHS Does study participant want to know his/her HIV Result? No Yes 
  0 1 
 
Q64_GHB HIV test results given to study participant? No Yes 
  0 1 
 
 
 
THANK YOU FOR YOUR HELP 
 
  
RECORD BLOOD SUGAR AND HIV RESULTS HERE 
RECORD BODY HABITUS AND BLOOD PRESSURE MEASUREMENTS 
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Appendix IX: Diabetes Fact Sheet  
 
What is diabetes? 
Diabetes is a disease commonly known as sugar disease. A person suffering from diabetes has 
too much blood sugar. 
What causes Diabetes? 
There are two major types of diabetes: 
Type 1: In type 1 (also called juvenile-onset or insulin-dependent) diabetes, the body 
completely stops producing any insulin, a substance in the blood which the body needs to use 
sugar. People with type 1 diabetes must take daily insulin injections to survive. This form of 
diabetes usually develops in children or young adults, but can occur at any age. 
Type 2: Type 2 (also called adult-onset or non insulin-dependent) diabetes results when the 
body doesn’t produce enough insulin and/or is unable to use insulin properly (insulin 
resistance). This form of diabetes usually occurs in people who are over 40, overweight, and 
have a family history of diabetes, although it is increasingly occurring in younger people, 
particularly adolescents. 
How do people know if they have diabetes? 
People with diabetes frequently experience certain symptoms. These include: 
· being very thirsty and the mouth feels dry 
· frequent urination which is more than normal 
· weight loss 
· increased hunger 
· inability to see clearly 
· itching around the genitals 
· tingling or numbness in the hands or feet 
· frequent skin, bladder or gum infections 
· wounds that don't heal 
· extreme unexplained fatigue 
In some cases, there are no symptoms — this happens at times with type 2 diabetes. In this 
case, people can live for months, even years without knowing they have the disease. This form 
of diabetes comes on so gradually that symptoms may not even be recognized. 
If you feel you have symptoms suggestive of diabetes, go to the health centre or Hospital to 
have your blood sugar checked 
Who is at risk for getting diabetes? 
Anyone, any age, anywhere can get diabetes. It is however more common in: 
· People who are physically inactive 
· People who are overweight; 
· The elderly 
· Those with a family history of diabetes. 
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Is there a cure for diabetes? 
NO! But there is effective treatment, and knowing how to take care of yourself, you could lead 
an active healthy life. 
What to do if you are found to have diabetes? 
· Avoid eating food containing a lot of sugar 
· Avoid eating food which contains a lot of fat 
· Eat a lot of food that contains a lot of fibre such as beans, peas, roller meal and brown 
bread 
· Eat a well balanced diet with a lot of fruits and vegetables 
· Avoid alcoholic drinks 
· Avoid smoking 
· Avoid being overweight 
· Exercise regularly 
· Always remember to take medicines as recommended by the healthcare provider 
· Go for regular checkups as recommended by the healthcare provider 
What the complications of diabetes? 
Immediate complications: There are two immediate complications and these are medical 
emergencies. 
1. High Blood sugar 
High blood sugar can occur if diabetes is inadequately treated or in persons who do not know 
that they are diabetic and are not on treatment. 
Signs of high blood sugar include: 
· Initially excessive urination, leading on to no urination due to severe dehydration 
· Dehydration with a dry mouth 
· Loss of consciousness 
Follow instructions given by your healthcare provider about how to take your medicine. Go 
to a health facility if you are diabetic and you suspect that your blood sugar is high 
2. Low blood sugar 
Low blood sugar can occur in known diabetics if: 
· They inject themselves with insulin or take tablets for diabetes without eating enough 
food 
· If they exercise too much after injecting insulin or taking some types of tablets for 
diabetes 
Signs of low blood sugar include: 
· Feeling Shaky and Jittery 
· Feeling Nervous 
· Feeling Dizzy 
· Feeling hungry 
· Feeling the heart beating fast 
· Sweatiness 
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If you experience any of these signs, immediately eat or drink something sweet such as sweets, 
a sugary drink or even a sugar solution 
Can diabetes be prevented? 
YES! Sometimes. There is a lot one can do to delay or prevent the onset of diabetes. 
· Maintain a healthy body weight 
· Exercise regularly 
· If you have a relative with diabetes, go for regular checkups 
· Eat a well balanced diet with a lot of fruits and vegetables 
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Appendix X: Diabetes Referral Letter 
 
 
Referral letter – Blood sugar is abnormal 
 
Name:.................................................... 
 
Date:...................................................... 
 
Your blood has been tested for the presence of sugar and the test results show that you have a 
sugar level of ……………….mmol/L in your blood. You had a second test to confirm whether or 
not you have a condition called diabetes (this test was a fasting blood sugar test) which 
showed a sugar level of ...................mmol/L in your blood. These tests suggest that you do 
have diabetes.  
 
We have therefore booked an appointment for you to see a clinic doctor at ............................ 
Health Centre. The doctor will explain more about diabetes to you and you will be able to ask 
the doctor any questions that you may have about diabetes. The doctor will assess your health 
and arrange for any treatment or further management that may be needed. In the mean time 
please read our diabetes fact sheet to find out more about diabetes and if you have any 
concerns please speak to a member of the study team or visit your local health centre. 
 
Your appointment is on ................ (date) at .............. (time).  
 
 
PLEASE PRESENT THIS LETTER TO THE RECEPTION AT THE HEALTH FACILITY 
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Appendix XI: HIV Fact Sheet 
 
What is HIV/AIDS? 
Acquired Immune Deficiency Syndrome (AIDS) is the end stage of the infection caused the 
Human  Immunodeficiency Virus (HIV). HIV is a virus that weakens the immune system. 
How can one get HIV/AIDS? 
HIV is transmitted through: 
 Unprotected sex: you can become infected with HIV if you have unprotected vaginal, 
anal or oral sex with an infected person 
 Exchanging body fluids such as blood transmission: HIV virus can be transmitted 
through blood transfusion if blood is not properly checked 
 Sharing sharp utensils (e.g. razor blades and needles) 
 The virus can also be transmitted from mother to child during pregnancy, at birth or 
during breast feeding 
Signs and Symptoms HIV/AIDS 
The symptoms of HIV/AIDS vary. You may remain symptom free for many years, but as the 
virus continues to multiply and destroy immune cells, you may develop chronic symptoms such 
as: 
 Swollen lymph nodes- often one of the first signs of HIV infection. 
 Diarrhoea 
 Weight loss 
 Fever 
 A cough and shortness of breath 
If you suspect you have contracted HIV go for VCT at any nearest clinic as soon as possible 
HIV/AIDS treatment 
HIV/ AIDS is not curable. Early testing and positively living is the key to the prevention of HIV 
infection. 
Management of HIV/AIDS involves: 
 Treatment of infections that come due to HIV infection 
 Anti-retroviral Therapy (ART) to reduce HIV viral load. ARVs are to be taken throughout 
one's life 
 ARVs, like any other drugs, have some side effects. If you experience any side effect 
you should consult your health care provider as soon as possible 
How can HIV/AIDS be prevented? 
 By avoiding multiple and unprotected sex 
 By avoiding sharing utensils such as needles and razor blades 
 By practicing safe motherhood. Pregnant mothers should attend antenatal clinics 
regularly  
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Appendix XII: HIV Referral Letter  
 
 
 
Referral letter – HIV clinic 
 
 
Name:.................................................... 
 
Date:...................................................... 
 
Your blood has been tested for the presence of the HIV virus. As has been discussed with you 
by the research staff, your HIV result is positive. You had a second test which confirmed the 
presence of the HIV virus in your blood.  
Treatment is available for HIV to enable you to lead a long and healthy life. We have therefore 
booked an appointment for you to see a health care worker at ............................ Health 
Centre. The health care worker will explain more about HIV to you and you will be able to ask 
them any questions that you may have about HIV. The health care worker will assess your 
health and arrange for appropriate treatment and/or any further management that may be 
needed. In the mean time please read our HIV fact sheet to find out more about HIV and if you 
have any concerns please speak to a member of the study team or visit your local health 
centre. 
 
Your appointment is on ................ (date) at .............. (time).  
 
PLEASE PRESENT THIS LETTER TO THE RECEPTION AT THE HEALTH FACILITY 
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Appendix XIII: Sputum collection poster 
   
DARTZ 
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Appendix XIV: Blood Glucose Testing 
Standard Operating Procedures 
 
Instructions for blood glucose testing using a glucometer 
In this study blood glucose measurement for both random and fasting blood glucose will be 
carried out using a glucometer through the collection of a capillary blood sample. The 
glucometer is a rapid method of determining the blood sugar level. This SOP outlines 
procedures for collection of a capillary blood sample, handling and discarding of the test strips, 
use of the glucometer and giving results back to the participants. 
Materials for the test 
· Disposable gloves 
· Sharps and biohazards disposable container 
· Alcohol swabs 
· Gauze/cotton pads 
· Auto-lancets 
· Glucose test strips 
· Glucometer 
· Batteries 
Performing the test 
· Prepare a place where the test can be done. This should be a flat surface and there 
should be no clutter around. 
· Wash your hands thoroughly. If water is not available, rub your hands with gel or with 
an alcohol swab. 
· Use standard precautions – wear gloves. 
· Confirm that the test strip is within the expiry date. 
· Turn on the glucometer and place the test strip in the glucometer. 
· Touch drop but not finger to test strip. Press the skin puncture site with dry 
cotton/gauze. 
· Wait for the glucometer to read the test strip. 
· Dispose of waste in biohazard waste container. 
· Read the result given on the glucometer. Note whether the result falls outside the 
normal or reportable range. 
· Record the result on the questionnaire (on the PDA) at the relevant position. 
Quality control and maintenance policy 
This should be performed whenever a new container of test strips are opened: 
· Proceed in exactly the same way as when carrying out a blood glucose test. 
· Remove control bottle cap. 
· Wipe the tip of the bottle with a tissue. 
· Hold the dropper horizontally with the tip pointed directly at the front edge of the 
yellow window of the test strip. 
· Gently squeeze the bottle to form one small drop. 
· Touch the drop to the front edge of the yellow window of the test strip. 
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· Allow the test strip to automatically draw in the control solution until you see the 
flashing eggcup in the display. 
· Close the bottle tightly after use. 
· A result appears on the display with a control bottle symbol and a flashing "L". Do not 
remove the test strip yet. 
· Press the right arrow button once for a Level 1 control (low glucose control). 
· Press the right arrow button a second time for a Level 2 control (high glucose control). 
· Press the on/off button to set the level in the meter. 
· "OK" and the result alternate in the display if the result is in range. 
· "Err" and the result alternate in the display if the result is not in range. 
· You can also compare the result with the permitted range given on the test strip 
container label. 
· If the result obtained is within the permitted range, correct functioning of the system 
is assured. If the result obtained lies outside the range given or if "Err" is displayed, it is 
necessary to repeat the test. If the same applies to the second test, discuss with Dr. 
Bailey. 
Giving results to the study participant 
· Explain the results as given on the glucometer. 
· If the random blood glucose level is above the normal range explain that a 
confirmatory test needs to be done the following morning. Explain to the participant 
that this test needs to be done early in the morning before breakfast or at least 6 
hours after eating or drinking anything except water. Therefore it can be done the 
following morning when the participant returns to collect their TB medication. 
· If the fasting blood glucose level is above the normal range explain that the participant 
needs to return to see a clinic doctor. Fill in a referral letter with them and arrange an 
appointment with the doctor at the earliest opportunity. 
· Give all study participants diabetes information sheets. 
Interpreting blood glucose results 
Abnormal glucose levels if: 
· Random blood glucose is ≥8.9mmol/L (or ≥160.2mg/dL) 
· Fasting blood glucose is ≥7.0mmol/L 
Any study participant with either an abnormal random or fasting blood glucose level should be 
referred to the clinic doctor for further screening. 
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Appendix XV: HIV Testing Standard 
Operating Procedures 
 
Instructions for HIV testing using a Determine™ and UniGold™ HIV tests 
1. Equipment required 
· Test Kits (Abbot and Unigold) 
· Self- retracting lancets 
· Alcohol cotton swabs 
· Cotton(dry) 
· Sharps disposal containers 
· Disposable gloves 
· Pipettes 
· Plastic bag waste bin for biohazards 
· Markers 
· Stationery 
· Timer 
· Kit bag 
· Chase buffer 
2. HIV Testing Kits 
· Test kits should be stored between 2oc and 30oc, away from direct sunlight 
· Allow test kits to come to room temperature prior to use. 
3. Where test can be done 
The HIV test should be carried out in the TB clinic or within the grounds of the health centre. 
Testing should only be carried inside a building and not outside. Ensure that you can have 
privacy whilst carrying out the test. 
4. Doing the HIV test (Determine and UniGold) 
HIV testing should only be carried out after pre-test counselling has been done and the 
participant has accepted to have a test done. 
· Prepare a place where the test can be done. This should be a flat surface and there 
should be no clutter around. There should be enough light to read the test. 
· Wash your hands. If water is not available, rub your hands with gel or with an alcohol 
swab. Put on gloves. 
· Ask the participant to rub his/her hands together. 
· Select the middle finger of the right or left hand and massage it with your fingers 
· Clean the selected finger with an alcohol swab 
· Remove the lancet from its packaging 
· Place the lancet off-centre on the fingertip. Firmly press the lancet against the finger 
and puncture the skin. Immediately discard the lancet in the sharps disposal container. 
· Wipe off the first blood, and then massage the finger using up and down motions. 
Ensure that the finger is pointed down whilst you are doing this. 
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· When there is enough blood, place a drop of the blood onto the HIV testing strip and 
on the glucose testing strip (see blood glucose SOP for full details of the procedure). 
Press the finger stick site with dry cotton. 
· Apply a drop of chase buffer on the testing strip 
· Set your timer and wait 10-15 minutes before reading the results 
· Throw away all other NON-SHARP biohazard stuff in a sealable plastic bag 
5. Reading the test results 
· The results are ready between 10-15 minutes 
· Check that the result is valid before reading and communicating the results 
 
· Explain the result to the study participant. Follow the algorithm below to explain the 
results. 
· If  the result is invalid, explain this to the client and ask to repeat the test. 
· If the test is negative, counsel the patient and follow the current guidelines for 
advising on repeat testing. 
· If the test is positive, confirm results with Unigold, if confirmatory test is positive, give 
results as positive. 
· If confirmatory test is negative, explain that results are inconclusive and refer patient 
to health centre for further testing. 
· Enter results in appropriate section in the questionnaire (on the PDA). 
 
  
Invalid Result 
C 
T 
C 
T 
C 
T 
Negative Result 
C 
T 
Positive Result 
266 
 
Figure 1: HIV testing algorithm 
HIV Test
(Abbot [Determine])
NEGATIVE INVALID
POSITIVE
Explain result and 
give advise on 
future repeat 
testing
Repeat HIV Test
(Abbot [Determine])
NEGATIVE
POSITIVE
Confirm Result
(UNIGOLD)
Positive Negative
Explain result
Refer to Routine ART 
Clinic for care
Explain Result as 
indeterminate
Refer client for tie 
breaker test
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Appendix XVI: CD4 Testing Standard 
Operating Procedures 
 
1. Equipment 
1. FACSCount machine 
2. FACSCount Coring Station 
3. FACSCount work station 
4. FACSCount Software Protocol Diskette 
5. FACSCount Thermal printer paper 
6. Timer 
7. Pipette capable of delivering 50 µl 
8. Cleaning Tubes and Dispensing bottles 
2. Reagents 
1. The BD FACSCount Reagent kit 
2. The BD FACSCount Control kit 
3. System fluid (FACSflow) 
4. Distilled water 
5. Bleach (Sodium Hypochlorite) 
3. Procedure 
3.1 Collecting Patient Blood Samples 
1. Blood must be collected in a 4mL K3EDTA (liquid) VACUTAINER tube. 
2. Blood should not be stored for more than 48 hours at room temperature (20-25oC) 
3.2 Sample preparation 
1. Place the patient blood in the workstation. 
2. Remove one reagent pair for each patient. Reseal the foil bag and return the unused 
reagent pairs to the refrigerator. 
3. Label the tab of the reagent tube pair with the patient accession number or number 
that identifies the tube of blood. 
4. Vortex the pair upside down for 5 seconds. Set the vortex speed to a midrange setting. 
5. Vortex the pair upright for 5 seconds. 
6. Open the reagent tubes with the coring station. Refer to manual for details. 
7. Mix the patient whole blood by inverting the tube five times. 
8. Pipette 50µl of the whole blood into each of the two reagent tubes. Change tips 
between tubes. (Discard tips in the provided sharps container). 
9. Cap the tubes and vortex upright for 5 seconds. 
10. Incubate the tubes for 60 to 120 minutes at room temperature (20-25oC). Do not 
expose the tubes to direct sunlight. 
11. Uncap the tubes and pipette 50µl of fixative solution into each reagent tube. Change 
tips between tubes. (Discard caps and tips in appropriate waste bags). 
12. Recap the tubes and leave to stand until they are ready to be run. 
13. Vortex upright for 5 seconds immediately before running. 
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14. Run the tubes on the FACSCount instrument within 48 hours after fixation. (Store 
samples at room temperature in the workstation until they are run on the instrument. 
3.3 Preparing the FACSCount machine 
3.3.1 Preparing the Fluidics 
Before running controls or samples, prepare the fluidics by first filling the system fluid 
reservoir and then emptying the waste reservoir. 
3.3.1.1 Filling and emptying the System Fluid Reservoirs 
1. Open the fluidics compartment door to access the system fluid. 
2. Disconnect the system fluid tubing and the system fluid detection probe connector 
from the fluidics panel. 
3. Remove the fluid reservoir from the instrument and stand it on end before removing 
the cap. 
4. Fill the reservoir with system fluid. 
5. Recap the reservoir and replace in the instrument. 
6. Reconnect the system fluid tubing and fluid detection probe connector. 
7. Check to see that the system fluid filter is filled with fluid. If air is present in the filter, 
unclamp the plastic pinch clamp located on the air vent tubing to allow air to escape. 
Refer to manual for details. 
Note: System fluidics reservoir shall be rinsed once every 2 months with bleach and distilled 
water. 
3.3.1.2 Emptying the Waste Reservoir 
1. Disconnect the waste tubing and the waste fluid detection probe connector from the 
fluidics panel. 
2. Remove the waste reservoir from the instrument and stand it on end. Do not dispose 
waste reservoir contents until at least 30 minutes after the completion of the last run, 
this helps inactivate the bio hazardous material before disposal. 
3. Empty the reservoir and rinse it with bleach and water. 
4. Add 200mL of undiluted bleach to empty reservoir. 
5. Recap the reservoir and replace in the instrument. 
6. Reconnect the waste tubing and fluid detection probe detector. 
3.3.1.3 Priming the System 
1. Press [UTILITY] from the FACSCount screen to display the UTILITY screen. 
2. Press [DRAIN]. 
3. Press [DRAIN] again. 
4. When all the fluid has drained from the flow cell, press [STOP]. 
5. Press [MAIN] to return to the FACSCount screen. 
3.3.1.4 Entering Patient and Reagent Information 
1. From the FACSCount screen or the Control results screen, press [SAMPLE] 
2. Enter or verify the reagent lot code and reference bead counts and press [CONFIRM] 
3. Enter the patient accession number (up to 15 characters). 
N.B. For further details refer to manual. 
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3.4. Running Patient Samples 
1. After you enter sample information, the instrument prompts you for the CD4 tube 
(green top). 
2. Vortex the reagent pair for 5 seconds. 
3. Uncap the CD4 tube and set the cap aside. Place the reagent pair in the sample holder 
so the CD4 tube is in the run position. 
4. Press [RUN]. 
5. Remove the reagent pair and recap the CD4 tube. Uncap the CD8 tube (clear top) and 
set the  cap aside. Place the CD8 tube at the run position. 
6. Press [RUN]. 
7. Remove the reagent pair and recap the CD8 tube. 
8. The results are displayed on the screen of the machine and automatically printed per 
sample. 
9. Check if the results are passed. If not repeat the whole process again. If the sample 
fails twice a new blood sample needs to be drawn. 
N.B. If you need to run more samples you continue by entering patient and reagent 
information. Cleaning does not have to be done at this stage. 
10. After all runs have been done clean the machine. 
11. After cleaning leave a tube of distilled water on the instrument and bring the sample 
holder up. 
12. Turn off the power of the instrument. 
4.0 Report Results 
If the test is valid the result of CD4, CD3 and CD8 appears on the print out. The results should 
be entered into the laboratory database. The result print out should be attached to the 
request form and filed appropriately and also recorded in a laboratory CD4 results book. 
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Standard Operating Procedures 
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1. Introduction 
This document deals with the processing of sputum samples for culture and smears 
1.1. Endpoints 
For each sputum specimen received by the laboratory the following should be 
prepared: 
I. Sputum archive 
II. Inoculation on two MGIT tubes 
III. Concentrated smear (stained, read and reported)-Auramine stained 
IV. Capilia TB test 
Safety Precautions 
All sputum specimens should be treated with utmost care as they may be infectious. 
Universal safety precautions towards infectious materials should be followed. All 
processing must be done in a Bio-Safety cabinet.  
This SOP is targeted at staff that are qualified to work in a TB culture laboratory 
1.2. Abbreviations 
AFB Acid Fast Bacilli 
AMGIT 
Automated Mycobacteria Growth Indicator 
Tube 
BA Blood Agar 
BSC Bio-Safety Cabinet 
MOTT Mycobacteria other than tuberculosis 
Mtb Mycobacteria tuberculosis 
NTM Non Tuberculosis Mycobacteria 
RT Room temperature 
SOP Standard Operating Procedure 
ZAMBART Zambia AIDS Related Tuberculosis 
  
2. Specimen Handling 
2.1. Collection 
Specimens must be collected into 50ml falcon tubes with a tight fitted lid. They should 
be placed in a leak proof plastic bag for transportation to the laboratory. One spot 
samples should be collected from each patient.  
2.2. Transportation 
Specimens should be transported to the laboratory as soon as possible after collection. 
Delays in transportation may increase the risk of contamination of cultures. Specimens 
should be transported in   a cooler box with ice packs, in which temperature is 
maintained as low as possible.   
Specimens must be packaged to withstand leakage of contents, shocks, pressure changes 
and other conditions incident to ordinary handling practices. Primary specimen 
container (containing actual specimen) must be placed first in simple plastic bag that is 
tied, and then placed in self-zipped bags which is then placed in secondary container.  
2.3. Storage  
Samples should be processed as soon possible after receipt. If samples are not processed 
on the same day of receipt, they should be refrigerated at 2-8oC. DO NOT FREEZE 
SPECIMENS 
All specimens must be processed within 4 days of submission.  
3. Specimen Receipt and log in 
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Samples will be received at ZAMBART laboratory.  All samples should arrive with a 
request form packed in the side pocket of the specimen transfer bag with a barcode 
stuck on the request form. The samples from one patient will be packed in one sample 
transfer bag. 
3.1. Sample receipt 
 Check for sample examination request form 
 Remove from bag and check that barcode on request form matches that on 
samples 
 Samples where barcodes are not matching: Field staff should be contacted for 
verification. Samples should be discarded where the mismatch cannot be 
verified or resolved 
 Leaked out samples should be discarded if they cannot be salvaged 
 Indicate number of samples received by ticking appropriately on the request 
form 
 Sign request form to indicate that samples have been checked and received 
 Place signed off request form in designated Box folder (pending registration) 
 Place samples in appropriate drawer in the Fridge if they are not to be processed 
immediately 
 Samples that have not been received and checked should be placed in the 
electric cool box until someone is available to receive them 
Note: Samples that have not been received as described above should not be placed 
in the fridge. If samples cannot be appropriately received at the time of arrival, 
they should be placed in the electric cool box marked UN RECEIVED Samples. 
3.2. Sample registration 
 Remove sample examination request forms from folder 
 Scan in barcode from request forms 
 Enter date sample collected for each sample that is indicated on the request form 
 Enter all samples to be processed on that day 
 Once all samples are registered, print sample registration form 
 Samples can now be moved from the fridge into BSC1 
 After registration, request forms are placed in appropriately labeled box folder 
“Request forms, registered samples” 
Note: Take care that only samples indicated as received are registered. Once all 
samples for processing on the day are registered, print sample registration form. 
3.3. Unpacking samples from transfer bag 
This should be done in BSC1 
 Wipe BSC1 surface with appropriate disinfectant 
 Place samples in BSC1 and carefully check samples for breakages or leakages 
before removing from bag 
 Broken or leaked out samples should be recorded on the registration form and 
then discarded 
Note: Samples that are not completely leaked out can be salvaged by transferring 
into another falcon tube 
 Remove samples from the sample transfer bag and place on a rack 
 Wipe down with disinfectant and place samples in centrifuge bucket 
 Spin down samples for 1 minute 
 Remove from centrifuge, wipe down with disinfectant 
 Check and record volume and sample quality on the registration form 
 Enter sample volume and quality into data base 
3.4. Specimen rejection 
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 Sputum is leaked out completely and cannot be salvaged 
 Sputum container is broken 
 Sputum container is empty 
3.5. Batch Creation 
 Group samples into batches of maximum 26 (fewer if insufficient number of 
samples) with 2 control tubes included 
 For each specimen place one blue top screw cap vial (sputum archive vial), one 
slide and two AMGIT tubes on a rack 
 Label each MGIT tube with an individual barcode and another unique barcode. 
Ensure not to cover the inbuilt barcode on the AMGIT tube 
 Label the sputum archive and slide with unique barcodes 
 Place two extra MGIT tubes on the rack for negative and positive controls. 
These should have unique barcodes  
o Paste a red/pink sticker on top of the positive control tube and a green 
sticker on the negative control tube. 
o Write “PC” on the positive control tube and an “NC” on the negative 
control tube 
 Take an empty MGIT box rack and paste a sticker and label with date of sample 
processing. All batches (samples) run on the same day use the same rack for 
incubation 
 Create batch, enter batch number automatically 
 Scan in individual barcode for sample followed by the unique MGIT tube 
barcodes, slide and sputum archive 
 Scan in MGIT positive and negative control (every batch should have an 
accompanying positive and negative control tube) 
Warnings! 
 From this point forward all techniques must be carried out in the biosafety 
lab1, 2 
 No material may leave the lab unless it has been decontaminated or autoclaved 
 Procedures that can cause the generation of an aerosol must be minimised and carried 
out in a bio-safety cabinet 
 In order to minimize cross-contamination of cultures the following measures must be 
adhered to:  
 A single hood is dedicated to the isolation of mycobacteria from sputum. Fully-
grown cultures (MGIT) are to be dealt with in a separate hood or later in the day 
after sample processing is complete. If a second hood is not available an interval of 
at least 30 minutes should be allowed between processing sputum samples and fully-
grown cultures and handling of cultures should always be done after sputum 
samples have been processed and before to reduce cross contamination 
 After shaking or spinning, aerosols are to be allowed to settle for 5 minutes. 
4. Adding PANTA and OADC to each AMGIT tube 
Note: All reagents should be at room temperature before use. PANTA/OADC 
mixture should be added to AMGIT tubes just before adding samples 
 Reconstitute the PANTA with 15ml of OADC 
 Mix by carefully shaking 
 Put a sterile 10 ml syringe onto the multi-pipette 
 Add 0.8ml of the PANTA/OADC mixture into each AMGIT tube 
 Do not store MGIT tubes after addition of PANTA/OADC mix  
Note: MGIT tubes to which PANTA/OADC has been added should be used within 
30 minutes of adding PANTA/OADC 
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Left over PANTA/OADC should be used within 5 days of opening but should be kept at 
4oC. Do not freeze. Label the PANTA/OADC mixture with the date mixed 
 
6. Preparing positive and negative control 
    In BSC2 
1. Label one empty falcon tube “NC” for negative control and “PC” for positive 
control 
2. Add 3 ml of saline1 to the negative control container, and add 2 ml of saline to 
the positive control container 
3. Add 1ml of the positive control (H37Rv) culture broth from a pre-prepared vial 
to the positive control container 
4. Nothing is added to the negative control container 
NOTE: positive control samples are always placed at the end of the sample row and 
will only be opened if handling of the other clinical samples and negative control is 
done for the particular step of the protocol 
7. Specimen Decontamination 
 Processing should be done in batches. The Batch size is a maximum of 26 
specimens plus 2 control tubes. 
 For actual decontamination, the batch is split into 2 if the maximum number is 
reached so that only a maximum of 13 samples is processed for maximum batch 
size. 
7.1. Materials and Methods 
 Disposable 50ml plastic tubes (falcon tubes) 
 Digestant (Sterile NaOH/Citrate/NALC (home made)) 
 Phospate buffer pH 6.8 (aliquoted into McCartney bottles) 
 Graduated pasture pipettes 
 Centrifuge 
 Vortex mixer 
 Timer 
 Gloves 
 Waste bags 
 Media(2 AMGIT tubes)  
 Normal saline 
7.2. Prepare fresh digestant 
1. Place the required number of Falcon tubes containing 0.25g pre-weighed NALC 
into BSC1. 
2. Add sterile NaOH-Na-citrate upto the 50ml mark and mix well. 
Note: Label the tubes with name of reagent, date and time activated. Keep 
refrigerated and use within 24 hours of activation. 
 
7.3. Decontamination procedure 
1. Place a batch of sputum samples into BSC 1 
2. Place Negative and positive control tubes at the end of the rack 
3. Add the digestant solution in equal volume to that of the specimen using a sterile 
pipette. Tighten the cap 
4. Start timer when you have added the digestant to the first sample 
                                                          
1 See Appendix…. For preparation of Normal saline 
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5. Put samples in orbital shaker and vortex the tube for 15-30 seconds and invert 
the tube to ensure that the  mycoprep solution contacts all surfaces of the tube 
6. Wait 20 minutes after adding the NaOH-NALC solution.  Vortex lightly every 
5-10 minutes or put tubes on a shaker and shake lightly during whole 
decontamination time 
3. Make sure specimen is completely liquefied. If specimen is still mucoid, add a 
small quantity NALC-powder (30-35 grams) directly to the specimen tube, mix 
well 
4. At the end of 20 minutes, add phosphate buffer (pH 6.8) up to the top ring 50ml 
mark on the centrifuge tube. Tighten tube. Mix well by light vortexing or 
inverting several times 
5. Place tubes in centrifuge and close lid tightly. Centrifuge at 3800 X g for 20 
minutes at 4-16oC. Let the tube stand for 5 minutes after centrifuging to allow 
aerosol to settle but do not leave to stand for too long after centrifuge. If 
refrigerated centrifuge is not available use, use cold (2-6oc buffer) 
6. Remove tubes from centrifuge 
7. Decant supernatant from tubes into bin containing mycobactericidal disinfectant, 
leaving only sample pellet in the tube 
8. NB at this stage it is especially critical that only one specimen be open at a 
time and generation of aerosols be minimised to avoid cross-contamination of 
samples 
9. Re-suspend the pellet sediment with 2mls of phosphate buffer pH 6.8 using a 
sterile Pasteur pipette to achieve a final volume of 1- 3mls. Vortex the 
suspended sample 
10. Wipe down the container containing the pellet, move the rack to BSC2 
11. Spray the centrifuge buckets with 1% Virkon. Move to sink in readiness for 
washing 
12. Clean the BSC with 1% Virkon 
Note: Decontamination should be done on maximum sample volume of 5ml. Samples 
that are greater than 5ml should be aliquoted into another falcon tube to achieve 
volume of less or equal to 5 ml. 
Note: Inoculation will be done in BSC2 only 
 
8. Inoculation  
For each specimen two MGIT cultures will be inoculated. Automated reading will be 
done  
Materials and reagents 
a. AMGIT Media (7ml) 
b. BACTEC MGIT 960 growth Supplement (enrichment) 
c. BBL MGIT PANTA 
Note; for reconstitution of PANTA/OADC see section 4 above 
 
8.1. Inoculation of MGIT media 
1. Place specimens back in order with the corresponding AMGIT tubes, sputum 
archive vial and slide 
2. Using a sterile transfer pipette; 
a. Add 0.5 ml of well mixed processed/concentrated specimen to the 
appropriately labeled   2 AMGIT tubes 
b. Add 1ml to the appropriately labeled sputum archive vial 
c. Add two drops to the appropriately labeled FM slide and spread into an 
oval area approximately 2 x 3cm. 
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Note: Wipe tubes and caps with a mycobactericidal (1% virkon) disinfectant and 
leave inoculated tubes at room temperature for 30 minutes before incubating 
 
8.2. Incubation  
All inoculated 7ml MGIT tubes should be entered into the BACTEC MGIT 960 
instrument for incubation 
 
1. Follow the instrument prompts for loading samples (please refer to the BACTEC 
MGIT 960 instrument manual for details) 
2. Scan the inbuilt AMGIT barcode, then the unique barcode.  
      NOTE: do not scan the individual barcode when loading samples in the 
instrument. 
3. Place the tube on the automatically instrument allocated slot. 
4. MGIT tubes should be incubated until the instrument flags them positive 
5. If there is no growth in the tube after 6 weeks( 42 days) the instrument flags the 
cultures as negative  
6. Instrument positive cultures should be entered into the data base using the mass 
positive button. 
7. Cultures that are flagged negative after 6 weeks must be inspected for any 
growth. Any showing any growth-cloudy, crumby particles etc must be captured 
as positive and entered as positive and worked up for positive samples 
8. Instrument negative cultures are entered into the data base using the mass 
negative button if  showing no visible growth 
9. Mass negative cultures must be autoclaved before discarding. They should be 
discarded in the bag destined for incineration 
 
 
 
 
9. Storage of archived sputum 
 Place the sputum archive vials in a blue storage box (use one box that is labeled 
by week number and date) 
 Store at  -20oC 
10. Staining concentrated smears 
Auramine O stain is used. See appendix 2 for FM staining procedure 
Notes:  
 Remember not to leave smears exposed to UV light in the safety cabinet 
 Do not leave stained slides exposed to light as this may cause them to fade 
 Positive and Negative controls should be included when staining and 
reading a batch of slides 
11. Workup for cultures with growth 
 
Note: ZN Stain work List should be available upon entering of positive cultures 
into the data base 
 
11.1. Materials and reagents 
 Slides 
 Pasteur pipettes 
 Sterile loops 
 Methylene Blue -0.3% 
 3% Acid-Alcohol 
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 Carbol Fuchsin solution 0.3% 
 1% Bovine albumin 
 Capilia(Tauns)TB test strips 
11.2. AFB smear from MGIT tube with growth  
1. Place a drop of 1% bovine albumin on the slide using a sterile pippette 
2. Use a sterile pipette to remove an aliquot from the bottom of the tube 
3. Place 1-2 drops on the slide and spread over a small area 
4. Allow the smear to air dry 
5. Heat fix using an electric warmer at 65oC-70oC for 2 hours to overnight 
Note: Do not leave the smear openly exposed to the UV light of the safety cabinet. 
Heat fix smears that are air dry 
6. Stain fixed slides with ZN 
7. Place a drop of oil on the stained and completely dried smear and screen under a 
low power objective(x40) to locate bacteria. Switch to an oil immersion 
objective lens (x100) for detailed observation 
8. Check for AFB presence and record smear results on the work sheet 
9. Enter ZN stain results, scan in MGIT culture and MGIT DNA archives 
10. Print Capilia TB work list 
11. Capilia work list is printed after ZN stain results are captured 
12. Capilia TB test (MPB64 antibody test) 
1. ZN stain positive cultures are further identified to differentiate between Mtb and 
MOTT using the Capilia TB Test 
2. Positive control culture should have a ZN stain done as well as Capilia test 
12.1. Performing Capilia TB test MGIT isolates and archiving of isolates 
 Apply 1 ml of culture broth to DNA archive tube 
 Apply 0.5 ml of culture broth to MGIT culture archive tube(tube should have 
0.5ml 20% glycerol) 
 Apply 100µl of the positive media to the sample well on the slide directly 
without any manipulation 
 Leave for 15minutes (all results should be read within 1 hour after dispensing 
the sample into the sample well) 
 Check for the presence or absence of red to pink bands on both the test and 
control bands 
 Enter results onto results onto the Capilia work sheet 
 Enter Capilia TB  test results  
 Print results and send results to the PI 
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12.2. Interpretation of Capilia results 
1. Positive for Mycobacterium tuberculosis complex 
 Red-purple colour appears in both the T and C result windows. The result is read 
as positive if window T shows red-purple colour that is lighter than, the same as, 
or darker than the colour window C 
2. Negative for mycobacterium tuberculosis complex 
 Red-purple colour appears in results Window C but NOT in results window T 
3. Invalid Test 
 A test is invalid, if red-purple colour does not appear in result Window C 
 If a test is invalid, report as invalid on results form. Repeat test using a new test 
Plate, preferably from a newly opened foil pouch 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    POSITIVE                                     NEGATIVE                                    INVALID 
   C                T    C                T C                  T 
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Appendix 1: Flow diagram culture process 
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Appendix 2: FM staining Procedure 
Excerpt from SOP ZPLgen/001.  
Details for preparing stains see SOP ZPLgen/001 or section  
5.0 Smear preparation. 
5.1 Materials 
1. New frosted end clear glass slides 
2. Pencils or barcodes 
3.  Pasture pipettes 
4. Cotton wool  
5. Disinfectant 
6. Waste container 
5.2 Procedure 
1. Smear one drop of concentrated smear onto an appropriately labeled slide  
2. Spread the specimen on the slide by smearing repeatedly in a coil like pattern, to 
an approximately 2 x 3 cm or 1 x2 cm oval shape with a thickness good enough to 
read a news print.  
3. Use a separate pasture pipette for each specimen 
4. Allow the smear to air-dry completely; do not dry smears under direct sunlight, 
slide warmer or over a flame 
5. When dry, heat fix the smear by heating on a slide warmer for 2 to 3 hours 
6. If fixed smears will not be stained immediately store in slide storage boxes in a 
cool dry place 
6.0 Staining 
6.1 Reagents/Equipment 
1. Auramine O solution 
2. Distilled water  
3. 0.5% acid alcohol (Decolorizing solution) 
4. Potassium Permanganate (Counter stain) 
5. Timer 
 
 
6.2 Procedure 
1. Carefully place the fixed smears in a batch together with the positive and 
negative control slides on a staining rack (smeared side up)  
2. Flood the smears with Auramine O solution and allow to stain for 15 minutes 
3. Rinse the smears with distilled water and drain. Tap water contains chlorine 
which may interfere with florescence 
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4. Flood (decolorize) with 0.5% acid alcohol for 2 minutes 
5. Rinse with distilled water and drain 
6. Flood with potassium permanganate to counter stain for 2 minutes. 
Counterstaining for longer time may  quench florescence of the acid-fast bacilli 
7. Rinse with distilled water and drain  
8. Allow smears to air dry. Do not blot or dry using heat 
9. Examine slides as soon as possible or otherwise keep slides in the dark to prevent 
fluorochrome from fading 
7.0 Slide Examination and Recording of results 
1. Use the X40 magnification fluorescent microscopy  
2. The bacilli appear bright yellow against a dark background  
3. Report results according to the guidelines in the table below 
 
Fluorescent Microscopy Magnification Report 
400X  
0/100 fields or 1 length No AFB seen 
1-19/100 fields or 1 length Report exact number 
20-199AFB/100 fields or 1 length 1+ 
5-50/1 Field on average 2+ 
>50/1 field on average 3+ 
 
 Record results directly onto the FM smear work sheet 
 Use red ink for positive results 
 For a negative result report: “Acid-fast bacilli were not seen.” 
 For a positive result: report quantification of AFB seen. (It should not be 
assumed that all AFB are tubercle bacilli.) 
 Never report “No TB” (or equivalent wording). 
 
 
8.0 SOP DISTRIBUTION 
Distributed to  Number of copies 
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9.0TRAINING RECORD FOR THIS SOP 
The following personnel have been trained and do understand the contents of this 
SOP 
Name of Personnel Position Signature  Date 
    
    
    
    
    
    
    
 
 
  
284 
 
Appendix XVIII: Height, Weight and 
Abdominal Circumference Standard 
Operating Procedures 
 
INSTRUCTIONS FOR WEIGHT, HEIGHT AND ABDOMINAL CIRCUMFERENCE RECORDING 
Step 1: Eligibility 
Height, Weight and Abdominal circumference should only be measured in individuals who are 
eligible. The groups of people that are not eligible to have their measurements done are: 
 Chair bound  or bedbound participants 
 Individuals who are unsteady on their feet 
 Individuals who find it painful to stand straight 
 Pregnant  women 
 Individuals who cannot stand without support 
 Individuals with very high hair styles 
Step 2: Site for taking measurements 
It is preferable that weight and height are measured on a floor which is level and not carpeted 
(hard flat surface). 
Step 3: Height Measurement 
Equipment: Stadiometer- This is a portable collapsible device with a sliding head plate, a base 
plate and three contacting rods marked with a measuring scale. 
The Protocol 
1. Ask the participant to remove his/her shoes in order to obtain a measurement that is 
as accurate as possible. 
2. Assemble the stadiometer and raise the head plate to allow sufficient room for the 
participant to stand underneath it. Double check that you have assembled the 
stadiometer correctly. 
3. The participant should stand with his/her feet flat on the centre of the base plate, feet 
together and heels against the rod but not leaning on it. He/she should have his/her 
arms hanging loosely by their sides. He/she should be facing forwards. 
4. Move the participant's head so that the Frankfort Plane is in a horizontal position (ie 
parallel to the floor). The Frankfort Plane is an imaginary line passing through the 
external ear canal and across the top of the lower bone of the eye socket, immediately 
under the eye. This position is important if an accurate reading is to be obtained. An 
additional check is to ensure that the measuring arm rests on the crown of the head, 
i.e. the top back half. To make sure that the Frankfort Plane is horizontal, you can use 
the Frankfort Plane Card to line up the bottom of the eye socket with the flap of skin 
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on the ear. The Frankfort Plane is horizontal when the card is parallel to the 
stadiometer arm. 
5. Instruct the participant to keep his/her eyes focused on a point straight ahead, to 
breathe in deeply and to stretch to their fullest height. If after stretching up the 
participant's head is no longer horizontal, repeat the procedure. It can be difficult to 
determine whether the stadiometer head plate is resting on the participant's head. If 
so, ask the participant to tell you when she/he feels it touching their head.  
6. Ask the participant to step forward. If the measurement has been done correctly the 
participant will be able to step off the stadiometer without ducking their head. Make 
sure that the head plate does not move when the participant does this.  
7. Look at the bottom edge of the head plate cuff. There is a red arrowhead pointing to 
the measuring scale. Take the reading from this point and record the participant's 
height in centimetres and millimetres, at Height  space in the Questionnaire (on the 
PDA). 
8. Height must be recorded in centimetres and millimetres, e.g. 176.5 cms. If a 
measurement falls between two millimetres, it should be recorded to the nearest even 
millimetre. Eg. if an participant's height is between 176.4 and 176.5 cms, you should 
round it down to 176.4. Likewise, if the participant's height is between 176.5 and 176.6 
cms, you should round it up to 176.6 cms.  
9. Push the head plate high enough to avoid any member of the household hitting 
his/her head against it when getting ready to be measured.  
Step 4: Weight Measurements  
Equipment: Electronic bathroom scales  
 The protocol 
1. Turn the display on by pressing firmly with your hand or foot on the top of the 
scales (the scales will turn themselves off after a short while). The readout 
should display 888.8 momentarily as a check for the operation. If this is not 
displayed check the batteries, if this is not the cause you may need to report 
the problem to the Principal Investigator. While the scales read 888.8 do not 
attempt to weigh anyone.  
2. Ask the participant to remove shoes, heavy outer garments such as jackets and 
cardigans, heavy jewellery, loose change and keys.  
3.  Turn the scales on with your foot again. Wait for a display of 0.0 before the 
participant stands on the scales.  
4. Ask the participant to stand with their feet together in the centre and their 
heels against the back edge of the scales. Arms should be hanging loosely at 
their sides and head facing forward. Ensure that they keep looking ahead - it 
may be tempting for the participant to look down at their weight reading. Ask 
them not to do this and assure them that you will tell them their weight 
afterwards if they want to know.  
The posture of the participant is important. If they stand to one side, look 
down, or do not otherwise have their weight evenly spread, it can affect the 
reading.  
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5. The scales will take a short while to stabilize and will read 'C' until they have 
done so. If the participant moves excessively while the scales are stabilizing 
you may get a false reading. If you think this is the case re-weigh the 
participant.  
6. The scales have been calibrated in kilograms and 100 gram units (0.1 kg). 
Record the reading  in the space provided for weight on the questionnaire.  
WARNING  
The maximum weight registering accurately on the scales is 130 kg (20 stone). If you 
think the participant exceeds this limit do not attempt to weigh them. Tick the box 
'Weight exceeds scale maximum' on the Questionnaire. 
 
Step 5: Abdominal circumference 
Equipment:  Insertion (SECA) measuring tape calibrated in mm, with a plastic buckle at the 
end. 
 The Protocol 
1.   Prepare the participant by asking him/her to; 
 Remove all outer clothing such as jackets, cardigans, waist coats, and heavy or 
baggy jumpers.  
 Remove shoes with high heels. 
 Remove tight garments that are intended to alter ones shape such  as corsets 
or body suits. 
 Belts should be removed or loosened. 
 Pockets should be emptied. 
 If the study participant is not willing to remove bulky outer garments or tight garments and 
you are of the opinion that this will significantly affect the measurement, do not proceed 
with the measurement 
2. Ask the participant to stand erect in a relaxed manner. The arms should be hanging 
loosely at their sides. 
3. If possible, sit or kneel on a chair to the side of the participant. 
4. Pass the tape around the body of the participant and insert the clip into the holder. 
Ensure that the tape is horizontal by peering around the participant. 
5. Measure the abdominal circumference at the level of the navel (belly button) 
6. Hold the buckle flat against the body and flatten the end of the tape to read the 
measurement from the outer edge of the buckle. Do not pull the tape towards you as 
this will lift away from the participant’s body, affecting the measurement. 
7. Record the measurement to the nearest centimetre on the questionnaire. 
 
